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Foreword
The relationship between tobacco use and detrimental effects on
health is clear. It is less clear how we can best assist those who
are dependent on tobacco in their efforts to control or abstain
from its use.
Tobacco dependence, with its pharmacological and behavioral
complexity, has been the object of numerous and diverse forms of
intervention. No single technique has been generally effective.
This is not surprisng. Rather, substantial clinical and laboratory
research efforts have pointed to multiple determinants in the
maintenance of the behavior. This in turn dictates that the most
effective interventions will, likewise, have multiple components.
In general, administration of drugs to treat drugs dependence is
neither novel nor universally effective; this generalization
certainly holds true for tobacco. Over the years, many drugs have
been tried as treatments for tobacco dependence; most have been
proven to be ineffective when tested under well designed research
conditions. Yet, given the millions of smokers who have difficulty
stopping their use of tobacco, the potental value of a pharmaco-
logical agent as an adjunct to the treatment of tobacco dependence
is evident.
Recently, several agents have been introduced or recommended on the
basis of controlled trials. This volume reviews and samples the
most recent literature and scientific work on nicotine and tobacco
dependence. The findings point to the utility of integrating
behavioral and pharmacological treatment strategies in tobacco
dependence and have implications for the development of therapeutic
interventions for other dependence disorders.
Jerome Jaffe, M.D.
Acting Director
National Institute on Drug Abuse
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Tobacco Use, Treatment
Strategies, and Pharmacological
Adjuncts: An Overview
John Grabowski, Ph.D., and Sharon M. Hall, Ph.D.
INTRODUCTION
The colorful history of tobacco use has been reviewed by several
authors (e.g., Bell and Grabowski 1983; Jaffe and Kanzler 1981;
Surgeon General's Report, (USDHEW) 1964, 1979; Ray 1972; Jarvik 1970
and has been described in numerous historical treatises and papers.
The suggested hazards of tobacco use were enumerated shortly after
its introduction to Europe in the 16th century. At the same time
its presumed virtue as a general purpose medicament was extolled
(Ray 1972). Since then the proponents and opponents of tobacco use
have vigorously debated their positions. Ample evidence of
potential harm has accumulated indicating disease conditions
correlated with tobacco use. These data have been presented in many
scientific articles and in the summaries provided by the Surgeon
Generals' Reports between 1964 and 1984.
The wealth of findings on adverse health effects of tobacco use have
generated vigorous efforts in two domains. The first is development
of techniques to prevent young nonusers from initiating tobacco
use. The second is to establish optimal techniques for eliminating
tobacco use in those who smoke or otherwise consume tobacco
products. A concise statement of the character of the dilemma is
often attributed to Mark Twain: “I can quit smoking if I wish; I've
done it a thousand times." Recent restatements of this problem by
scientists are evident in the change of focus from cessation alone
(i.e., quitting). to maintenance of cessation (e.g.. USDHHS 1980;
Hall 1980, 1984).
Efforts to eliminate tobacco use began a short time after its
introduction. Diverse remedies have been described, some ludicrous,
others macabre. In recent years, five categories of reasonable
cessation efforts have had prominence, including: (1) public
intervention or information campaigns, (2) "self-help" programs, (3)
group support programs, (4) individualized behavioral intervention
programs, and (5) pharmacological interventions. Although
identified as distinct and separate, many efforts, of course, have
combined elements of the various approaches. Indeed, most recently
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it has become evident that optimal programs may include combinations
of behavioral intervention, group support, and use of
pharmacological adjuncts (e.g.. Hall and Killen, this volume).
INFORMATION AND LEGISLATIVE MASS INTERVENTIONS
The five cessation intervention categories differ in a variety of
ways. One dimension is degree of external intervention which
usually covaries with the size of the population intervened upon.
For example, there have been several forms of governmental efforts
to reduce tobacco use. One is announcements to the press. Although
these efforts have been ongoing for many years, they became clearly
focused following publication of the first Surgeon General's Report
(USDHEW 1964). Other widely distributed public health messages are
the advertising campaigns developed by the National Cancer
Institute, National Heart, Lung, and Blood Institute, Office on
Smoking and Health, and the National Institute on Drug Abuse.
Still another media-based effort is that developed by the National
Cancer Institute and the National Heart, Lung. and Blood Institute.
The program had a local television news personality go through his
or her personal smoking cessation program in full view of the
public. Throughout the several weeks of the program, viewers were
encouraged to follow the instructions and guidance by the status
model provided. These broad-based public efforts reach large
numbers of people, with varying degrees of effect. An advertising
campaign reaches many people but can, by virtue of the technique,
convey only simple messages. The "Status Model" strategy reaches a
lesser number. provides many specific and clear instructions on
smoking cessation techniques, but has no genuine followup
interaction provisions.
Other broad efforts with less personal "direction" have taken the
form of substantial tax increases on tobacco products and labelling
of tobacco products as well as advertising (in the United States,
cigarettes only) with warnings. Indeed, the rotational warning
label system used in other countries will soon be introduced in the
United States.
Taxation, an indirect mechanism, can have a dramatic effect on many
people if properly implemented. To the extent that price affects
purchase, consumption is likely to be dramatically altered if the
increase is large. Data from a Canadian report (Ontario Council of
Health 1982) indicated a clear relationship between cigarette price
and consumption. With some exceptions, it is evident that cigarette
consumption is highest in countries where price is lowest. In those
countries where extremely high taxes have been levied (e.g.,
Norway), the consumption of manufactured cigarettes declines, but
there is increased likelihood that smokers will "roll their own."
However, they do not override the effect of the tax; i.e.,
consumption remains lower than before the tax. The Canadian report
suggests that the optimal taxation is one which doubles the price.
It results in decreased consumption but does not induce a dramatic
shift from manufactured to hand-rolled cigarettes. It appears that
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price increases are most likely to decrease purchases by young
people (Lewit 1983). This may generate a considerable benefit in
prevention.
Large-scale programs sacrifice precision, are variably successful,
and resultant indicators of change are indirect. However, it is
probable that these advertising and social intervention approaches
have had an effect, since major shifts in populations smoking and
numbers of smokers have occurred. Since at least some of these
efforts are based on advertising strategies with documented
effectiveness, parallel consequences in affecting smoking behavior
can justifiably be assumed.
Nevertheless, it has been suggested that mass communication
strategies do have limits. For example, they appear to require an
underlying foundation of receptive personal views, social influence,
and environmental circumstances favorable to enhancement of the
message (USDHHS 1982, 1984). In the case of tobacco use, this
change in perspective is only gradually occurring. In addition, it
is unclear whether the message and favorable conditions extend to
all forms of tobacco use or are limited to cigarette use. If
current public understanding of hazards is limited to cigarette
smoking, one unfortunate effect of current mass communication
efforts might be a shift by some individuals from one preparation
form to another (e.g., cigarettes to chewing tobacco).
Overall it appears likely that just as an integrated effort is
optimal at the individual level, it is necessary to combine diverse
elements in the health and behavior messages aimed at broad
audiences. Legislative, health agency, and broadcast media efforts
in concert will be most effective, interacting with the messages
provided at the individualized program level.
SELF-HELP PROGRAMS IN SMOKING CESSATION
There has been recent emphasis on self-help and other "cost-
effective" approaches. The concept of self-help has gained pop-
ularity for a number of reasons. Popularity derives in part from
popular notions of "self-control," "free will," and "bootstrap"
progress. Such efforts are also considered to be economical of time
and money by some. Evidence of less immediate cost in a given
program can probably be provided. However, "self-help" programs may
rely heavily on diverse long-term efforts which are both expensive
and time-consuming. Thus, the actual effectiveness of the program
may reflect decades of costly advertising, legislation. and
influence on the individual and his or her social group. These
efforts include the time and money spent in preparing elaborate
self-help materials, as well as media and other public health
efforts supportive of nonsmoking. Also, the success rates for
unassisted self-help "bibliotherapy" (Glasgow and Rosen 1978) are
generally not substantial, although some favorable results have been
noted (USDHHS 1982).
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Self-help materials probably require a user well versed in the
strategy and goal of the self-help approach. The level of
sophistication required of the user may deter some individuals and
preclude success of others. Thus, it is likely that such materials
are best used in concert with instruction from a knowledgeable
professional. It is perhaps ironic that substantial efforts have
been made to develop intensive clinically guided therapies for users
of various other drugs associated with less persistent drug-seeking
than cigarettes. The cigarette smoker is more often relegated to
the self-help efforts.
A comment is warranted about the individuals who quit "cold turkey,"
without assistance. In this culture, the volume and scope of the
antismoking campaigns and materials are such that most, if not all,
smokers have been influenced in some degree, and thus have received
some aid in quitting. It should also be noted that only a small
percentage (10%-27%) of those who engage in "spontaneous cessation"
continue as nonsmokers for 1-5 years. In addition, as many as 90%
of smokers verbalize an interest in quitting. There- fore, the need
for effective intensive interventions remains.
GROUP AND SOCIAL SUPPORT PROGRAMS
A number of public agencies (e.g., American Cancer Society; National
Heart, Lung, and Blood Institute), private nonprofit groups (e.g.,
American Lung Association). and for-profit groups (e.g., Smokenders)
have implemented smoking cessation programs. The common element in
the programs resides in use of a standardized intervention package
with groups which meet regularly. Social pressure and social
reinforcement are common treatment mechanisms. The leaders of all
such programs typically strive to develop behavioral analysis skills
in the participants. The smokers (now exsmokers) learn to examine
the behavior itself and the conditions under which it occurs, and
they plan a cessation date. Some form of followup intervention is
characteristic. These programs have varying degrees of success,
which may be influenced by many factors, including leader expertise
and subject characteristics. Unfortunately, few data are available
on the long-term results of such programs. That is. all tend to be
effective in producing cessation, but the rate at which cessation is
maintained is not clear. Furthermore, it is likely that particular
intervention strategies will be more effective with some people than
with others. Indeed, the problem in terms of success is likely to
parallel that observed for the common treatment approaches for many
behavioral disorders. That is, there is a need to match each client
with an appropriate therapy.
INDIVIDUALIZED PROGRAMS
Individualized smoking programs are uncommon. The number of
cigarette smokers who actually seek a clinician for an
individualized behavioral intervention program is probably minimal,
although no data are available. However, this does not take into
account physician-implemented, pharmacological interventions which,
with the introduction of nicotine gum, will likely be extremely
common but lacking in meaningful behavioral intervention
components. For example, 700,000 prescriptions for the gum were
written in its first 2-1/2 months on the market (Consumer Reports
1984). The appropriateness of applied behavioral techniques
coinciding with administration of this pharmacological adjunct is
unknown, despite the manufacturer's efforts to educate physicians in
its optimal use. However, the effort may well be enhanced by recent
coverage in professional information sources (e.g., JAMA 1984).
A substantial literature of case reports, as well as more systematic
experimental analyses of smoking behavior and cessation attempts has
been reviewed. The primary problem with individualized programs
will be, of course, that they are costly. On the other hand, if
individualized programs, or standardized programs with latitude for
individual modification, can be demonstrated to be effective for
many clients. the long-term benefits in reduced medical costs may be
substantial. It appears that integrated programs of the sort
described by Hall and Killen (this volume) or Pomerleau and
Pomerleau (1977) will prove most useful in the quest for successful
intervention. Again, the broader view suggests that all will be
more effective against a backdrop of concerted public health
advertising, legislation, and other social interventions.
PHARMACOLOGICAL INTERVENTIONS
Over the years, a wide range of agents has been proposed as possible
pharmacological adjuncts for treatment of cigarette smoking. In an
interesting review, Kozlowski (1984) has noted that completely
ineffective pharmacological techniques have been promulgated as
"cures" for tobacco use. Various studies have also examined
mechanisms by which pharmacological agents demonstrably effective
for other purposes might alter cigarette smoking.
Pharmacological Interventions for tobacco use derive from several
assumptions in part related to putative "reasons" for smoking.
While many properties of nicotine align it with prototypic
"stimulant-like" drugs, cigarette smokers often refer to calming
effects.
Multiple possible origins exist for these reported disparate
effects. There may, of course, be dose-dependent variations in the
dominant effect of nicotine (Domino 1973). The behavioral effects
of nicotine may be dependent on the baseline level of activity of
the individual. This has been amply demonstrated with other
behaviorally active agents. Thus, a rate-dependent decline, or
"subduing effect," may occur under conditions of high activity,
while rate-increasing, or "activating" effects may emerge when
baseline activity is low. The possibility of interaction between
certain classes of behavior and observed effect may be important.
Interaction of doses, behaviors, and environmental conditions may be
perceived as enhancing or decreasing activity. For example,
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increasing focus of attention and decreased distractibility may,
despite their derivation from a stimulant action, be effectively
calming to the smoker.
An entirely different and seldom considered mechanism by which
"sedative" actions might be achieved are those associated with
regulation of carbon monoxide levels or potential interactions
between this gas and nicotine. Thus, while nicotine is likely the
dominant pharmacological reinforcer in tobacco use, maintenance of
comparatively high carbon monoxide levels cannot be ignored in terms
of potential behaviorally relevant physiological effects. Finally,
another source for the apparent disparity in the reported effects of
smoking may also reside in the pharmacological profile of nicotine
itself. While nicotine is often noted for its similarity to drugs
such as dextroamphetamine. it differs along several dimensions
(Domino 1973), although the effects on standard measures of rates of
behavior are similar. The critical issue in all such discussions
appears to be dose. It must be recalled that the doses obtained via
smoking are relatively low, and it is in the low dosage range that
primarily stimulant-like effects have been reported.
Depending on the effects of nicotine thought to be dominant in
maintaining tobacco use, sedatives, anxiolytics, or stimulants might
be administered to decrease cigarette smoking. Indeed, the range of
options parallels that for other forms of pharmacological
intervention in cases of drug dependence. Another alternative
approach is blocking of nicotine's effects. The most obvious and
direct strategy, however, is to administer nicotine itself in an
alternative form. Several authors have provided overviews of the
rationale for various pharmacological strategies for smoking
cessation (e.g.. Kozlowski 1984; Schuster et al. 1977; Jarvik
1973). In the main, these reside in substitution for the presumed
primary effect.
The optimal and practically unattainable drug would, of course,
reduce cigarette use independent of the subject or client's "desire"
to stop smoking. Sedatives and anxiolytics have generally been
noted to be ineffective in reducing smoking in either acute or
longer term demonstrations (e.g., Whitehead and Davies 1964;
Schuster et al. 1977; Kozlowski 1984). Thus the notion of parallels
with "anxiety-reducing" agents is minimized despite the common
subjective report of this property of tobacco self-administration.
Conversely, the view of tobacco use as having generalized energizing
characteristics for which other "stimulant-like" drugs might
substitute is countered by the results of Whitehead and Davis (1964)
and Schuster et al. (1977). Indeed, Schuster et al. (1977) reported
acute increases in cigarette smoking as a function of dextro-
amphetamine administration.
Other drugs administered to decrease tobacco use have included
lobeline, naloxone, propranolol, alkalizing agents, and
mecamylamine. Schuster et al. (1977) demonstrated that lobeline has
no practical effect at the doses recommended. It is nevertheless
sold over the counter under several brand names. Naltrexone. a
relatively short-acting narcotic antagonist, has been reported to
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reduce puffs/cigarette, and number of cigarettes over its duration
of action (Karras and Kane 1980), although the elaborate
neurochemically based rationale for its effectiveness is not
compelling, since general reductions in food and water intake have
also been observed. Nevertheless, given the current availability of
longer acting variants, e.g., naltrexone, further research might be
of interest. In addition, some investigators appear to be defining
more precisely the specific neuroregulatory and reinforcement
mechanisms of smoking (Pomerleau and Pomerleau 1984). Propranolol,
an effective antihypertensive which has also been noted to relieve
some physiological correlates of anxiety, has been reported to be
ineffective in a large double-blind study (Farebrother et al. 1980).
The rationale for the use of sodium bicarbonate or other alkalizing
agents to change urine pH and thereby sustain nicotine blood levels
has complex underpinnings. As Schachter et al. (1977) noted,
increasing urine alkalinity "can have at best trivial effects on
plasma level nicotine." Nevertheless, the approach gained some
acceptance because of presumed interactions between stress, nicotine
metabolism, and urine pH, and the belief that the alkalizing effect
would, under certain conditions, not be trivial. There are at
present few proponents of using the alkalizing strategy in smoking
cessation programs. However, much has been published in the
scientific and popular press on the topic.
One other proposed pharmacological intervention, mecamylamine, is
logically reasonable but may be lacking practical merit. It has
been argued, as is mentioned by Henningfield and Nemeth-Coslett
(this volume) and Henningfield et al. (1982) that mecamylamine, as a
nicotine blocking agent, might be a useful adjunct in smoking
cessation. There is clear evidence of mecamylamine's effectiveness
in blocking nicotine's action at doses which have no untoward
effects. Theoretically, its value is apparent, and a cogent case
for its utility was made more than a decade ago by Jarvik (1973).
However, Jaffe (1973) noted, with respect to use of narcotic
antagonists in treatment of opiate abuse, that antagonist treatment
is "largely a promise unfulfilled." The problem parallels that
arising in the use of dlsulfram in the treatment of ethanol abuse,
or naltrexone for opiates, i.e., patients select other options.
In the main, pharmacological adjuncts without at least modest
inherent reinforcing properties have not been widely accepted by
patients (e.g., Grabowskl et al. 1979; Grabowski 1984). In this
regard, mecamylamine would likely be no exception, particularly when
more reinforcing options such as nicotine exist. Nevertheless, the
potential utility of the drug in patients who are "highly motivated"
or for whom nicotine is contraindicated is considerable.
Effectively blocking nicotine's direct effects may therefore have
promise if combined with behavioral intervention strategies.
Indeed, the potential clinical utility of mecamylamine has been
demonstrated in a study by Tennant et al. (1983) and was considered
a "viable withdrawal treatment for some case of recalcitrant
nicotine dependence." The most obvious pharmacological adjunct is
nicotine itself, and it is the major focus of the present volume.
Introduction of a nicotine-laced chewing gum approved by
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the U.S. Food and Drug Administration in the spring of 1984 has
generated considerable interest in both the scientific and lay
communities. It has been extensively discussed in the scientific
and quasi-scientific literature and lay press (e.g., Consumer
Reports 1984). The origins of the widespread interest are likely
three-fold. First, the U.S. distributor has, of course, made
sweeping publicity efforts. Second, the scientific community is
encouraged not only by the therapeutic implications of the product,
but also by its usefulness in human research requiring nicotine
administration. Third, it is probable that much of the
cigarette-using population of the U.S. has been awaiting a "magic
bullet" which would eliminate the behavior and alleviate all
discomfort coinciding with cessation, however ill-advised this view
may be.
The rationale for administration of nicotine gum to maintain
cigarette abstinence is clear. It entails substitution of one
nicotine preparation form for another. It parallels in some
respects administration of methylphenidate or antidepressants for
treatment of cocaine abuse (Kleber and Gawin 1984; Khantzian 1983),
the use of methadone for heroin abuse, or perhaps controlled
administration of various sedatives or anxiolytics in the treatment
of alcohol abuse.
Since nicotine is dominantly "stimulant-like" at the lower doses
typically self-administered by tobacco users, the
cocaine-methylphenidate analogy is perhaps most apt (e.g..
Henningfield and Nemeth-Coslett, this volume). Therefore, positive
reinforcing effectiveness, rather than "withdrawal symptoms," may be
the primary factors maintaining self-administration (Hatsukami et
al., this volume). Substitution of a distinctly similar alternative
agent, or the same agent in a different form, is reasonable. It
precludes the loss of reinforcing effects of self-administration
while terminating the behavioral components which exist at high
strength in long-time smokers.
Krivokapich et al. (this volume) have evaluated cardiovascular
effects of nicotine gum. They have further substantiated its
apparent absence of pronounced cardiovascular effects within the
recommended dosage range. Given the fact that for individuals in
good health, the effects of nicotine at standard doses are
relatively safe, clear advantages exist in self-administration of
nicotine via the buccal route, rather than combined with the diverse
chemical and particulate constituents in cigarette smoke. Indeed,
while not specifically approved for treatment of chewing tobacco
use. nicotine-laced gum conceptually approximates the behaviorally
ideal adjunct in this case also.
The issue of effectiveness of nicotine gum in smoking cessation is,
of course, as complex as the behavior itself. As discussed by
Herning and Jones (this volume). differing behavioral patterns exist
among smokers, most of which lead to inhalation of significant
amounts of nicotine; these can be modulated by administration of
gum. Henningfield and Nemeth-Coslett (this volume), among others,
make an excellent case for the role of nicotine in the maintenance
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of cigarette smoking and report data concerning the characteristics
of nicotine self-administration via the buccal route (gum
preparation form).
Further supporting the case for nicotine self-administration as an
important factor in maintaining cigarette smoking for some
individuals is the report by Hatsukami et al. (this volume) which
provides data suggesting the importance of positive reinforcement as
a major factor sustaining smoking behavior. Their data add to the
case that behavioral correlates of smoking and cessation, rather
than physiological symptomatology per se, must be the primary focus
of cessation maintenance efforts. The data also further support the
potential usefulness of nicotine-laced chewing gum in attaining this
goal. Hughes and Hatsukami (this volume) further delineate the
physiological and behavioral parameters of nicotine administered via
the buccal route.
The crucial issue concerning nicotine gum as a pharmacological
adjunct is whether it does, in fact, increase cessation maintenance,
an issue explicitly addressed in this volume by Schneider and
Jarvik. Russell and Jarvis, Fagerstrom and Melin, and Hall and
Killen. It is evident that smoking is a behavior modulated and
determined by complex interacting behavioral, social, sensory, and
pharmacological factors.
Schneider and Jarvik (this volume) address the clinically pertinent
individual characteristics. Their data point to the relationship
between degree of behavioral dependence on cigarette smoking and the
effectiveness of the gum. Russell and Jarvis (this volume), in
addition to providing a thorough review, address the relevance of
individual social factors and the role of the clinician in cessation
efforts. They note on one hand the direct effect of the gum, but
likewise note that whatever placebo effects may exist can be used to
advantage.
Fagerstrom is among the most experienced investigators of the gum's
effects in clinical settings. Fagerstrom's notable efforts with
both development of innovative measures of dependence and analysis
of the usefulness of the gum in clinical settings have been of value
to numerous investigators. These studies and strategies are
reviewed in this volume.
It appears that behavioral programs combined with nicotine gum and
emphasis on relapse prevention produce the best outcome (e.g., Hall
et al. 1985; Hall and Killen, this volume). These group-based
procedures, which rely on social reinforcement, including a variety
of specific positive reinforcement and punishment techniques, and
which include followup support, will likely prove the most
beneficial strategy for most smokers.
AN INTEGRATED VIEW OF PHARMACOLOGICAL ADJUNCTS AND TREATMENT
Concerns which have existed about pharmacological adjuncts for other
drug-use problems also prevail with respect to nicotine gum and
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would likely arise for any other new agent. Many of these concerns
were addressed during the course of the U.S. Food and Drug
Administration's review of data in support of efficacy of nicotine
gum.
The fundamental question, of course, is whether or not the gum will
effectively enhance smoking cessation. If nicotine is the primary
pharmacological agent maintaining tobacco use, then administration
of nicotine in alternative forms providing similar nicotine blood
levels should be effective in terms of the pharmacological
component. Nicotine gum does this, but there are differences in
onset characteristics which make it less likely to be effective as a
reinforcer (although Henningfield and Nemeth-Coslett, this volume,
indicate that chewing characteristics can alter onset).
If it is effective as a reinforcer, the question arises whether it
is likely to be misused or used excessively for its positive
reinforcing effects. An objective analysis suggests that this is
possible, although the most likely form of "misuse" will probably be
continuation of use beyond the tentatively recommended period of 3
to 6 months. Indeed, several investigators have already suggested
that use of the gum at higher doses for longer periods will probably
generate more favorable long-term abstinence percentages.
Interestingly, this parallels data available for other substitution
treatments (Dole and Nyswander 1983).
The issue is whether "misuse" or prolonged use of the gum is likely
to be a significant problem. In Switzerland, where the gum is
available without prescription, no significant problems have been
reported. In any case, another point arises when prolonged use is
considered. Chronic use of the gum results in nicotine levels
paralleling those which an individual would attain through smoking.
These are achieved without the bolus and rapid onset produced by
smoking which could arguably be a problem to individuals with
cardiovascular problems. Thus, the hazards of carbon monoxide,
hydrocarbons, particulate matter, and numerous chemicals are
eliminated when the individual chews the gum rather than smokes
cigarettes. Obviously, the gum does not have the hydrocarbon and
chemical hazards associated with chewing tobacco. Overall, the
health advantages in terms of reduced risk using the gum are
numerous.
Questions about conditions of use and usefulness do exist. Results
of many studies with the gum have been equivocal. Others have
produced more favorable results. However, as with other
pharmacological adjuncts for drug abuse or tobacco use which have
been mentioned, the gum is not a "magic bullet" or panacea. It is
likely that many people will at first use the gum without success.
The critical determinants of successful use appear to be related to
whether the gum is, in fact, used as a pharmacological adjunct in
conjunction with an appropriate array of behavioral intervention
techniques and environmental influences. This volume and the
literature in general adequately amplify the need for such a
combined strategy in this and other areas of health and behavior.
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Rational Basis for Chemotherapy
of Tobacco Dependence
R. Nemeth-Coslett, Ph.D., and Jack E. Henningfield, Ph.D.
The forms of tobacco use are many, and it is likely that their
number is matched by equally varied controlling variables. All the
usual forms of tobacco use, however, share at least one
commonality: nicotine is extracted from the tobacco and ingested in
a manner that permits its distribution to the central nervous
system. The tobacco cigarette is the prevalent means of nicotine
self-administration in Western society, and cigarette smoking is the
primary form of tobacco use addressed by legislative, research, and
treatment efforts.
In 1983, the United States Public Health Service categorized
cigarette smoking as a form of drug dependence in which nicotine was
held to be the critical substance (USPHS 1983). Consistent with the
drug dependence model of cigarette smoking, in 1984 a
pharmacotherapeutic aid (nicotine gum) for the treatment of tobacco
dependence was approved by the Food and Drug Administration. This
paper will briefly review nicotine dependence and its implications
for the use of chemotherapy in the treatment of tobacco dependence
with respect to cigarette smoking.
TOBACCO DEPENDENCE: A DECEPTIVELY COMPLEX PHENOMENON
At first brush. tobacco dependence would seem readily amenable to
study. In the form of cigarette smoking. the behavior is public,
practiced by many, and appears to involve a simple act with a simple
product. However, cigarette smoking has resisted many attempts at
quantitative study, and studies have yielded data which often
appears contradictory at the most elemental levels. For instance,
the role of dose in the control of cigarette smoking has remained
unclear despite decades of study. Since dose-response relations are
arguably the most critical quantitative relations to be assessed in
pharmacologic studies, the absence of consensual agreement as to the
nature of dose-response relations has undoubtedly hindered the
understanding and treatment of cigarette smoking.
There are specific reasons for some of the ambiguity concerning the
role of dose in cigarette smoking. Table 1 provides a partial list
of factors which obscure quantitation of dose-response functions.
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These factors and others have been more thoroughly discussed
elseswhere (cf. Benowitz, 1983; Henningfield, 1983, 1984;
Kozlowski, Rickert, Robinson and Grunberg, 1980). In brief,
compared to most other forms of drug self-administration, cigarette
smoking involves a wider variety of confounding factors. In alcohol
studies, for instance, ounces of ethanol ingested can be specified
with great reliability, and resulting blood ethanol levels are
related in some orderly fashion to these values. Similarly, in
studies of sedatives, stimulants and opioids, the number of
milligrams of actual drug which is swallowed or injected may be
readily specified. In the case of cigarette smoking there is often
disagreement as to which parameter to specify and the means of
specification. One consequence of these difficulties was to delay
the positive classification of cigarette smoking as a form of drug
dependence. The next two sections will provide the evidence for
this classification.
TABLE 1. Obstacles to the quantitation of dose-
response functions in studies of cigarette smoking.
o Many reports do not include any quantitative
measure of dose.
o Multiple dose parameters (e.g.. nicotine, tar
and CO are frequently confounded.
o Substances of possible functional significance
(e.g., tar. CO, CO2) are especially difficult
to specify since they are not even present in
an unlit cigarette.
o Federal Trade Commission dose level estimates
are not necessarily related to either cigarette
content or yield by the smoker.
o The behavior of cigarette smoking varies across
smokers and even across puffs within a single
cigarette.
o A variety of factors may affect absorption of
smoke constituents (e.g., smoke pH, inhalation
depth).
COMMONALITIES AMONG CIGARETTE SMOKING AND DRUG ABUSE
For centuries, a variety of parallels have been drawn between
tobacco use and the use of opiates, alcohol and other substances.
It seemed obvious to many observers of social behavior and
physiologic effect that these substances were different from other
substances of ingestion. such as food. Indeed, the American Indians
knew that as other vegetables were "food for the stomach," "tobacco
provided food for the spirit." Beyond these general observations, a
variety of points common to cigarette smoking and classically
studied forms of drug dependence (e.g., narcotic addiction and
alcoholism) have been identified. The various commonalities have
been described in greater detail elsewhere (Henningfield, Griffiths
and Jasinski; 1981; Jaffe and Kanzler, 1979) and are summarized in
Table 2.
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TABLE 2. Common factors in tobacco use and drug dependence.
o Spread is socially mediated and is persistent.
o Patterns of relapse are similar following
treatment.
o Use persists in face of damage (individual &
social).
o Personality types overlap.
o Centrally (CNS) acting substance (drug) is
delivered.
o The drug is a reinforcer for animals.
o Deprivation increases drug seeking behavior.
o Tolerance develops with repeated use.
o "Therapeutic effects" may be produced.
o Patterns of self-administration and dose-
response functions are orderly.
These commonalities among various forms of drug dependence and
tobacco use provide a rational basis for the theory that tobacco use
may occur as a form of drug dependence. In brief, tobacco use,
particularly in the form of cigarette smoking, is an orderly
behavior that is lawfully controlled by the same behavioral and
pharmacologic variables as are more commonly studied forms of drug
dependence. The commonalities also suggest that treatment
strategies which have proven effective in drug dependence may be
applied to the treatment of cigarette smokers.
NICOTINE AS A DEPENDENCE-PRODUCING DRUG
While any substance may, under some conditions, be compulsively
used, substances characterized by a certain constellation of
features are likely to be compulsively used and abused under a much
broader range of conditions, including those which lead to damage.
In brief, the compound must be psychoactive (produce centrally
mediated effects on mood and feeling states), must have euphoriant
qualities similar to those of reference drugs (e.g., morphine,
amphetamine. ethanol). and must serve as a biologic reinforcer (be
voluntarily self-administered). Other qualities such as the ability
to produce tolerance and physiologic dependence are interesting and
may be of functional significance but are neither necessary nor
sufficient determinants of drug dependence.
Two lines of study involving human subjects were undertaken by the
Addiction Reseach Center of the National Institute on Drug Abuse.
The first involved pharmacodynamic analyses which assessed the
psychoactivity of nicotine and its possible qualities as a
euphoriant. A variety of parameters were assessed when nicotine was
given in the form of tobacco smoke and intravenous injections. The
second line of study assessed the reinforcing properties of
intravenous nicotine in cigarette smokers. The intravenous studies
were critical in determining whether nicotine, in the absence of the
usual confluence of stimuli involving the cigarettes themselves
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(e.g., social and cultural), was characterized by the constellation
of pharmacologic properties typical of those of known drugs of abuse.
Psychoactivity and Euphoriant Properties of Nicotine
The initial study showed that nicotine was psychoactive and produced
orderly effects on measures of psychoactivity (Henningfield et al.
1985). Following either smoke inhalation or i.v. administration,
nicotine was discriminated from placebo, and dose strength estimates
were directly related to nicotine dose. These self-reported effects
peaked within about 1 minute and dissipated within 3 to 5 minutes.
Certain physiologic responses were also dose-related and showed
similar temporal patterns of onset and offset: heart rate, pupil
diameter, electroencephalographic response (Lukas and Henningfield
1983). A subsequent study showed that the ganglionic blocker,
mecamylamine. attenuated physiologic and self-reported effects of
nicotine (Henningfield et al. 1983). Variability of response on
self-report measures was lower when nicotine was given intravenously
than when it was given in the form of tobacco smoke, suggesting that
the stimuli provided by cigarette smoking confound discrimination of
the effects of nicotine.
Euphoria is objectively defined by the observation that
administration of the drug, under controlled experimental
conditions, produces dose-related increases in scores on the Liking
scale of the Single-Dose Questionnaire, and scores on the Morphine
Benzedrine Group (MBG or Euphoria) scale of the Addiction Research
Center Inventory (ARCI) (Jasinski et al. 1984). In this study,
nicotine, like drugs known to be abused, produced significant
dose-related increases in scores on both the Liking and MBG scales
(Henningfleid and Jasinski 1982; Jasinski et al. 1984).
Additionally, intravenous injections of nicotine were most commonly
identified as a prototypic euphoriant drug (cocaine) by subjects
with extensive drug abuse histories.
These studies confirmed that nicotine produced critical functional
effects of tobacco smoke and that nicotine is a psychoactive drug
with properties of a euphoriant. These findings are consistent with
those obtained in animal drug discrimination studies in which it has
been shown that nicotine is readily discriminated and that its
discriminative properties are more stimulant-like than
depressant-like (cf.. review by Henningfield and Goldberg 1984).
Reinforcing Properties of Intravenous Nicotine
The ultimate test of whether nicotine is a dependence-producing drug
is, in the abstract, a very simple test: namely, to determine if
nicotine injections serve as positive reinforcers and thereby
strengthen behavior leading to their administration. Practically,
however, there are many difficulties in the safe and ethical conduct
of such a study, and the initial study was only completed about 2
years ago (Henningfield et al. 1983). The critical finding of this
study was that intravenously available nicotine was
self-administered by each of the subjects tested. Furthermore,
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patterns of self-administration were similar to those of humans
smoking cigarettes or of animals self-injecting cocaine in analogous
experimental preparations (Griffiths et al. 1980).
When saline was substituted for nicotine, patterns of injection were
irregular and total number of Injections generally was lower. In a
subject who stated that he disliked taking injections of any kind,
the pattern of acquistion was similar to that of animals which are
given access to intravenous nicotine for the first time (see
Goldberg et al. 1982): Number of injections gradually increased
across sessions; then, when saline was substituted for nicotine, the
number of injections rapidly declined across sessions. Subsequent
studies showed that nicotine was preferred to saline when both
substances were concurrently available (Henningfield and Goldberg
1983a); that mecamylamine pretreatment attenuated the nicotine
preference (Henningfield 1983); and that the lever was pressed as
many as 1600 times per nicotine injection (study in progress).
The human self-administration study findings are consistent with
animal studies in which nicotine has been shown to serve as a
positive reinforcer in a variety of species including primates and
nonprimates, and under a variety of experimental conditions (cf.
review by Henningfield and Goldberg 1983b). It is noteworthy that
establishment of nicotine as a reinforcer in animals eluded many
investigators until effective confluences of parameters were
discovered. Such Initial difficulty was not unique to nicotine but
also characterized initial efforts to determine whether or not
ethanol would serve as a reinforcer in animals (Melsch 1977).
CIGARETTE SMOKING AS A FORM OF DRUG DEPENDENCE: SUMMARY AND
IMPLICATIONS FOR NICOTINE-BASED CHEMOTHERAPY
Nicotine is a prototypic drug of abuse, and many cigarette smokers
are likely to be dependent. Strong, albeit circumstantial, evidence
was provided by observations of the many critical commonalities
between cigarette smoking and more commonly studied forms of drug
dependence. Direct evidence was that the drug itself (nicotine, in
isolation from tobacco smoke). was characterized by a profile of
pharmacologic effects typical of that of known drugs of abuse such
as opiates, stimulants, and alcohol. These data indicate that the
role of nicotine in cigarette smoking is similar to the role of
other constituent drugs of abused substances. That is, despite the
apparently lower biologic reinforcing efficacy of nicotine than some
of the more commonly studied drugs of abuse (Henningfield and
Goldberg 1983b), the functional role of nicotine in tobacco smoke is
similar to the role of cocaine in coca leaf use, to the role of
morphine in opium poppy use, to the role of tetrahydrocannabinol
(THC) in marijuana use, and to the role of ethanol in alcoholic
beverage consumption.
The perspective that cigarette smoking often occurs as a form of
drug dependence has specific implications for chemotherapeutic
treatment strategies. A variety of nonspecific chemotherapeutic
approaches to the treatment of cigarette smokers has been
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reported. Most provide little documented efficacy; they have been
reviewed elsewhere (Grabowski and Hall, this volume; Gritz and
Jarvik 1977; Jarvik 1977).
One specific chemotherapeutic approach for drug dependence is to
substitute a safer and more manageable form of the drug for the
substance of abuse. The ultimate goal of such an approach is
subsequently to withdraw the patient from the substituted drug. The
currently available substitution pharmaceutical is the nicotine
resin complex or nicotine chewing gum (American Hospital Formulary
Service 1984). Use of nicotine gum in treatment of cigarette
smoking is the subject of other chapters in this monograph and will
not be discussed in detail here. Rather, a few observations will be
made, following directly from the above-presented data, which show
that cigarette smoking is a form of drug dependence. In addition,
some preliminary data which bear on these observations will be
presented.
Effective chemotherapy of other kinds of drug dependence is complex
and involves systematic application of a variety of pharmacologic
and behavioral strategies (cf. Grabowski et al. 1983). A major
pharmacologic factor concerns the dose level of the chemotherapeutic
drug. Table 3 summarizes a few of these dose-related issues.
TABLE 3. Dose-related issues in chemotherapy of drug dependence
o Dose must be sufficient to provide relief of
withdrawal or deprivation effects.
o The rate of drug entry to the CNS is critical and
may determine whether the particular route of
administration used provides an acceptable
substitute.
o Patient compliance in taking the therapeutic agent
may vary as a function of dose.
o The degree to which nontherapeutic drug taking is
suppressed may vary as a function of dose.
The importance of control over dose suggested the need for further
study of such relations regarding the nicotine-delivering chewing
gum. Two issues were of interest. The first was the possible
functional effects of the rate at which individual pieces of gum
were chewed. Since the nicotine in the gum is bound to an
ion-exchange resin, chewing is required for its release; thus, rate
of chewing should be one determinant of the rate at which nicotine
is extracted from the gum. Results from a preliminary study of the
effects of chewing rate are described below. The second issue
concerned the fact that only one dose level of the gum is
commercially available. In preliminary studies we found that rates
of voluntary smoking were not affected by scheduled administration
of either placebo or 2 mg gum, but were suppressed when subjects
were given 4 mg gum (Jasinski et al. 1984; Nemeth-Coslett and
Henningfield 1985). Furthermore, in a subpopulation of
20
heavy-smoking male polydrug abusers, little subjective or
physiologic response was observed following administration of either
2 mg cr 4 mg gum. This observation suggested that, as is the case
with other therapeutic drugs. there is a wide range of individual
variability in response to a given dose, and that doses which are
not tolerated by some patients may be safe and even necessary for
others. Results from a preliminary study are also presented below in
which such subjects were given either two or four pieces of 4 mg gum
to chew.
PRELIMINARY STUDY: EFFECTS OF CHEWING RATE RESPONSE TO NICOTINE GUM
Four male subjects (average age = 34 years, range = 20-50)
participated while residing on a pharmacology research ward. Their
average weight was 75 kg (range = 67-100kg). and they smoked an
average of 30 cigarettes per day (range 20 to 40 cigarettes, each
delivering 1.1 mg nicotine). Mean scores on the Fagerstrom
Tolerance Questionaire (Fagerstrom 1978) were 10.0 (range = 9-11).
During predesignated days, each subject was cigarette deprived for 8
hours, after which time a l-hour test session was begun.
Physiologic and self-report measures were collected during the
initial 10 minutes of the test session. Subjects were then provided
with one 4 mg piece of nicotine gum (Nicorette) which they were
instructed to chew at a fixed rate for the next 10 minutes. Rates
were set at one chew every 1, 2, 4, or 8 seconds, and compliance was
assured by a nurse who observed that the subject was chewing in
response to a timed "beep" which had been pretaped on a recorder.
Each subject was exposed to the four different chew rates using a 4
x 4 Latin Square design. Most physiologic and self-reported
responses were measured at 5-minute intervals. Visual line analog
scores of positive ("pleasurable") and negative ("unpleasurable")
were collected at 15-second intervals for the first 240 seconds
after gum chewing and then at 5-minute intervals for the remainder
of the test session. Additionally, measures of expired air carbon
monoxide level were collected immediately before and after each
session.
Preliminary analysis of the data suggests that chewing rate altered
magnitude and duration of self-reported effects of the gum. Figure
1 shows the total visual line analog score (sum of negative and
positive responses) at each observation for subject CO. Variability
across subjects was considerable, however, and precluded meaningful
lumping together of the data. No chewing rate produced significant
increases on scales of the Addiction Research Center Inventory or
the Single-Dose Questionnaire (Jasinski et al. 1984).
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MINUTES POST-GUM
FIGURE 1. Values of self-reported scores on a
visual line analog scale, summed from both pos
negative effects, as a function of chewing rate
the gum was chewed (x-axis).
lo-centimeter
itive and
and time after
This study suggests that chewing rate does make a difference in the
response to gum-delivered nicotine. It also raises several
additional issues, some of which are being addressed in an ongoing
study in which the amount of nicotine extracted from the gum, and
nicotine plasma levels, will be assessed. An immediate implication
is that the same kinds of difficulties in quantification of
dose-response relations which occur when subjects are given
cigarettes to smoke under uncontrolled conditions may arise when
subjects are given gum to chew with no specification of the rate at
which It is to be chewed.
PRELIMINARY STUDY: HIGH DOSES OF NICOTINE GUM
This study assessed the safety and effects of nicotine in subjects
who were known to be relatively insensitive to 2 mg gum. The
average age of the subjects was 33 years (range = 23-53). and they
had smoked an average of 13 years (range = g-17). Their mean score
on the Fagerstrom Tolerance Questionaire was 9.7 (range = 8-11).
Subjects chewed either two or four pieces of 4 mg gum (total
nicotine dose either 8 mg or 16 mg). Each piece of gum was chewed
at a rate of 1 chew every 2 seconds for 10 minutes. Two subjects
were tested at each of the dose levels twice a day for 2 days while
two other subjects received one dose a day for 2 days. Immediately
following gum chewing, subjects were asked to report verbally any
side effects, their liking for the gum, and to rate the strength of
the gum. Additionally, a staff nurse was required to record any
observable signs or symptoms displayed by the subject.
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The most common signs reported by the staff nurse were belching and
hiccups. which showed a slight increase following exposure to 16 mg
when compared to 8 mg. Other signs included restlessness, watery
eyes, and irritability. However, for the six observations collected
at each of the two doses, no observable effect was noted on four of
the occasions following B mg chewing, and no effect was noted on two
occasions following 16 mg chewing.
Subjects reported nausea and throat irritation more than any other
symptoms. One subject reported no effect at either the 8 mg or 16
mg dose. Other complaints included nervousness, dizziness,
headache, and heartburn. There was little increase at the 16 mg
dose when compared to the 8 mg dose. Two subjects reported a
dose-related increase in magnitude of effects between 8 mg and 16
mg, and three of the four subjects said that they would not
voluntarily chew four pieces again but would chew two pieces. Two
of these three subjects reported effects similar to those produced
when marijuana was smoked ("high") at both doses and reported liking
the feeling. The fourth subject reported no effects at either dose
and identified the drug as placebo ("blank").
This study showed that high doses of nicotine-delivering chewing gum
can be safely given. It is not clear what specific subject
characteristics determine the tolerable dose level. For example,
both body weight and level of nicotine intake would be factors of
suspected importance. It is also remains to be determined whether
high doses are of greater therapeutic efficacy for this population
of cigarette smokers. The high doses produced some effects
characteristic of those produced by drugs of abuse ("high"), but did
not elevate scores on objective scales used to quantitate abuse
liability.
DISCUSSION
A variety of theoretical, social, and treatment implications result
from the identification of cigarette smoking as a form of drug
dependence which is functionally similar to other forms of drug
dependence. One implication related to nicotine-based chemotherapy
is the role of dose, whether altered by chewing rate or by amount of
nicotine-containing gum that is chewed. The results of the
preliminary studies which were described raised more questions than
they answered. However, some tentative conclusions may be drawn.
First, rate of chewing may have functional consequences with regard
to the effects produced by the gum. Second, subjects can tolerate
higher chew rates and gum dosage levels than are typically employed
in current treatment approaches (e.g.. Hughes and Miller 1984).
The observation that manipulations which affect the effective dose
of a chemotherapeutic agent may have functional consequences is not
surprising. Dose is a critical factor in other kinds of
chemotherapy, and studies with nicotine in human and animal subjects
show that nicotine's effects are dose related. Additionally,
clinical observations (e.g.. one patient's description of how he
used the nicotine gum: "I chew quick till I get the taste, then I
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taper off") suggest that some patients have discovered on their own
that chewing rate makes a difference in the effects of the gum.
What is surprising is the lack of attention paid to dose in many
studies of the behavioral pharmacology of the gum and of its
treatment efficacy.
The finding that cigarette smoking may occur as a form of drug
dependence offers exciting possibilities, burdens, and hope:
Possibilities of applying chemotherapeutic treatment strategies to
the treatment of cigarette smoking; the burdens of closely examining
existing cigarette treatment programs and applying fundamental
principles from drug dependence and alcoholism programs; and hope
that these efforts will improve on the past rather dismal treatment
programs. As shown by Hall and Killen elsewhere in this monograph.
treatment approaches which apply both behavioral and pharmacologic
treatment strategies are more effective that those which address
only the pharmacologic or the behavioral aspects of tobacco
dependence.
ACKNOWLEDGMENT
Dr. R. Nemeth-Coslett is supported
Pharmaceutical Company through the
in the Sciences. The provision of
Merrell Dow Pharmaceutical Company
gratefully acknowledged.
REFERENCES
at NIDA/ARC by the Merrell Dow
Foundation for Advanced Education
the nicotine and placebo gum by
for the studies reported here is
American Hospital Formulary Service. Drug Information
84 (Supplement B). Bethesda, Maryland: American Society of
Hospital Pharmaceuticals, 1984. pp. 39B-44B.
Benowitz, N.L. Biochemical measures of tobacco smoke
consumption. In: Grabowski, J., and Bell, C.. eds. Measurement
in the Analysis and Treatment of Smoking Behavior. National
Institute on Drug Abuse Research monograph 48. DHHS Pub. No.
(ADM) 83-1285. Washington, D.C.: Supt. of Docs., U.S. Govt.
Print. Off., 1983. pp. 6-26.
Goldberg, S.R.; Spealman, R.D.; and Goldberg, D.M.
Persistent high-rate behavior maintained by intravenous
self-administration of nicotine. Science, 214:573-575, 1981.
Grabowski, J.; Stitzer, M.L.; and Henningfield. J.E.,
eds. Behavioral Intervention Techniques in Drug Abuse
Treatment. National Institute on Drug Abuse Research Monograph
46. DHHS Pub. No. (ADM) 84-1282. Washington, D.C.: Supt. of
Docs., U.S. Govt. Print. Off., 1984.
Griffiths, R.R.; Bigelow, G.E.; and Henningfield, J.E.
Similarities in animal and human drug taking behavior. In:
Mello, N.K., ed. Advances in Substance Abuse: Behavioral and
Biological Research. Greenwich, CT: JAI Press, 1980. pp. 1-90.
Gritz, E.R. Smoking behavior and tobacco abuse. In:
Mello, N.K., ed. Advances in Substance Abuse: Behavioral and
Biological Research. Greenwich, CT: JAI Press, 1980. pp.
91-158.
24
Gritz, E.R., and Jarvik, M.E. Pharmacological aids
for the cessation of smoking. In: Steinfield, J.; Griffiths,
w.; Ball, K.; and Taylor, R.M., eds. Proceedings of the Third
World Conference -- Smoking and Health, Vol. II. Washington,
D.C.: Supt. of Docs. U.S. Govt. Print. Off., 1983. pp. 575-591.
Henningfield, J.E. Measurement issues in cigarette
smoking research: Basic behavioral and physiologic effects and
patterns of nicotine self-administration. In: Grabowski, J.,
and Bell, C.. eds. Measurement In the Analysis and Treatment of
Smoking Behavior. National Institute on Drug Abuse Research
Monograph 48. DHHS. Pub. No. (ADM) 83-1285. Washington, D.C.:
Supt. of Docs., U.S. Govt. Print. Off., 1983. pp. 27-38.
Henningfield, J. E. Behavioral pharmacology of cigar-
ette smoking. In: Thompson, T., and Dews, P.B. eds. Advances
in Behavioral Pharmacology, vol. IV, in press.
Henningfield, J.E., and Goldberg, S.R. Control of
behavior by intravenous nicotine injections in human subjects.
Pharmacol Biochem Behav 19:989-992, 1983 (a).
Henningfield, J.E., and Goldberg, S.R. Nicotine as a
reinforcer in human subjects and laboratory animals. Pharmacol
Biochem Behav 19:1021-1026, 1983 (b).
Henningfield, J.E., and Goldberg, S.R. Behavioral
Pharmacology: The Current Status. Seiden, L.S., and Balster,
R.L., eds. New York: Alan R. Liss, 1984.
Henningfield, J.E.; Griffiths, R.R.; and Jasinski,
D.R. Human dependence on tobacco and opioids: Common factors.
In: Thompson, T.. and Johanson. C.E., eds. Behavioral
Pharmacology of Human Drug Dependence. National Institute on
Drug Abuse Research Monograph No. 37. Washington, D.C.: Supt.
of Docs., U.S. Govt. Print. Off., 1981. pp. 210-234.
Henningfield. J.E.; Myasato, K.; and Jasinski, D.R.
Abuse liability and pharmacodynamic characteristics of
intravenous and inhaled nicotine. J Pharmacol Exp Ther, in
press.
Henningfield, J.E.; Miyasato, K.; and Jasinski, D.R.
Cigarette smokers self-administer intravenous nicotine.
Pharmacol Biochem Behav 19:887-890, 1983.
Henningfield, J.E.; Miyasato, K.; Johnson, R.E.; and
Jasinski, D.R. Rapid physiologic effects of nicotine in humans
and selective blockade of behavioral effects by mecamylamine.
National Institute on Drug Abuse Research Monoaraph 43.
Problems of Drug Dependence 1981. Washington,-D.C.: Supt. of
Docs., U.S. Govt. Print. Off.. 1982. pp. 259-265.
Hughes, J. R., and Miller, S. A. Nicotine gum to help
stop smoking. JAMA, in press.
Jaffe, J.H., and Kanzler, M. Smoking as an addictive
disorder. In: Cigarette Smoking as a Dependence Process.
National Institute on Drug Abuse Research Monograph 23. DHEW
Pub. No. (ADM) 79-800. Washington, D.C.: Supt. of Docs. U.S.
Govt. Print. Off., 1979, pp. 4-23.
Jarvik, M.E. Can drug treatment help smokers? In:
Steinfeld, J.; Griffiths, W.; Ball, K.; and Taylor R.M., eds.
Proceedings of the Third-World Conference -- Smoking and Health,
Vol. II. Washington, D.C.: Supt. of Docs. U.S. Govt. Print.
Off., 1977. pp. 509-513.
25
485-874 o - 85 - 2
Jasinski, D.R.; Johnson. R.E.: and Henningfield, J.E.
Abuse liability assessment in human subjects: Trends in
Pharmacol Sci 5:196-200, 1984.
Kozlowski, L.T.; Rickert, W.S.; Robinson, J.C.; and
Grunberg, N.E. Have tar and nicotine yields of cigarettes
changed? Science 209:1550-1551, 1980.
Lukas, S., and Henningfield, J.E. EEG correlates of
physiological and behavioral effects of intravenous nicotine in
humans. Paper presented at the 2nd World Conference on Clinical
Pharmacology and Therapeutics, Washington, D.C., 1983.
Meisch, R.A. Ethanol self-administration: Infrahuman
studies. In: Thompson, T., and Dews, P. B. eds. Advances in
Behavioral Pharmacology. New York: Academic Press, 1977. pp.
35-84.
Nemeth-Coslett, R., and Henningfield, J.E. Dose-
related effects of nicotine delivering chewing gum on rate of
cigarette smoking. Manuscript in preparation, 1985.
U.S. Department of Health and Human Services, Public
Health Service. Why People Smoke Cigarettes. Washington,
D.C.: Supt. of Docs. U.S. Govt. Print. Off., 1983.
AUTHORS
R. Nemeth-Coslett
Jack E. Henningfield
National Institute on Drug Abuse
Addiction Research Center
4940 Eastern Avenue
c/o Baltimore City Hospitals
Baltimore, Maryland 21224
26
The Titration Hypothesis
Revisited: Nicotine Gum Reduces
Smoking Intensity
Ronald I. Herning, Ph.D., Reese T. Jones, M.D.,
and Patricio Fischman, M.D.
INTRODUCTION
Smokers alter puffing and inhalation patterns in response to
changes in the characteristics of the cigarettes they smoke.
Increasing ventilation or decreasing draw resistance increases
smoking intensity (Dunn 1978; Sutton et al. 1978; Henningfield
and Griffiths 1980). Shortening cigarette length increases
puffing rate and the total number of cigarettes smoked (Goldfarb
and Jarvik 1972; Gritz et al. 1976; Ashton et al. 1978; Russell
et al. 198Oa). When smokers take more puffs per cigarette, the
intercigarette interval increases (Griffiths et al. 1982). When
forced to smoke at more frequent intervals, they reduce puff
volume (Gritz et al. 1983). Smokers who switched from middle to
low tar cigarettes increased their puff size and a mathematically
derived exposure index, but not the number of puffs, puff dura-
tion, interpuff interval, or butt length (Pawbone et al. 1978).
Decreasing the machine-determined nicotine yield of cigarettes
increased the number of cigarettes smoked in the 16 studies
reviewed by Stepney (1980). Decreasing machine-determined nico-
tine delivery of cigarettes smoked increases puff volume (Adams
1978; Creighton and Lewis 1978; Herning et al. 1981; Gust and
Pickens 1982). Only Dunn and Freiesleben (1978) reported no
relationship between puff volume and decreased machine nicotine
delivery.
These studies support the nicotine titration hypothesis. That is,
smokers adjust their smoking patterns to obtain an optimal dose of
nicotine from whatever cigarette they are smoking. Presumably,
this dose produces some optimal blood or brain level of nicotine.
Had nicotine blood levels been measured in these studies, the
titration hypothesis might have been confirmed.
Studies where smokers were given cigarettes of different machine-
determined yields and nicotine blood levels were obtained do not
appear to support the titration hypothesis. When smokers are
switched from mid-nicotine yield cigarettes to high machine yield
cigarettes, nicotine blood levels are higher (Ashton et al. 1979,
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1981; Benowitz et al. 1982). when smokers are switched from mid-
to low-yield cigarettes, the corresponding blood levels decrease
(Russell et al. 1972; Ashton et al. 1979 1981; Benowitz et al.
1982). If smokers actually titrate, the nicotine blood levels for
the different cigarettes should be similar. However, only Russell
et al. (1972) found equal blood levels when cigarettes yielding
1.32 mg and 3.2 mg nicotine were compared. Hill and Marquardt
(1980) noted similar nicotine metabolite levels (cotinine) when
tar and nicotine machine yield were manipulated.
Thus, these cigarette-switching studies have adequately demon-
strated that subjects change puffing patterns in the direction
predicted by the titration hypothesis, but they have failed to
show that the adjustment leads to similar blood levels. The
interpretation of these studies is complicated because high- and
low-yield commercial cigarettes contain equivalent amounts of
nicotine (Renowitz et al. 1983), and blood nicotine or cotinine
levels do not correlate with machine yield of nicotine in large
samples of smokers (Russell et al. 1980b; Benowitz et al. 1982;
Herning et al. 1983b).
Supplemental nicotine or pharmacological manipulations which modu-
late nicotine's effects or its excretion alter smoking patterns.
Oral doses of nicotine or infusions reduced smoking (Johnston
1942; Lucchesi et al. 1967; Jarvik et al. 1970). Stolerman et al.
(1973) found mecamylamine, a nicotine antagonist, increased smok-
ing rate. Naloxone, an opiate antagonist, reduced the number of
puffs on a cigarette as well as the number of cigarettes smoked
per day (Karras and Kane 1980). The manipulation of urinary pH
to alter nicotine excretion modified cigarette smoking (Schachter
et al. 1977). Except for a study by Kumar et al. (1977, experi-
mental alterations which either blocked nicotine effects or
increased nicotine blood levels produced the expected changes in
smoking behavior.
The latter studies provide support for the nicotine titration
hypothesis and support the use of supplemental nicotine as adjunct
to smoking cessation therapy. Slow release buffered nicotine gum
(Nicorette) now available provides the researcher another oppor-
tunity to test thenicotine titration hypothesis in controlled
laboratory studies. The previous studies giving supplemental
nicotine did not measure nicotine blood levels. Although smoking
behavior changed, there is no evidence that the experimental mani-
pulation produced similar nicotine blood levels. If subjects are
indeed titrating nicotine, blood levels should be equal when
supplemental nicotine and placebo are given. The present study
evaluates whether smokers given placebo or nicotine gum reduce
the intensity with which they smoke as compared with smokers given
placebo and whether blood levels are reasonably similar on nico-
tine and placebo gum test sessions.
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METHODS
Subjects
One female and five males served as subjects. They were 31.7 ±
3.3 (mean and standard deviation) years old The subjects smoked
30.8 ± 7.4 cigarettes per day with 6.0 ± 26 of these cigarettes
smoked in the morning. All subjects had smoked for at least 10
years and smoked their current brand for 2 years or more. The
machine-determined nicotine yield of their current cigarette was
1.14 ± 0.19 mg. They smoked their current brand during each of
the two ad lib smoking sessions.
Experimental Procedure
During each of two morning sessions, the subjects smoked their
self-selected brand of cigarette while chewing either nicotine or
placebo gum in a counterbalanced order. The subjects were asked
to remain abstinent from cigarette smoking from the night before.
The experimental sessions lasted 4 hours. The subject sat in a
comfortable reclining chair during this time and either read or
listenedto music. During this period the subject could smoke at
anytime. Before and 2 minutes after smoking, blood was drawn for
nicotine &terminations. Expired breath samples were collected 10
minutes after each cigarette and tested for carbon monoxide level.
During smoking, puff and inhalation patterns were monitored (see
below). During the first half hour of each hour the subjects
chewed either placebo gum or gum containing 2 mg of nicotine in a
buffered slow release resin (Nicorette, supplied by Merrell Dow)
according to the instructions in the package insert. Before and
25 minutes after chewing, blood was drawn for nicotine levels.
During a given morning session, each subject received four pieces
of one type of gum or the other. The gum was administered in a
double-blind fashion The lab sessions were separated by 5 or
more days. Heart rate and blood pressure were measured at half-
hour intervals.
Measurement of Smoking Patterns
Puff volume and duration were measured by a single transducer
flow meter. The flow meter consists of a plastic cigarette holder
connected via flexible tubing to a Statham pressure transducer
(Model PM5TC). Each cigarette smoked was precalibrated with known
air flows, as in our previous studies (Herning et al. 1981 1983a,b).
Inhaled volume and duration were measured by an Ambulatory Moni-
toring inductance plethysmograph Respitrace). The plethysmograph
was calibrated with a Collins (Model 06031) water spirometer using
the method described by Watson (1979).
The analog signals from the flow meter and plethysmograph were
digitized every 40 ms from start of the puff for a period of 8
seconds. Puff and inhalation measures were numerically calculated
from digital values. We calculated puff volume from flow using
numerical integration which involves dividing the area under the
flow curve into small trapezoids. These trapezoids are then added
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together to obtain volume. Puff duration is the interval from
start to end of puff where the flow values are nonxero. Inhaled
volume is volume at maximal inhalation after a puff. The duration
of inhalation is interval from start of the puff to maximal inha-
lation. Thus, it is half the actual duration of inhalation. Puff
and inhalation duration were measured to the nearest 1/25 of a
second while interpuff interval was measured to the nearest second.
Biochemical Measures
Blood samples were drawn from a forearm vein at half-hour inter-
vals, immediately before smoking, and 2 minutes after the last
puff. Samples were assayed for nicotine using the gas chromate
graphic method described by Jacob et al. (1981). An Ecolyzer
(Series 2000) monitor was used to determine the CD levels from the
expired breath samples.
Data Analysis Concerns
We hypothesized that the subjects would reduce the frequency and
intensity of smoking when given nicotine gum compared to placebo.
Since our hypothesis implied the direction each measure would
change when the subjects chewed nicotine gum, one-tail probability
values were appropriate for the t-test on these smoking measures.
For example, our hypothesis tests especially for reduction in the
number of cigarettes smoked on the nicotine gum day as compared to
the placebo day.
We also hypothesized that nicotine blood levels would be equal on
both test days. Thus, in such a test the area under the nicotine
blood level curves (AUC) on both sessions should be equal. This
statistical test is a test of the null hypothesis. Such a test
presents some statistical problems. The lack of differences, if
observed, could be due to excessive variability in the measures or
to no actual difference in the means. One cannot be sure. One
method to protect against this problem is basing the test against
the null hypothesis by adjusting the probability levels to make
finding a difference easier. Thus, for the test on nicotine AUC,
a probability level of 0.10 was used. An additional problem in
testing whether nicotine blood levels are equal revolves around
the issue of what is a biologically significant difference in
levels. Certain differences in the WC may be found, but are they
biologically important? Thus, testing the titration hypothesis
has some practical problems.
RESULTS
The area under the curve (AUC) for nicotine tended to be higher
during the nicotine gum session (2945 ng•min•ml-1) as compared to
the placebo gum session (1925 ng•min•ml-1). This difference was
significant (t=2.16, df=l,5, p<.10) at the increased probability
level. That is, our test subjects appear not to be titrating.
The individual nicotine curves are presented in figures 1, 2, and
3. Before it was concluded that the subjects were not titrating,
an unexpected complication was noted. Three of the subjects had
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FIGURE 1. Nicotine blood level curves for Subjects 1 and 2. Bars
indicate placebo or nicotine gun chewing periods.
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FIGURE 2. Nicotine blood level curves for Subjects 3 and 4. Bars
indicate placebo or nicotine gun chewing periods.
32
FIGURE 3. Nicotine blood level curves for Subjects 5 and 6. Bars
indicate placebo or nicotine gun chewing periods.
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higher blood nicotine levels on the gum day. These subjects
smoked all or the majority of their cigarettes during the nicotine
session while actually chewing the nicotine gum. Both theactive
and placebo gum have an alkaline buffer which increases buccal
absorption of the nicotine. These subjects were perhaps obtaining
more nicotine with the gum than they might have without chewing
it We tested for this possibility. A two factor analysis of
variance with gum (placebo versus nicotine) and smoking period
(chewing versus not chewing) as factors was used to test for any
differential increase in nicotine blood levels while chewing gum
The increase in nicotine blood levels with smoking was signifi-
cantly (F=4.4, df=1,53, p<.05) larger when the subjects were
chewing gum (8.0 mg/ml) than when they were not chewing (5.1
mg/ml). Thus, regardless of the type of gum, nicotine blood
level increased more during periods of gum chewing. Under such
unexpected nicotine delivery conditions, titration may have been
difficult.
Smoking patterns were modified by the nicotine gum. The mean
number of cigarettes smoked during the I-hour session was signifi-
cantly less (t=2.23, df=5, p<.05, one-tailed) for the nicotine gum
(4.3) than the placebo gum session (5.3). Mean interpuff inter-
val, puff volume, puff duration, inhaledvolume, and inhaled dura-
tion are listed in table 1 for all subjects on both test sessions.
The means are calculated from all puffs during a given session.
To simplify the analysis of these measures, a single exposure
index (EI) was calculated for each session from equation (1).
where N equals the number of cigarettes smoked.
Each EI is calculated by (2) for each cigarette.
EIi=(b0+b1•MDOSEi+b2•NPi+b3•IPIi+b4•PVI+b5•PDi+b6•IVi+b7•IDi) (2)
MDOSEi = machine determined yield for cigarette i
Npi = number of puffs for cigarette i
IPIi = interpuff interval for cigarette i
PVi = puff Volume for cigarette-i
PDi = puff duration for cigarette i
IVi = inhalation volume for cigarette i
IDi = inhalation duration for cigarette i
The b0, b1 . . . b7 were derived from a multiple regression of the
above measures used to predict the increase blood  nicotine levels
in a large sample (N=104) of smokers used in our previous study
(Herning et al. 1983b). Thus, the bi's were calculated from an
independent sample of subjects. The bi's were 15.35, 8.35, -0.18,
-0.25, 0.12, -3.06, -4.46, and 0.59, respectively.
34
TABLE 1
Mean Smoking Patterns for Placebo and Nicotine Gum Session
No. of
Smoking Measure
Subject Type Cigar- No. of Interpuff Puff Inhaled
Number of Gum ettes Puffs Interval volume Duration Volume Duration
(sec) (ml) (sec) (L) (sec)
1 Placebo 6 51
Nicotine 4 36
2 Placebo 8 7 4
Nicotine 7 73
3 Placebo 6 43
Nicotine 5 38
4 Placebo 3 34
Nicotine 4 48
5 Placebo
Nicotine
6 Placebo
Nicotine
Placebo
Nicotine
4
3
5
3
5.3±
1.7
4.3±
1.5
22
20
46
33
45.0±
17.5
41.3±
18.0
51.5±17.7
54.1±20.2
37.4±20.0
29.±15.3
54.2±35.3
45.7±27.1
39.5±25.5
29.6±17.1
71.8±28.0
66.1±42.9
45.5±28.6
38.1±30.2
49.3±14.8
43.1±16.5
49.1±16.1
58.±20.6
54.9±15.8
41.7±15.4
43.8±18.6
46.2±21.3
45.7±12.7
49.2±8.8
65.8±24.5
83.2±28.6
22.1±8.7
18.6± 6.7
47.2±14.6
49.9±19.6 1.9±0.5
2.2±0.6
2.4±0.6
1.8±0.5
1.7±0.7
1.8±0.7
2.1±0.9
1.6±0.7
1.5±0.4
2.1±0.7
2.2±0.6
1.2±0.4
1.1±0.4
1.8±0.4
0.68±0.22
0.46±0.16
0.67±0.15
0.44±0.12
0.45±0.10
1.77±0.64
0.82±0.47
1.32±0.47
1.14±0.64
1.67±0.73
0.42±.14
0.58±0.23
0.68±0.35
1.03±0.70
2.7±0.5
3.1±0.6
4.6±1.2
4.4±1.4
3.2±0.8
3.9±1.4
4.0±1.3
3.4±0.8
5.0±1.3
4.8±2.0
4.4±2.0
3.3±1.5
4.1±1.1
3.8±0.8
The EI for the placebo session (81.6) was significantly larger
(t=2.l4, df=5, P<.05) than the corresponding EI (63.6) for the
nicotine gum session. The area under the curve for CO tended to
be lower on the nicotine session (2222 PPM•sec) than the placebo
session (2606 PPM•sec), but the difference in means was not signi-
ficant. Although CO did not clearly indicate increased smoking on
the placebo day, it paralleled the EI measure. The values for
each subject are plotted in figure 4. Points below the diagonal
line indicate an increase in the intensity of smoking on the
placebo day. Points above the diagonal line indicate an increase
in the intensity of smoking on the nicotine day. Distance from
the diagonal line indicates the magnitude of change. The plots
are remarkably similar. Subject 4 is the only smoker not reducing
his smoking behavior while on the nicotine chewing gum.
Heart rate (F=4.65, df=9,45, P<.05) increased over the smoking
session from a pre mean of 62.9 to a maximum of 69.2. No differ-
ence in the increase was observed on the two test sessions. The
changes in systolic blood pressure over a given session or over
both sessions were not statistically significant from the pre
test. Diastolic blood pressure increased with smoking from a pre
mean of 69.3 to a maximum level of 75.2. This increase, although
significant (F=3.17, df=9,45, p<.05), was similar on both test
sessions. The maximal increase for both heart rate and diastolic
blood pressure occurred at the 2-hour sample No further in-
creases were observed.
DISCUSSION
Nicotine chewing gum reduced the frequency and intensity of
smoking in our subjects. The change in smoking behavior was
reflected in a composite index of number of puffs, inter-puff
interval, puff volume, puff duration, inhaled volume and duration.
A decrease in carbon monoxide was also observed, but the differ-
ence in CO AUC between sessions was not statistically different.
The composite exposure index appeared to be the more sensitive of
the two measures. Since the composite index weights all aspects
of smoking behavior, individual differences in regulation can be
taken into account. However, a very simple measure of smoking,
that is, number of cigarettes smoked, was also significantly
reduced. Whether smoking behavior measures were simple or COm-
plex, our subjects smoked less on the nicotine gum session than
on the placebo session.
The reduction in smoking is similar to that found by Johnston
(1942) and Lucchesi et al. (1967) with intravenous doses of nico-
tine and by Jarvik et al. (1970) with nicotine tablets. It is
unclear why Kumar et al. (1977) did not find such a reduction in
smoking intensity. One possible reason is that the subjects in
the Kumar experiment were not abstinent before testing as were
the subjects in other studies and thus were relatively nicotine
satiated at the time of testing.
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P L A C E B O  G U M
FIGURE 4. The CO AUC values (top) and exposure index values
(bottom) are plotted for each subject on both test sessions.
The placebo session values are plotted on the x-axis and nicotine
session values are plotted on the y-axis. Each point is labeled
with a subject number. Values below the diagonal indicate in-
creased smoking intensity on the placebo day.
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In previous studies testing the titration hypothesis by admin-
istering supplemental nicotine while the subjects were free to
smoke, nicotine blood levels were not measured. If subjects are
titrating, one might expect the nicotine blood levels to be
similar in sessions where supplemental nicotine was given and
sessions where no supplemental nicotine was administered. Despite
variability, the nicotine levels were higher in the nicotine gum
session at the 0.1 level of significance The increase in nico-
tine levels was due to half the subjects smoking their cigarette
while chewing gum on nicotine sessions. The gum (both placeboand
nicotine) changed the pH of the mouth which resulted in increased
nicotine absorption. The increased nicotine absorption may have
made titration more difficult.
Since only six subjects were tested, these results mayor may
not generalize to a heterogeneous sample of smokers. Different
results might he obtained with less dependent or older, more
dependent smokers Cur sample of smokers were in their late
twenties and early thirties, had smoked for 10 years, and were
now smoking one and a half to two packs a day.
In our study, the nicotine AUC was different between sessions.
However, differences in nicotine blood levels between the two
experimental sessions did not produce significant cardiovascular
changes between sessions. Thus, it could be argued that the
differences in blood levels between sessions were not physio-
logically meaningful. Smokers may have a range of blood levels
which are sufficient to produce the cardiovascular andsubjective
effects they desire or to reduce the withdrawal symptoms they seek
to avoid. Precise titration to identical blood levels may not be
necessary.
SUMMARY
Supplemental nicotine gum reduced the intensity of smoking in six
one-and-a-half to two-pack-a-day smokers. The study involved two
4-hour self-paced smoking sessions where nicotine and placebo
chewing gum were administered in a double-blind fashion. Puff
volume, puff duration, inhaled volume, inhaled duration, and
interpuff interval were calculated for each puff on each cigar-
ette. Blood was drawn for nicotine levels at regular intervals as
well as before and after each cigarette Cardiovascular measures
were made at regular intervals. The nicotine gum reducedsmoking
frequency and intensity as predicted by the titration hypothesis.
Precise titration (i.e., equal nicotine blood levels on both test
days) was confounded by changes in smoked nicotine delivery pro-
duced by the gum. The gum, whether placebo or active, increased
smoked nicotine absorption. However, while nicotine blood levels
were slightly higher on nicotine gum day, the differences may not
be biologically meaningful since heart rate and blood pressure
increases were similar on both days. Difficulties testing the
titration hypothesis are discussed.
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Cardiovascular Effects of Nicotine
Gum and Cigarettes Assessed by
ECG and Echocardiography
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INTRODUCTION
Cigarette smoking is one of the most firmly established risk
factors for coronary heart disease (Kannel 1981). This risk can
be dramatically reduced by discontinuation of cigarette smoking
(Doll and Peto 1976; Hammond and Garfinkle 1969; Kannel 1981).
Unfortunately, smoking cessation programs have low long-term suc-
cess rates (Evans and Lane 1980; Raw 1978; Schwartz 1979).
Several investigators attribute the maintenance of smoking
behavior to a dependence upon nicotine (Gritz 1980; Jarvik 1970;
Russell 1980). Nicotine induced withdrawal symptoms and nicotine
seeking may account for cessation difficulty and high relapse
rates. Nicotine chewing gum was introduced as a means of treating
the pharmacological dependence during cessation of smoking (Ferno
et al. 1973). The 4 mg dose results in blood levels of nicotine
similar to a cigarette although without the “bolus” effect (see
Russell and Jarvis in this volume). The 2 mg dose results in even
lower blood levels. The purpose of using nicotine gum is to
prevent abrupt withdrawal from nicotine and consequent symptoms
and craving while supplying a substitute oral activity. Several
recent studies attest to its efficacy in the alleviation of
withdrawal (Hughes et al. 1984; Schneider et al. 1984; West 1984).
Enhanced success rates in smoking cessation have been demonstrated
in a number of recent placebo-controlled trials (Fagerstrom 1982:
Hjalmarson 1984; Jarvis et al. 1982; Killen et al. 1984; Schneider
et al. 1983). Since its introduction in the United States in
1984, this preparation is now widely available by prescription for
the treatment of smoking dependence.
The purpose of this study was to examine and compare the acute
effects on the cardiovascular system of nicotine delivered by
smoking cigarettes versus chewing nicotine gum. Low and high
nicotine cigarettes (0.2 mg and 2 mg) and 2 mg and 4 mg nicotine
gum formed the four treatment conditions with each subject serving
as his own control for all conditions. Cardiovascular evaluation
included blood pressure, heart rate, electrocardiographic
monitoring, and N-mode echocardiography, performed before and at
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intervals up to 90 minutes after nicotine was introduced in eith
form to healthy male smokers. Psychological responses wer
elicited to determine whether there were any subjective response
to treatment.
MATERIALS AND METHODS
Subjects
Fourteen paid volunteers were obtained through advertisements i
the UCLA school newspaper. Subjects selected were males wh
smoked at least one pack a day for two years or more and who wer
healthy and active. Exclusion criteria included any history o
cardiac, respiratory, gastrointestinal, or peripheral vascula
disease. Subjects were required to be free of medications. On th
first day of the study, a brief medical history was taken and
pertinent physical examination was performed on each subject by
cardiologist. This was followed by obtaining a resting bloom
pressure (BP) measurement, a 12-lead electrocardiogram (ECG), an
an M-mode echocardiogram (ECHO). If these tests were all withi
normal limits and the echocardiogram was easily obtainable and o
good quality technically (i.e. the subject was echogenic), the
subject was recruited for an additional four days of study. Si
males, ages 23 to 32 (mean age 27.3 ± 3.6 years), formed the final
study group. Subjects smoked an average of 26 ± 5 cigarettes pe
day for an average of 8.8 ± 5.1 years. Results of the
cardiovascular tests were available to subjects' physicians upo
request.
Materials
High nicotine (2.0 mg) and low nicotine (0.2 mg) cigarettes were
provided by the National Cancer Institute. Merrell Dow Pharma-
ceuticals of Indianapolis, Indiana, provided 2 mg and 4 mg nico-
tine gum which was manufactured by A.B. Leo in Sweden. The gum
(Nicorette) contained nicotine bound to an ion exchange resin
which permitted the controlled release of nicotine. The gum was
buffered to allow for rapid absorption through the buccal mucosa.
Chewed gum was sealed in plastic containers and returned to
Merrell Dow Pharmaceuticals for determination of residual nico-
tine. The residual amount was then subtracted from the initial
dose to estimate the nicotine dose delivered.
Measurements
Cardiovascular measurements were taken in the supine position. A
sphygmomanometer was used to obtain the systolic and diastolic
blood pressure (BP) from the right arm in mm mercury (Hg). The
mean BP was calculated as the difference between the systolic and
diastolic BP, divided by three, and added to the diastolic BP.
Electrocardiograms were taken with a Hewlett-Packard
electrocardiograph. Standard echocardiographic techniques were
used to obtain M-mode echocardiograms. The following measurements
from the echocardiogram were made in triplicate and averaged wing
a mini-computer (ECHO COMP by Digisonics, Inc., Houston, Texas):
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1) left ventricular end-diastolic dimension (LVEDD) in mm at the
onset of the R wave of the simultaneously recorded
electrocardiographic lead II; 2) left ventricular end-systolic
dimension (LVESD) in mm; 3) left ventricular ejection time
(LVET) in seconds from the duration of aortic valve systolic
opening; and 4) heart rate. From these measurements the left
ventricular fractional shortening percent (FS%=LVEDD-LVESD/LVEDD)
and velocity of circumferential fiber shortening (VCF=FS%/LVET)
were calculated.
Carbon monoxide levels were measured by having the subject hold
his breath for 20 seconds and then exhale into a carbon monoxide
(CO) collection bag. The CO level was measured in parts per
million on an Ecolyzer. A baseline CO level was taken on the
first day of the study before the subjects were asked to abstain
from smoking after 12 am on the day of study. On the following
four treatment days, CO levels were obtained prior to treatment
after abstinence from cigarettes for at least 11 hours and at 10
and 90 minutes after the beginning of each treatment.
psychological measures were obtained to determine whether subjects
experienced subjective state changes over time and across
treatments. Four items were tested on a lo-point verbal scale. The
four items were: Are your hands shaky? Is your heart beating
faster? Do you feel more alert? and Do you feel lightheaded?
This scale was used previously and found sensitive to subjective
changes from pre- to post-smoking (Schneider 1978). On the 10-
point scale 1 represented “not at all" and 10 represented “very
much.” In order to reduce random error and give the subject an
opportunity to respond as exactly as possible, the immediately
preceding response was read to the subject just before he gave his
cur rent response.
Protocol
After informed consent was obtained, potential subjects who were
still smoking were individually screened at 11:00 AM on Mondays.
Six subjects were recruited for an additional four days of study.
Subjects underwent testing of the four conditions (2 mg and 4 mg
nicotine gum and 0.2 mg and 2 mg nicotine cigarettes) from 11:00
AM to 1:00 PM on the next four days in a randomly assigned order.
Subjects were asked to abstain from smoking after 12:00 AM on each
test day but not prior to the initial Monday visit. In addition,
they were to abstain from caffeine in any form after 9:00 AM on
each treatment day. Smoking abstinence was verified by testing
the exhaled carbon monoxide levels. The dose of nicotine in the
gum or cigarette was unknown to the investigator at the time of
testing and the echocardiograms and ECG’s were read by two
observers without knowledge of subject identity or of test
condition.
On each test day, baseline heart rate (HR), BP, ECG, and ECHO were
performed with the subject supine in a hospital bed prior to
smoking a test cigarette or chewing a gum. Following the baseline
measurements, repeat RR, BP, ECG leads 1, aVF, and V5, and ECHO of
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the left ventricle and aortic root were performed at 5, 10, 20,
30, 45, 60, and 90 minutes after the test condition was started.
The test questions were repeated at 5, 30, 60, and 90 minutes
after the beginning of a treatment and carbon monoxide measurement
was made at 10 and 90 minutes.
Smoking and chewing procedures were strictly controlled as fol-
lows: The cigarette was lit and held by the subject, who was
instructed to take one puff every 30 seconds, hold each puff in
for 5 seconds, exhale, and relax for 25 seconds. The timing was
monitored and 10 puffs were completed in 5 minutes. For the gum
treatment the subject chewed hard for 5 seconds and then held the
gum in the cheek (for absorption) for 25 seconds. This cycle was
timed and repeated every 30 seconds for 30 minutes. This
procedure maximized and controlled the nicotine release while
minimizing side effects.
Design
The design of the study was a 2x2x8 factorial for HR, BP, and
echocardiographic measures, The first factor was type of treat-
ment (gum vs. cigarettes); the second factor was dose (high vs. low
nicotine); and the third factor was the 8 time periods at which
measurements were taken. Psychological testing results made up a
2x2x5 factorial and CO measurements a 2x2x3 factorial.
Statistics
Repeated measures analysis of variance (ANOVA) with trends were
performed on the data using a BMDP Statistical Software Program.
One-way analysis of variance was used to compare baseline values
across treatments for each measure. F tests for repeated measures
were used to compare differences between baseline and 5 minute
values and baseline and 30 minute values for heart rate and mean
BP. These analyses were pre-planned and based on data for peak
blood levels of nicotine reported after cigarette smoking (5
minutes) and after gum chewing (30 minutes) (Russell et al. 1980).
Level of significance was chosen as p < 0.05 unless otherwise
stated.
RESULTS
Nicotine Content in Chewed Gum
The average amount of nicotine absorbed by the subjects from the 2
mg and 4 mg nicotine gum was 1.1 ± 0.2 mg and 2.7 ± 0.4 of nico-
tine, respectively. These were estimated from values obtained for
nicotine remaining in chewed gum. Thus, the high dose nicotine
gum appeared to supply at least twice as much nicotine as the low
dose nicotine gum. Five of six subjects reported an aversive or
burning taste with the 4 mg gum and two of six subjects reported a
burning taste with the 2 mg gum. Additional side effects
consisted of nausea and belching in two subjects, and soreness of
the throat in two others.
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Carbon Monoxide Levels
Baseline levels of CO obtained before the subjects were asked to
abstain from smoking are listed in table 1. CO levels obtained
immediately prior to each treatment and at 10 minutes and 90
minutes after the treatment began are also listed in table 1 with
ANOVA statistics presented in table 2. A main effect of condition
(p=0.02) was noted which can be attributed to the significant rise
in CO at 10 minutes for the cigarettes compared to the gum. The
condition x time interaction was significant at the p<.005 level.
There was no significant main effect of dose or dose x treatment
interaction.
Heart Rates
The baseline and post-treatment HR responses are listed in table 3
as means ± SD for each condition with ANOVA statistics listed in
table 2. The means are plotted in figure 1. There were no
TABLE 1. Carbon Monoxide Levels (ppm)
2
26.0
3
5.0
4
26.0
5 6
57.0 40.0
1
25.0
X ± SD
29.8±17.4
C1
Pre
10'
90'
CH
Pre
10'
90'
GL
Pre
10'
90'
G H
Pre
10'
90'
17.0
13.0
14.0
14.0
4.5 11.0 10.0 21.0 12.9±5.8
7.5 22.0 19.0 33.0 20.4±10.5
6.0 16.0 14.0 27.0 15.0±6.8
6.5 17.0
* 25.0
9.0 18.0
4.0
10.0
6:0
11.0 8.5 21.0 11.3±6.5
20.0 19.5 30.0 20.9±7.4
16.0 13.5 23.0 14.2±6.2
17.5 12.5 3.0 11.0 8.0 21.0 12.2±6.5
* 14.5 4.0 12.0 9.0 20.0 11.9±6.0
15.0 11.5 3.5 9.0 7.0 14.0 10.0±4.4
19.5
12.5
10.5 4.0 11.0 8.0 24.0 12.8±7.5
12.0 5.0 16.0 9.0 25.0 13.4±7.6
10.5 4.0 13.0 8.0 19.0 11.2±5.1
Sub
Base
Base, CO levels on Day 1 of study prior to abstention; CL,
cigarettes containing low (0.2 mg) nicotine; CH, cigarettes
containing high (2 mg) nicotine; GL, gum containing low (2 mg)
nicotine; GH, gum containing high (4 mg) nicotine; Pre,
immediately prior to intervention after at least 11 hours
abstention from cigarettes: ppm, parts per million: Sub, subject;
*, 10 minute CO measurement had not been added to protocol at the
time of study.
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Cond
Dose
Time
Cond X Dose
Cond x Time
Dose x Time
Cond x Dose
x Time
TABLE 2. Analysis of Variance Statistics (p values)
CO HR SBP DBP MBP LVEDD LVESD
0.02 0.61 0.74 0.54 0.57 0.92 0.76
0.18 0.01 0.01 0.06 0.31 0.11 0.20
0.005 0.001 0.001 0.0009 0.0001 0.08 0.0004
0.12 0.67 0.71 0.26 0.30 0.78 0.87
0.0005 0.003 0.001 0.10 0.01 0.37 0.11
0.77 0.29 0.96 0.43 0.61 0.51 0.33
0.70 0.16 0.57 0.53 0.85 0.91 0.50
FS% VCF
0.69 0.95
0.88 0.87
0.0008 0.09
0.54 0.16
0.46 0.99
0.61 0.43
0.24 0.11
Cond, condition of cigarette vs gum; dose, low vs high nicotine; CO, carbon monoxide; HR,
heart rate; SBP, systolic blood pressure (BP); DBP, diastolic BP: MBP, mean BP; LVEDD,
left ventricular (LV) end diastolic dimension; LVESD, LV end systolic dimension; FS%,
fractional shortening; VCF, velocity of circumferential fiber shortening; n=6 for all
measures except n=4 for CO.
significant differences among the baseline values. A main effect
of time (p=0.001) was observed with an increase in heart rate from
baseline for all conditions with a return to near baseline values
by 90 minutes. The significant dose effect (p=0.01) indicated
that the higher doses of nicotine regardless of condition had a
greater effect on heart rate than the lower doses. This dose
effect was not interactive with time or condition. A significant
condition x time interaction (p=0.003) revealed different peaks in
time dependent on treatment (i.e., cigarettes vs. gum). The peak
HR for the 90-minute study period was recorded at 5 minutes after
the intervention began for the 0.2 mg and 2 mg nicotine cigarettes
with an increaseover baseline of 7% and 28%, respectively. The
increase in HR noted with the 2 mg nicotine cigarettes was
significant (p<0.001). There was an insignificant 6% increase in
baseline HR with the 2 mg nicotine gum observed at 5, 20, and 60
minutes. The peak HR for the 4 mg nicotine gum recorded at 30
minutes post-treatment represented a 12% increase which was also
not significant (p=0.18).
Electrocardiograms
No changes occurred in the QRS complexes, ST segments, or T waves
in leads 1, avF, or V5 at any time during the various interven-
tions. In addition, no ectopy was detected.
TABLE 3. Cardiovascular Measures
GH
Mean BP
Baseline
5 min
10 min
20 min
30 min
45 min
60 min
90 min
Systolic BP
Baseline 101±7 103±10 103±10 106±8
5 min 103±9 112±7 lOl±7 lO1±12
10 min lOO±12 lO4±7 lO2±7 103±9
20 min 97±ll lO2±lO 98±7 103±6
30 min 96±10 lOl±7 99±8 102±9
45 min 97±7 99±10 99±6 l01±10
60 min 96±l2 lOO±7 97±5 lO2±1O
90 min 97±ll l00±9 99±9 104±11
CL CH GL GH
Heart Rate
67±9
72±9
70±11
7O±9
66±ll
65±9
62±1O
66±9
64±7 64±9
82±10 68±lO
74±l0 65±ll
73±7 68±ll
69±9 66±7
71±7 65±lO
70±11 68±11
66±8 60±5
67±7
71±9
72±8
75±6
75±9
72±7
69±8
65±11
CL CH GL
72±3 73±8 7l±7
74±2 8O±8 7O±5
7l±6 75±4 71±5
68±7 73±8 70±4
67±5 7l±6 7O±4
67±5 69±7 72±2
67±6 7l±6 70±3
68±6 73±3 7l±3
Diastolic BP
57±3 58±8 56±7
60±3 64±7 55±5
57±6 60±5 56±7
53±8 58±7 57±4
52±6 55±6 56±4
53±6 55±7 58±2
52±5 57±6 57±3
53±6 60±2±57+4
73±7
73±8
74±8
73±5
73±7
73±6
70±6
73±5
57±8
59±7
59±9
58±7
59±7
58±7
54±8
58±7
CL, low (0.2 mg) nicotine cigarettes; CH, high (2 mg) nicotine
cigarettes: GL, low (2 mg) nicotine gum; GH, high (4 mg) nicotine
gum; heart rate in beats/min; BP in mm Hg; values are means ±SD.
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Figure 1. Mean heart rate in beats/min plotted versus time
(minutes) for the four test treatments: , low (0.2 mg) nicotine
cigarettes; , high (2 mg) nicotine cigarettes; , low (2 mg)
nicotine gum; , high (4 mg) nicotine gum. n=6. B, baseline.
Figure 2. Mean blood pressure in mm Hg plotted versus time
(minutes) for the four test treatments: , low (0.2 mg) nicotine
cigarettes: , high (2 mg) nicotine cigarettes: , low (2 mg)
nicotine gum; , high (4 mg) nicotine gum. n=6. B, baseline.
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Blood Pressure
The systolic, diastolic, and mean blood pressurevalues for the
four conditions are listed in table 3. The mean BP is plotted in
figure 2. No significant differences among baselinevalues for
treatment conditions for systolic, diastolic, or mean BP's were
noted. There was a significant condition x time interaction for
systolic (p=0.001) and mean (p=0.01) BP. 'Ibis is attributed to an
increase in both of these measures for cigarettes at 5 minutes in
contrast to a decrease or no change in these measures after gum
treatment (table 3). A peak rise in systolic BP of 2% and 9% and
peak rise in diastolic BP of 4% and 12% were recorded at 5 minutes
for the 0.2 mg and 2 mg nicotine cigarettes, respectively. The
systolic BP did not rise above baseline for the 2 mg and 4 mg
nicotine gum, and the diastolic BP rose less than 4% at anytime
interval for both the 2 mg and 4 mg nicotine gum. The mean blood
pressure rose a maximum of 3% and 10% for 0.2 mg and 2 mg nicotine
cigarettes, respectively, at 5 minutes. The mean BP did not rise
more than 1% above baseline at any time for the nicotine gum.
Echocardiographic Measures
The mean values for LVEDD and LVESD from ECHO are listed in table
4 in mm. No significant differences among baselines for the 2
variables were observed. A significant time effect for LVEDD of
0.08 and for LVESD of 0.0004 was present. However, there were no
significant effects on LVEDD or LVFSD by dose or condition, and no
significant interactions (table 2). The normal range for LVEDD in
our laboratory is 38 - 57 mm and the normal LVESD is 21-39 mm. No
value for the LVESD or LVEDD was out of the normal range during
any part of the study.
The fractional shortening (FS) per cent is normally between 28%
and 488. The values obtained in this study appear in table 4 and
were all within the normal range. There was a significant
(p=0.0008) main effect of time. The maximum change from baseline
values was recorded over the first 10-20 minutes post-treatment
and was a decrease of 3%, 3%, 11% and 9% for 0.2 mg and 2 mg
nicotine cigarettes and 2 mg and 4 mg nicotine gum, respectively.
By 90 minutes, FS% was within 3% of baseline values. There were
no significant condition or dose effects or any significant inter-
actions between or among condition, dose, and time (table 2).
Finally, the velocity of circumferential fiber shortening (VCF)
was within the normal range of 0.89 - 1.60 at all times for all 4
conditions (table 4). No significant time, dose, or condition
effects or any significant interactions were found (table 2).
Psychological testing
The only significant change (p<0.05) in subjective state reported
for the 4 questions was for "Do you feel lightheaded?" . For this
question there was a significant condition x time interaction
(p<O.004) manifested by a significant increase in perceived light-
headedness at 5 minutes for the 2 mg nicotine cigarettes, only.
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TABLE 4. Echocardiographic Measures
CL
Baseline
5 min
10 min
20 min
30 min
45 min
60 min
9O min
Baseline
5 min
10 min
20 min
30 min
45 min
60 min
90 min
33±3 34±2
35±1 35±3 l.l5±0.06 1.09±O.10 1.13±O.11 1.12±0.03
34±3 34±3 1.07±0.13 1.13±0.10 1.07±O.09 1.14±0.11
33±4 33±2 31±3 33±3 l.O8±0.11 l.O4±0.08 l.O2±0.14 1.07±0.10
33±3 34±2
33±3
33±3 32±4 1.08±0.13 l.lO±0.12 1.10±0.10 1.05±0.13
35±3 33±3 34±3 1.14±O.12 1.03±0.11 1.05±O.09 l.O5±O.13
34±3 34±2 34±2
35±3
33±3
37±2 34±3 35±1
1.08±0.12 1.08±0.12 l.96±O.lO 1.12±0.14
1.06±0.14 1.15±0.12 l.ll±O.09 l.ll±0.06
34±2 33±2 34±4 34±3 l.lO±0.lO 1.07±0.10 1.08±0.10 1.06±0.16
CL, low (0.2 mg) nicotine cigarettes; CH, high (2 mg) nicotine cigarettes: GL, low (2 mg)
nicotine gum; GH, high (4 mg) nicotine gum; LVEDD, left ventricular end diastolic dimension
in mm; LVESD, left ventricular end systolic dimension in mm; FS, fractional shortening in %;
values are means ±SD.
50±2 50±l 49±2 51±5 33±2 33±l 32±l 33±2
49±2 51±4
50±2 51±3
49±2 50±4 33±2 34±3 32±l 33±2
49±2 51±5
50±2 51±3 48±2 52±5
34±3 34±2 34±2 34±2
32±2
49±1 51±3 49±2
33±2 34±3 34±2
52±5 32±2 34±2 33±2 34±3
49±3 34±3
50±1
51±3 49±2 5l±5 32±2 33±2 33±l
50±5 49±2 51±4 32±2 32±4 32±l 33±3
48±2 50±2 50±3 51±6 32±2 33±2 32±2 34±3
FS VCF
CH GL GH CL CH GL GH
LVEDD LVESD
DISCUSSION
This study was designed to compare the cardiovascular effects of
smoking a 0.2 mg or 2 mg nicotine cigarette with chewing a 2 mg or
4 mg nicotine gum and to begin to examine the safety of using
nicotine gum as a method of smoking cessation.
The work of the heart, or oxygen demand, is dependent on four
major factors: RR, preload, afterload, and contractility. RR can
easily be directly measured. A significant increase in RR above
baseline was noted only for the 2 mg nicotine cigarettes and
consisted of a 28% increase from 64 ± 7 to 82 ± 10 beats/min noted
at 5 minutes. Tachmes et al. (1978) reported heart rate and BP
responses in eight healthy smoking subjects (five men and three
women) before and after smoking low nicotine (0.3 mg) and high
nicotine (2.0 mg) cigarettes. Their plotted mean values recorded
at baseline and at 5 minutes after smoking agree almost precisely
with our data, although S.D’s were not reported. The increase in
AR from baseline to 5 minutes for both low and high nicotine
cigarettes was significant at p<0.05 in their study. The
difference in sample size (n=8 vs. n=6) may account for the
difference. Aronow et al. (1971) performed a similar study in
male patients with a history of angina and found an increase in HR
from 71.0 ± 11.0 to 86.8 ± 9.2 after smoking a high nicotine
cigarette (2 mg) and an increase from 72.4 ± 11.1 to 81.0 ± 9.4
after smoking a low nicotine cigarette (0.3 mg). Both of these
increases were significant.
The peak HR for the 4 mg nicotine gum was recorded as a 12%
increase at 20 and 30 minutes, but this change was not
significant. The timing of the peak HR correlates with previously
reported peak plasma nicotine levels after chewing gum (McNabb et
al. 1982; Russell et al. 1980). Wyberg et al. have reported a 15%
increase in HR at 30 minutes after chewing nicotine gum containing
4 mg of nicotine for 30 minutes using a similar protocol (NYberg
et al. 1982). This corresponded with peak whole blood nicotine
levels which were also recorded by them at 30 minutes. Thus, a
single dose of nicotine gum resulted in no significant change in
HR in contrast to the significant increase observed with a single
high nicotine cigarette over the 90 minutes studied. However, it
is noteworthy that the peak HR achieved with 4 mg nicotine gum was
greater than that observed with 0.2 mg nicotine cigarettes.
The mean BP, which is dependent on both the systolic and diastolic
pressures, provides an indirect measure of afterload on the heart.
The only significant changes (p<0.05) observed in the systolic,
diastolic, and mean BPS were a 9%, 12%, and 10% increase from
baseline noted at 5 minutes for the 2 mg nicotine cigarettes. The
systolic and diastolic BPs recorded after gum chewing began were
all less than the baseline, although not significantly less,
indicating no effect of nicotine gum on BP. We did not observe
the 7% increase at 30 minutes in systolic BP reported previously
with 4 mg nicotine gum (Nyberg et al.). Their protocol differed
from ours in that their subjects chewed the gum for 10 seconds
instead of 5 seconds every 30 seconds. This may have been
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responsible for the higher absorption of nicotine that they
reported of 3.3 mg (range 2.9-4.0 mg) and may have resulted in the
increase in systolic BP at 30 minutes.
The two remaining determinants of cardiac work are the preload (or
stretch on the left ventricle) and contractility. The
echocardiographically derived LVEDD provides a measure of preload,
and FS% and VCF provide measures of contractility. None of these
echocardiographic measures showed treatment effects. Thus,
nicotine gum in a single dose given to healthy males with no known
cardiovascular disease does not increase the work of the heart or
adversely affect its function.
Raeder et al. (1979) assessed cardiac contractility using PEP,
(pre-ejection period corrected for HR) and PEP/LVET in healthy
male smokers and found no significant changes related to smoking
low nicotine (0.1 mg) and high nicotine (2.6 mg) cigarettes. Our
data is in agreement with this study but is in slight variance
with a study by Rabinowitz et al. (1979) in 16 subjects (14
smokers). They reported an increase in LVEDD of 6% (cf. our 2%
increase), in LVESD of 3% (cf. our 3% increase), and an increase
in VCF of 13% from 1.12 ± 0.06 to 1.26 ± 0.09 (cf. our 4%
increase) after smoking a high nicotine (2.5 mg) cigarette.
The experimental studies were performed after subjects had
abstained from cigarettes for at least eleven hours. Mean
baseline CO values for our six subjects were 29.8 ± 17.4 while
smoking, and 12.4 ± 6.2 after abstaining for at least 11 hours.
This average 58% reduction in CO levels is similar to data for 27
subjects previously studied with CO levels of 43.3 ± 15.3 while
smoking and 16.4 ± 6.7 after abstinence for less than 1 day
(unpublished data). This represented a 62% reduction in CO levels
and was consistent with abstinence.
As expected, CO levels increased for both cigarette conditions
immediately post-treatment, and such differences were not observed
for the gum conditions. The results are similar to previously
reported values (Aronow et al. 1971). No significant difference
in the increase in CO levels at 10 minutes between the 0.2 mg and
2 mg nicotine cigarettes indicated that the differential increase
in HR seen with the 0.2 mg vs. 2 mg nicotine cigarettes was likely
due to the nicotine content and could not be ascribed to a
variation in CO levels.
The only significant change in subjective state was an increase in
lightheadedness reported at 5 minutes for the 2 mg nicotine
cigarettes. The value for 0.2 mg nicotine cigarettes was in-
creased at 5 minutes but not significantly. This subjective
sensation may have been related to the increased CO and/or the
rapid delivery of nicotine by cigarette smoking. It is unlikely
that the increase in HR noted would be perceived as an increase in
lightheadedness.
In summary, our study has shown no significant effect of 2 mg or 4
mg nicotine gum after a single dose on HR, BP, electrocardio-
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graphic parameters, or echocardiographic measures of left ventri-
cular function. This suggests that this modality may be a safe
method from a cardiovascular perspective to use as an adjunct in
smoking cessation therapy. We did not, however, examine the
cardiovascular effects after multiple doses of gum as would be
used clinically or give the gum to patients with significant
cardiovascular or pulmonary disease. Both of these issues will
require further study of nicotine gum.
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Characterization of Tobacco
Withdrawal: Physiological and
Subjective Effects
Dorothy Hatsukami, Ph.D., John R. Hughes, M.D., and
Roy Pickens, Ph.D.
Tobacco deprivation has been found to produce many symptoms in
chronic smokers. While increased craving for tobacco is most com-
monly reported, a wide variety of other symptoms have also been
reported, including changes in physiological, psychomotor and sub-
jective functioning (see Jaffe and Jarvik 1978; USDHEW 1979; Shiff-
man 1979). This observation has led to the belief that a tobacco
withdrawal syndrome exists which implies a physical dependence to
tobacco. However, at the present time, it is unclear if all or any
of the reactions following tobacco deprivation are in fact indica-
tors of physical dependence. This uncertainty exists in part
because of the lack of systematic and comprehensive studies of
tobacco withdrawal similar to the classical studies such as those
which have examined opiate withdrawal symptoms (Himmelsbach 1942).
The classical studies of withdrawal phenomena have tended to ex-
amine a variety of signs and symptoms in a prospective fashion with
measurements obtained on repeated occasions both during baseline
and drug deprivation. In contrast, most previous investigations on
tobacco withdrawal symptoms have been either retrospective, em-
ployed only a limited number of measures, employed no baseline
period or failed to include control groups. Furthermore, in order
to define reactions to tobacco deprivation as a true withdrawal
syndrome, it is necessary to rule out the possibility that these
symptoms are attributable to removal of drug action, to a loss of a
reinforcer, or a disruption of a habit. A careful examination of
tobacco withdrawal is important not only to better understand fac-
tors which maintain smoking, but also to develop more effective
smoking treatment procedures. For example, if specific signs and
symptoms after tobacco deprivation are due to pharmacological with-
drawal, then pharmacological intervention to treat these symptoms
may provide the best treatment outcome.
Over the past few years we have been conducting studies to deter-
mine reliable and valid indicators of tobacco withdrawal. We have
also attempted to determine if nicotine replacement can reduce the
number or intensity of tobacco withdrawal symptoms. Two studies
have been completed describing the characteristics of tobacco
withdrawal, and one study has been completed determining if
withdrawal symptoms can be alleviated with nicotine replacement.
This paper will describe the results of these studies, as well as
investigations currently underway.
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TOBACCO WITHDRAWAL SYMPTOMS IN A CONTROLLED ENVIRONMENT
In the first study (Hatsukami et al. 1984), a prospective examina-
tion of tobacco withdrawal symptoms was undertaken while subjects
(chronic smokers) lived in a controlled environment. Subjects were
hospitalized in the General Clinical Research Center of the Univer-
sity of Minnesota Hospitals. This Center is a federally funded
unit established to support clinical research, and contains its own
staff of physicians, nurses, and dieticians as well as its own
biochemical laboratory and kitchen facilities. In the study, sub-
jects (N=27) were hospitalized for seven consecutive days. For the
first 3 days, they were allowed to smoke ad lib while a battery of
tests (see table 1) was administered 1-2 times a day. For the next
4 days, subjects in the experimental group (N=20) were required to
abstain from all tobacco use, while subjects in the control group
(N=7) were allowed to continue to smoke ad lib. Compliance was
monitored by random carbon monoxide breath samples and observations
by the nursing staff.
The study has yielded several interesting findings. First, few of
the measures changed significantly after tobacco deprivation. Of
the 37 measures examined, significant effects were found with only
9. Physical measures that changed significantly were a decrease in
heart rate, and increases in caloric intake and body weight. Sub-
jective measures increasing significantly were craving for tobacco,
confusion and depression-dejection scores on the POMS, and reports
of number of awakenings and duration of awakenings during the sleep
period. The only other significant change was reports by observers
that the subject had difficulty concentrating (table 2). The re-
maining 28 measures in table 2 did not change following tobacco
deprivation.
As part of the study, the time course of withdrawal measures was
examined over the 4 days of tobacco deprivation. Self-report symp-
toms such as craving for tobacco, confusion, number of awaken-
ings and duration of the awakenings, and depression-dejection
peaked within 24 to 72 hours after tobacco deprivation and then
declined. Caloric intake increased over the first 72 hours of
tobacco deprivation and decreased after 96 hours, while weight con-
tinued to increase. Similarly heart rate decreased initially with
a slight increase after 96 hours of deprivation. This finding
would indicate that some of these symptoms may not solely be due to
the removal of a pharmacological effect.
There may be several reasons for our failure to find significant
changes in measures that other studies have reported following
tobacco deprivation. One reason may be our inclusion of a control
group. We found that addition of the control group eliminated find-
ings that would have been significant if only a baseline/depriva-
tion comparison had been made. For example, restlessness increased
significantly from baseline to the deprivation period for subjects
in the experimental group. However, there was also an increase in
this measure for subjects in the control group over the same period
of time. Thus, the inclusion of a control prevented an erroneous
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Table 1
Measures Employed in the Studies on Tobacco Withdrawal Symptoms and
Effects of Nicotine Gum on Tobacco Withdrawal Symptoms
Measures Study I Study II Study III Study IV
(Inpatient) (Outpatient) (Nicotine (Recent
Gum) Investigation)
Objective Measures
Vital Signs
Heart Rate
Supine
Orthostatic
Blood Pressure
Supine Systolic
Supine Diastolic
Orthostatic Systolic
Temperature
Respiratory Rate
Appetitive Behavior
Body Weight
Caloric Intake/Eating
Fluid Input
Fluid Output
Psychomotor Behavior
Level of Activity
Reaction Times
Simple
Choice
Errors
Tremor
Self-Report Measures
Shiffman-Jarvik Tobacco
Withdrawal Questionnaire1
Profile of Mood States
Scale2
Self-Rating Checklist3
Stanford Sleep Scale4
Behavioral Qbservation
Checklist5
1 Includes scores on craving for tobacco, stimulation/sedation, appetite, psycho-
logical discomfort, physical symptoms scales.
2 Includes scores on anxiety-tension, anger-hostility, depression-dejection,
fatigue, confusion. vigor scales.
3 Incluses ratings of cigarette craving, irritability, anxiety, difficulty con-
centrating, restlessness. headache, drowsiness, gastrointestinal disturbances,
fatigue, impatience, hunger, eating, somatic complaints.
4 Includes reports on number of awakenings. durations of awakening, duration of
5 For Study I, includes observations on restlessness, argumentativeness, slow
sleep. quality of sleep, latency of sleep.
movements, drowsiness, poor concentration. For Study II. includes observations
on irritability, anxiety, restlessness and impatience.
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Table 2
Significant Changes Following Tobacco Deprivation
and Effects of Nicotine Gum on Tobacco Withdrawal Symptoms
Measures Study I Study II Study III Study IV
(Inpatient) (Outpatient) (Nicotine (Recent
Gum) Investigation)
Objective Measures
Heart Rate
Supine
Drthostatic
Body Weight
Caloric Intake/Eating
Tremor
Self-Report Measures
Shiffman-Jarvik
Craving
POMS
Tension-Anxiety
Depression-Dejection
Confusion
Anger-Hostility
Vigor
Self-Rating Checklist
Craving
Irritability
Anxiety
Difficulty Concentrating
Restlessness
Impatience
Hunger
Somatic Complaints
Sleep Problems
Standard Sleep Scale
Number of Awakenings
Duration of Awakenings
Behavioral Observation
Checklist
Difficulty Concentrating
Irritability
Anxiety
Restlessness
Impatience
a measure not employed in study
+ increase
- decrease
* significant effect of nicotine gum on tobacco withdrawal symptoms
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conclusion from being drawn, as would have happened if data from
only the experimental group had been analyzed.
A second reason we found few tobacco withdrawal symptoms may be
related to the type of environment in which the study was con-
ducted. In a controlled hospital environment, subjects are not
exposed to many of the stimuli that are typically associated with
their smoking. If environmental factors play a role in determining
the intensity of tobacco withdrawal symptoms (Pomerleau 1981), then
hospitalization may have minimized the intensity of those symptoms.
The third reason for our failure to find withdrawal symptoms that
others have reported may be the large between-subject variability in
our data. This would reduce the likelihood of our obtaining a sta-
tistically significant effect. For example, for blood pressure
and temperature, some subjects showed an increase, other showed no
change, while still others showed a decrease on these measures.
Across subjects, such effects tend to cancel out, leaving no net
change for the group.
TOBACCO WITHDRAWAL SYMPTOMS IN THE NATURAL ENVIRONMENT
In the first study, lack of environmental stimuli typically asso-
ciated with smoking was suggested as one reason for relatively few
withdrawal symptoms being found. A second study was therefore con-
ducted to examine tobacco withdrawal symptoms as they occur in the
natural environment. This study was part of a larger investigation
designed to examine the effects of nicotine gum on tobacco with-
drawal symptoms (Hughes et al. 1984). The project was conducted
with outpatients who returned to the smoking clinic for measurement
of withdrawal symptoms. After two evenings of baseline measure-
ment, subjects were randomly assigned to either nicotine or placebo
gum groups in a double-blind manner. Subjects were then asked to
stop smoking, chew nicotine gum or placebo gum ad lib, and return
to the smoking clinic for measurements on the first, second, and
fourth evenings of tobacco deprivation.
For our present purposes, only data from the placebo group (N=49)
will be examined. (The effect of nicotine gum on tobacco withdrawal
symptoms will be described in a later part of this paper.) Since
the study was double-blind, the effects of subject and experimenter
expectancy on tobacco withdrawal symptoms were controlled. The
measures employed in this study are shown in table 1.
In this study, the physiological measures that changed signifi-
cantly following tobacco deprivation were supine and orthostatic
heart rate. Both decreased with tobacco deprivation. Measures on
the self-rating checklist that changed significantly were craving
for tobacco, irritability, anxiety, impatience, difficulty concen-
trating, and restlessness. All increased with tobacco deprivation.
The results obtained with the Profile of Mood States (POMS) were
similar to the results obtained with the self-rating checklist,
where significant increases in the anger-hostility, anxiety-ten-
sion, and confusion scores, and decreases in the vigor score were
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obtained. Behavioral observations by others tended to confirm the
self-report results, where significant increases in irritability,
anxiety, restlessness, and impatience were obtained. Other signi-
ficant changes reported by subjects included decreased tremulous-
ness, increased hunger, increased eating, increased somatic com-
plaints, and increased number of awakenings during sleep and sleep
problems. As in the first study, most of these withdrawal symptoms
began shortly after onset of tobacco deprivation and peaked 24-48
hours later.
Compared to the inpatient study, the outpatient study found a
greater number of significant changes following tobacco withdrawal
(see table 2). The symptoms found in common in the two studies
were a decrease in heart rate and increases in craving for tobacco,
difficulty concentrating, eating behavior, and number of awakenings
during sleep. Unlike the previous study, however, the outpatient
study results included no statistically significant increase in
body weight, duration of awakening during sleep, or depression-
dejection score on the POMS. On other common measures, a decrease
in tremulousness, an increase in anger-hostility and tension-
anxiety scores, and a decrease in vigor score on the POMS were
found in the outpatient study but not in the inpatient study.
EFFECTS OF NICOTINE ADMINISTRATION ON TOBACCO WITHDRAWAL SYMPTOMS
Do tobacco withdrawal symptoms result from nicotine deprivation?
Other studies attempting to answer this question have focused on
whether frequency of smoking cigarettes is related to severity of
withdrawal and have obtained equivocal results (Shiffman 1979). In
the present study, however, we attempted to determine whether nico-
tine gum relieves tobacco withdrawal symptoms. This study is im-
portant not only in determining whether physiological dependence on
nicotine can occur, but also for clinical reasons. If relapse to
smoking is related to the appearance of aversive nicotine withdrawal
symptoms following tobacco deprivation, then attenuation of with-
drawal symptoms by other forms of nicotine administration could
improve smoking cessation success rates (Russell et al. 1980).
Subjects were 100 smokers who met the criteria for Tobacco Depen-
dence and who had a history of Tobacco Withdrawal as defined by the
DSM III criteria (APA 1981). Subjects were randomly assigned to
either a nicotine (2 mg) gum or placebo gum group. Following 2
days of smoking baseline, all subjects were required to undergo
4 days of tobacco deprivation, during which time they were
instructed to chew the gum (either nicotine or placebo) on a PRN
basis. Measures employed are shown in table 1. Only those symp-
toms that changed signficantly following tobacco deprivation in the
placebo group were examined in the analysis.
The nicotine gum group reported significantly less irritability,
anxiety, difficulty concentrating, restlessness, impatience, and
somatic complaints after smoking cessation than the placebo gum
group on the self-rating checklist. Reductions in these withdrawal
symptoms were confirmed by subjects' scores on the Profile of Mood
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States and by observer ratings. Nicotine did not reduce the in-
crease in cigarette craving, hunger, eating, and insomnia, or the
decrease in tremulousness and supine heart rate that occurred after
smoking cessation. The effect of the nicotine was evident on the
first day of deprivation and throughout the 4-day tobacco depriva-
tion period.
In summary, it appears the nicotine relieves some, but not all, of
the symptoms of tobacco deprivation. There are a number of factors
which may account for the failure of the gum to relieve all tobacco
withdrawal symptoms. For example, the gum dose that was used in
the study may have been inadequate. Second, it may be that nico-
tine must be given in a bolus form (i.e., as delivered in smoking)
to relieve some symptoms of withdrawal (Russell and Feyerabend
1978). Third, there may be other psychoactive ingredients in to-
bacco in addition to nicotine which are correlated with physiologi-
cal dependence on tobacco (Jarvik 1981). Fourth, tobacco with-
drawal symptoms may be controlled by behavioral or psychological as
well as a pharmacological factors (Falk 1971; Jaffe and Jarvik
1978).
CURRENT INVESTIGATIONS
A study is currently being undertaken to determine the within-
subject reliability of tobacco withdrawal symptoms. The study
employs a modified single-subject A-B-A-B experimental design.
Following an intial 48-hour period during which baseline measures
are obtained while subjects smoke ad lib, subjects are required to
undergo a 96-hour period of tobacco deprivation. After the depri-
vation period, subjects are asked to resume smoking for a 96-hour
period (during the latter half of which additional baseline meas-
ures are obtained). This second baseline period is followed by a
second 96-hour tobacco deprivation period. Preliminary analysis of
the data from three subjects showed that decreases in supine heart
rate and in vigor score on the POMS, and increases in caloric in-
take, anger-hostility, and number of awakenings during sleep occurred
consistently both within and across subjects during both periods of
deprivation. In five out of six measurement periods, craving and
confusion score on the POMS also increased. Measures which showed
consistent effects of tobacco deprivation within but not across
subjects include orthostatic heart rate change. All other vari-
ables showed inconsistent changes between and within subjects over
the two tobacco deprivation periods.
SUMMARY
In total, our studies show that changes which occur reliably and
consistently in chronic smokers after tobacco deprivation include:
(1) decreased heart rate, (2) increased caloric intake/eating, (3)
increased number of awakenings during sleep, (4) increased craving
for tobacco, and (5) increased confusion, as measured by the POMS.
Other changes that were found to occur after tobacco deprivation in
some but not all of our studies include decreased orthostatic heart
rate, increased irritability, and decreased vigor score on the
POMS.
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Previous investigators have found a consistent effect of tobacco
deprivation on heart rate (Gilbert and Pope 1982; Knapp et al. 1963;
Parsons and Hamme 1975; Weybrew and Stark 1967; Glauser et al. 1970;
Myrsten et al. 1977; Murphee and Schultz 1968). Although decreased
blood pressure (Knapp et al. 1963; Murphee and Schultz 1968) and
changes in other vital signs such as temperature (Gilbert and Pope
1982; Myrsten et al. 1977; Ague 1974) have been reported, our pre-
sent studies and studies by others (Weybrew and Stark 1967; Glauser
et al. 1970) failed to find a significant deprivation effect on
these measures. Perhaps the contradictory findings are a function
of the reliability of the measures themselves or of the population
tested.
Caloric intake has been found to increase in both animals and
humans after nicotine or smoking cessation (Gruneberg 1982; Myrsten
et al. 1977; Wack and Rodin 1982). These results are consistent
with studies which have found that smoking cessation causes an
increase in body weight (Wack and Rodin 1982). However, previous
studies disagree on how smoking cessation causes weight gain. Our
inpatient study is believed to be the first to simultaneously
measure changes in caloric intake, fluid retention, and physical
activity after tobacco deprivation. In the study, caloric intake
increased but fluid retention and physical activity did not change.
The increases in weight may not be accounted for solely by
increases in caloric intake. There may be other factors such as
decreased basal metabolic rate which cause the increase in weight.
Other studies have also reported sleep disturbance or insomnia
among tobacco-deprived smokers (Larson et al. 1961; Weybrew and
Stark 1967). Studies directly monitoring sleep have found a
decrease in duration awake (Soldatos et al. 1980), increased REM
sleep (Soldatos et al. 1980; Kales et al. 1970; Parsons et al.
1975), and increased Stage IV (>50% delta waves) sleep (Parson et
al. 1975; Parsons and Hamme 1975). Thus, objective data indicate
that after tobacco deprivation smokers actually sleep longer, which
contradicts subjective reports of insomnia.
Difficulty concentrating after tobacco deprivation has also been
reported by other investigators (Weybrew and Stark 1967; Franken-
hauser et al. 1971; Myrsten et al. 1977; Wynder et al. 1967). The
difficulty may be reflected in poor performance shown by tobacco-
deprived smokers on driving simulation (Heimstra et al. 1973) and
vigilance (Ashton and Stepney 1982) tasks. Furthermore, smokers
deprived of tobacco have shown an increase in slow wave activity
(Ulett and Itil 1969) and slower dominant alpha frequency (Knott
and Venables 1977) which are associated with a hypoexcitation state
and perhaps a decrease in attention (Knott and Venables 1977;
Ashton and Stepney 1982).
Subjective reports of craving for tobacco, increased irritability,
and decreased vigor have been widely cited in other studies (Shiff-
man 1979). Craving for tobacco has been found to be the most pre-
valent withdrawal symptom reported by exsmokers, with up to 90
percent of smokers who quit reporting a craving for tobacco (Guil-
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ford 1966). While most of these mood changes have been obtained by
self-report, two studies have employed objective measures of irri-
tability or anger. Hutchinson and Emley (1973) found that masseter
muscle contraction increased in frequency in 7 of 8 subjects with-
drawn from tobacco. Schechter and Rand (1974) found higher aggres-
sion scores in chronic smokers on the Buss Aggression Machine when
subjects were deprived of cigarettes than when allowed to smoke.
The time course for symptoms that were examined after tobacco
deprivation would suggest that some of the symptoms are not primar-
ily due to the removal of a pharmacological effect and consequently
a return to values prior to the onset of smoking. The onset of
most symptoms was rapid (within 24 hours of onset of deprivation),
reached a peak in 36 to 72 hours, and then gradually declined.
Other investigators have also noted that the peak in tobacco with-
drawal symptoms based on subjective reports occurs between 24 and
48 hours (Shiffman and Jarvik 1976). If these symptoms would have
been due to return to baseline, symptoms would not have shown the
"overshoot" or "rebound" pattern that has been found in the opiate
withdrawal syndrome (Himmelsbach 1942).
Our study indicates that nicotine appears to affect the occurrence
of some but not all symptoms of tobacco withdrawal. Previous stud-
ies have also found that administration of nicotine minimizes to-
bacco withdrawal symptoms (Hughes and Hatsukami, this volume). The
only symptom that has been consistently found to be reduced by the
administration of nicotine has been irritability.
Another method of determining whether tobacco withdrawal symptoms
are a result of nicotine deprivation is by examining the signs and
symptoms after nicotine gum deprivation. In a recent study, West
and Russell (in press) have shown that symptoms occur after cessa-
tion of long-term nicotine gum use. They found that among indivi-
duals who have been using 2 mg gum for at least a year, cessation
from gum use led to increases in reported irritability, depression,
hunger, tiredness and restlessness, and decrease in ability to con-
centrate and ability to cope. In addition, they found significant
decreases in heart rate. Interestingly, these symptoms are similar
to those we found among smokers undergoing tobacco deprivation
(i.e., irritability, hunger, decrease in ability to concentrate,
and decreased heart rate).
Inevitably, attempts to clarify the characteristics of tobacco
withdrawal generate questions that need to be addressed in further
investigations. More research is necessary to determine which
changes observed following tobacco withdrawal are specifically the
result of removal of the pharmacological effects of the drug and
subsequent return to baseline, the result of interrupting a posi-
tively reinforced behavior (Falk 1971), the occurrence of a disrup-
tive event, or true pharmacological withdrawal symptoms. In
addition, further research is required to determine which symptoms
of tobacco withdrawal result from deprivation from nicotine.
Determination of the symptoms which are a result of behavioral
dependence or physical dependence on nicotine can lead to more
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directed treatment approaches. For example, craving for tobacco
does not seem to be affected by nicotine replacement, therefore
behavioral management may be necessary for symptoms of craving
rather than pharmacological intervention with nicotine.
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Short-Term Effects of Nicotine Gum
John R. Hughes, M.D., and Dorothy Hatsukami, Ph.D.
Pharmacological treatments of drug dependence vary in their
approach. Medications may make drug administration aversive (e.g.,
disulfiram). block the reinforcing effects of the drug (e.g.,
naltrexone), substitute for the drug (e.g., methadone), or relieve
the discomfort of drug withdrawal (e.g., benzodiazepines).
Based on these approaches, several types of medications, such as
taste adulterants, stimulants, and tranquilizers have been tested as
aids to smoking cessation (Kozlowski, in press; Raw 1978; Grabowski
and Hall, this volume). Most of these medications have not been
efficacious. Nicotine chewing gum is the exception (Hughes and
Miller 1984). The major hypotheses to explain the efficacy of
nicotine gum are that the gum substitutes for the reinforcing
effects of cigarettes or that the gum relieves tobacco withdrawal
symptoms.
This article will review studies of the short-term effects of
nicotine gum that test these two hypotheses. Although we will
attempt some conclusions, the reader should be aware that, as with
most drugs (Thompson and Johanson 1981), the effects of nicotine
depend on several conditions. For example, differences in dose,
duration and route of administration, drug history, external
stimuli, genetics, personality, rate of ongoing behavior, schedule,
time since drug ingested and tolerance can produce marked differ-
ences in nicotine's actions (Aston and Stepney 1982; Emley and
Hutchinson 1984; Gilbert 1979; Goldberg et al. 1983; Henningfield
1984; Henningfield and Goldberg 1983; Hughes, in press; Mangan and
Golding 1984). For example, differences in external stimuli (Gold-
berg et al. 1983). instructional set (Hughes et al., in press-a).
and schedule (Goldberg et al. 1983) can determine whether nicotine
will serve as a reinforcer or a punisher. Thus, when we summarize
"the" short-term effects of nicotine gum, the reader should realize
the results obtained in laboratory studies may not generalize to
those obtained in medical practice.
EFFECT ON SMOKING BEHAVIOR
The effects of nicotine on smoking vary widely both between and even
within studies (Brantmark et al. 1973; Ebert et al. 1984; Kozlowski
et al. 1975; McM Turner et al. 1977; Ohlin and Westling 1975;
Russell et al. 1976; Westling 1976). Of the 16 comparisons in these
studies, 7 showed nicotine gum decreased smoking and 9 did not.
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These contradictory results may be due to differences in subjects
(those who were vs. were not trying to quit), sample size (8 vs. 92
Ss), design (within- vs. between-group design), dose (1 vs. 2 vs. 4
mg). schedule of dosing (e.g.. single vs. ad-lib administrations).
duration (30 min vs. 2 wks). and dependent measures (self-report vs.
objective measures and frequency vs. topographical vs. biochemical
measures). Whether any of these differences do, in fact, control
whether nicotine gum influences smoking might be determined by
looking for an association between positive results and a method-
ological procedure (e.g.. use of smokers trying to quit) across the
studies. Unfortunately, the small number of studies and the fact
that the different methods are confounded with each other prohibits
such an analysis. About the only conclusion that can be reached is
that, at this time, a conclusion cannot be reached.
EFFECT ON CIGARETTE CRAVING
Perhaps the major hypothesis to explain the efficacy of nicotine gum
is that the gum relieves craving for cigarettes during abstinence.
Tests of this hypothesis have thus far been restricted to examining
the effects of nicotine gum on subjects' endorsements of descrip-
tions of craving, such as desire to smoke, thoughts about cigar-
ettes, difficulty refraining from smoking, urges to smoke, hunger
for a cigarette, and awareness of not having a cigarette. Nicotine
gum decreased some of these measures of craving in some subjects in
three small studies (Russell et al. 1977; Ryden 1975; Schneider et
al. 1977). However, nicotine gum did not decrease these measures of
craving in large, placebo-controlled trials of the gum (Hughes et
al. 1984; Jarvis et al. 1982; Ohlin and Westling 1975; Schneider et
al. 1984; West et al. 1984). Thus, the weight of the evidence does
not support the hypothesis that the efficacy of nicotine gum is due
to its ability to relieve craving.
There are several reasons why nicotine gum might not reduce cigar-
ette craving. First, the route of administration (oral vs. inhal-
ation) might be crucial. Oral nicotine produces low levels of
nicotine (Hughes and Miller 1984) that might be insufficient to
reduce craving. However, previous studies have shown that nicotine
via other routes of administration, e.g.. capsules (Jarvik et al.
1970) or intramuscular (Johnston 1942) and intravenous (Henningfield
et al. 1983; Lucchessi et al. 1967) injections decrease smoking and
cigarette craving. Unfortunately, none of these studies reported
examining self-reported craving during abstinence. Oral nicotine
also does not reproduce the "bolus" injection of nicotine from smok-
ing. Bolus injections may be essential to replicate the effects of
smoking (Russell and Feyerabend 1978). However, Kumar et al. (1977)
found that intravenous bolt of nicotine did not decrease smoking
frequency. Second, other ingredients in tobacco may control the
desire for a cigarette. Although there are several reasons to be-
lieve nicotine is the major psychoactive ingredient in tobacco, the
psychopharmacological properties of several thousand other compounds
in tobacco have not been tested (Jarvik 1977). Third, craving may
be controlled by environmental factors. Smoking occurs many times
per day, in a variety of situations, and produces a psychoactive
effect quite rapidly (i.e.. within 7 seconds); thus, the opportun-
ities for environmental conditioning are great. Recent studies with
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amphetamines suggest that once a conditioned drug response is estab-
lished, the response may no longer be influenced by agonists or
antagonists of the drug (Benninger and Hahn 1983). If this is true,
then once tobacco craving is conditioned to environmental cues,
nicotine alone may no longer reduce craving.
A fourth possibility is that nicotine reduces craving only in the
more "dependent" smoker (Hughes. in press-b). The results of
Russell's study (1977) are consistent with this hypothesis in that
they suggest the reduction in cigarette craving by nicotine gum
varies widely across smokers. To test this hypothesis we divided
smokers in our study into a dependent and nondependent group accord-
ing to their scores on the Tolerance Questionnaire (Fagerstrom
1978). We then compared the reduction in cigarette craving from
nicotine and placebo gum between the two groups. The reduction in
craving was the same for dependent and nondependent smokers; thus,
the hypothesis that nicotine reduces craving only in the more
dependent smoker was not supported.
Finally, there is the possibility that self-reported craving is a
poor measure. Perhaps better measures would be direct, objective
tests of nicotine self-administration during abstinence such as
concurrent access (Hughes et al., in press) to tobacco and non-
tobacco cigarettes or the amount of work to obtain nicotine or
tobacco (Griffiths et al. 1982).
The inability to document that nicotine gum reduces craving during
abstinence may have clinical implications. At present, when smokers
are prescribed nicotine gum, they are told the gum will reduce
cigarette craving. Perhaps instead smokers should be told not to
rely on the gum to relieve all craving and be encouraged to develop
a plan to deal with craving that does not respond to the gum (e.g.,
engaging in alternative behaviors or avoidance of cues). When
smokers are prescribed nicotine gum, they are also told to use the
gum whenever craving for a cigarette occurs. If nicotine gum does
not reduce craving, perhaps they could be told to use the gum on a
fixed time schedule instead of a PRN schedule. Fixed time schedules
might be preferable to PRN schedules as the former schedule helps
extinguish conditioned craving responses and decreases the proba-
bility that use of nicotine gum itself will become conditioned to
craving cues. Another alternative is that smokers should be told to
use the gum not when cigarette craving occurs, but rather when
withdrawal symptoms occur (see below).
EFFECT ON TOBACCO WITHDRAWAL
Abstinence from smoking induces a variety of withdrawal symptoms
(Hatsukami, this volume; Shiffman 1979). Several double-blind,
placebo-controlled studies have tested the effect of nicotine gum on
tobacco withdrawal. Some studies correlated withdrawal symptom
ratings into a total withdrawal discomfort score. These withdrawal
scores consisted of a single global self-report rating (Russell et
al. 1976; Westling 1976). number of symptoms reported (Puska et al.
1979). or a cumulative score based on the sum of intensity ratings
for individual symptoms (Fagerstrom 1982; Hughes et al. 1984; Killen
et al. 1984: Schneider et al. 1984). In all but one of these
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studies (Puska et al. 1979). nicotine gum reduced total withdrawal
discomfort (see figure for an example).
In terms of individual withdrawal symptoms, the only effect of
nicotine that was consistent across studies was a reduction in
irritability, anger, and frustration (table 1). Depression was also
reduced by nicotine gum in two of the four studies.
Abstinence from cigarettes produces behavioral as well as self-
report changes (Hatsukami et al. this volume). Our study examined
the effects of nicotine gum on such behavioral changes by collecting
observer ratings of abstinent smokers. Observers (e.g., spouse or
employer) rated subjects who received nicotine gum less irritable,
anxious, restless, and impatient than subjects who received placebo
gum (table 2). Thus, nicotine gum produced behavioral changes that
occurred in the natural environment and were apparent to persons
near the smoker.
Abstinence often produces weight gain. Post cessation weight gain
may be due to several factors, e.g.. increased hunger, increased
consumption of sweets, decreased resting metabolic rate, or de-
creased motor activity (Grunberg. in press; Hatsukami et al. this
volume; Hughes et al. 1982; Wack and Rodin 1981). Nicotine de-
creases appetite, increases resting metabolic rate, and increases
physical activity (Grunberg, in press); thus, nicotine gum could be
expected to counteract the weight gain associated with smoking
cessation. Two double-blind placebo-controlled trials reported that
subjects who received nicotine gum reported less hunger (Jarvis
1982) and gained less weight (Bantmark et al. 1973) at 6-month
followup than subjects who received placebo gum. In contrast,
similar trials by Puska et al. (1979). Hall et al. (in press) and
Hjalmarson (1984) found no difference in weight gain or hunger be-
tween those on nicotine gum and those on placebo. Also, both West
et al. (1984) and we (Hughes et al. 1984) found that nicotine did
not reduce hunger during the first few days of abstinence.
Although this evidence suggests nicotine gum does not decrease post
cessation weight gain, clinical trials of nicotine gum may not be
fair tests. This is because some subjects in a clinical trial will
relapse to smoking. Since nicotine gum keeps people from smoking
and since abstinence increases weight. then nicotine gum will appear
to increase weight gain due to its-therapeutic efficacy. To truly
test the effect of nicotine gum on post cessation weight gain. a
study must prevent attrition-back to smoking and study the effect of
nicotine gum on weight gain only in abstinent smokers.
Another less well-documented effect of abstinence from smoking is
analgesia. Milgrom-Friedman et al. (1983) examined whether nicotine
gum would influence abstinence-induced analgesia. They studied non-
smokers, smokers smoking ad lib, abstinent smokers who chewed nico-
tine gum, and abstinent smokers who did not chew nicotine gum. Each
group had a tourniquet applied to one arm and then reported the time
to onset of pain and the time until the pain was intolerable. Ab-
stinent smokers who chewed nicotine gum reported pain onset similar
to that of abstinent smokers who did not chew gum. Both these
groups had a pain onset longer than that of smokers smoking and
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Figure. Mean and standard error of daily discomfort score by
experimental condition and drug group for our nicotine gum study
(Hughes et al. in press). Open circles = placebo, closed circles =
nicotine.
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Table 1. Effects of nicotine gum on the commonly reported
symptoms of tobacco withdrawal
Brantmark Puska Jarvis Hughes West
et al. 1973 et al. 1979 et al. 1982 et al. 1984 et al. 1984
DSM-III Criteria
Irritability/Anger/Frustration
Anxiety/Tension
Difficulty Concentrating
Restlessness/Impatience
Headache
Drowsiness/Alertness
Gastrointestinal Problems
Other Criteria
Depression
Fatigue
Hunger
Insomnia
None None
None None
None None
Reduced
None
Reduced
Reduced
Reduced
Reduced
Reduced
None
None
None None
Reduced
None
None
None
None
Reduced Reduced
Reduced None
None
None
Table 2. Behavioral effects of nicotine guma
Variable
F value for
Group Baseline Abstinence Nicotine < Placebob
Irritability Placebo 0.4
Nicotine 0.5
Anxiety Placebo
Nicotine
Restlessness Placebo
Nicotine
Impatience Placebo
Nicotine
0.6
0.6
0.4 0.9
0.6 0.8
0.5
0.7
0.9
10.7**
0.6
1.1
0.7
4.7*
7.5*
1.0
10.5**
0.7
a All ratings based on scale of 0=not present, 1=mild, 2=moderate,
and 3= severe. All standard errors <0.15.
b F value for the interaction that the increase in the behavioral
rating would be less for the nicotine group than for the placebo
group, df=(1,79).
* p<.05
** p<.01
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nonsmokers. Thus, nicotine gum did not reverse abstinence-induced
analgesia.
In summary, nicotine gum decreases both self-reported and observed
symptoms of tobacco withdrawal. The most consistent effect of nico-
tine gum is to decrease irritability/anger/frustration. Whether the
gum reduces other withdrawal phenomena, such as weight gain, is
unclear.
BIOCHEMICAL/PHYSIOLOGICAL EFFECTS
One hypothesis to explain the ability of nicotine gum to decrease
withdrawal symptoms is that the gum dampens the arousal associated
with tobacco withdrawal. The only biochemical effects of nicotine
gum that have been tested are its effects on serum glucose and ex-
creted catecholamines. Gennser et al. (1975) and Manning and
Feyerabend (1976) reported that neither the 2 mg nor the 4 mg gum
changed the blood glucose of pregnant women. West et al. (1984)
reported that the fall in excreted catecholamines during abstinence
was similar in nicotine (2 mg) and placebo groups.
The physiological effects of nicotine gum that have been examined
are its effects on cardiovascular function, tremor, and, in one
study, evoked potentials. Most studies of the cardiovascular
effects of nicotine gum on nonsmokers and nonabstinent smokers
report that the 4 mg gum, but not the 2 mg gum, increases heart rate
(Fredholm and Sjorgen 1979; Gennser et al. 1975; Jarvik 1982;
Manning and Feyerabend 1976; Nyberg et al. 1982). Neither dose of
gum influenced EKG measures or blood pressure (Fredholm and Sjorgen
1979; Nyberg et al. 1982). A report that the 4 mg gum decreases
skin temperature (Fredholm and Sjorgen 1979) was not replicated
(Nyberg et al. 1982). Among the studies of the effect of nicotine
gum on the cardiovascular response of abstinent smokers, two
reported that nicotine gum 2 mg dampened the fall in heart rate
during abstinence (Schneider et al. 1984; West et al. 1984);
however, our study (Hughes et al. 1984) failed to replicate this
finding. In addition, our study (Hughes et al. 1984) found that
nicotine gum tended to reduce the increase in orthostatic response
(i.e., the increase in heart rate upon standing) after abstinence.
The two other physiological responses that have been studied are
tremor and evoked potentials. The 4 mg, but not the 2 mg, dose of
gum increased hand tremor in nonabstinent smokers (Shiffman et al.
1983). The 2 mg dose also failed to counteract the decrease in
tremor after abstinence in our study. Finally, nicotine gum has
been reported to have the same effect as smoking on visual evoked
potentials (Milgrom-Friedman et al. 1981).
In summary, the effects of the gum on biochemical and physiological
indices of arousal appear to be dose-dependent; i.e., the 4 mg gum
does cause some changes, but the 2 mg gum does not appear to have
any significant effects.
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TIME COURSE OF NICOTINE EFFECTS
The time course of a drug's effects may be crucial to its ability to
produce therapeutic effects. The onset of nicotine gum's effects
appears quite rapidly (see figure). In two studies, the gum reduced
total withdrawal discomfort within 24 hours (Hughes et al. 1984,
West et al. 1984) and in a third study within 48 hours (Schneider et
al. 1984).
The duration of the effects of nicotine gum has not been well
studied. In our study, the effect of the gum tended to decrease
over four days (see figure) and a similar effect appeared to occur
in the study of Schneider et al. (1984). Unfortunately, no studies
have tracked gum effects over longer periods.
Schneider and Jarvik (1984) also demonstrated an interaction between
time of day and the effect of the gum such that the nicotine gum
reduced withdrawal symptoms later in the day more than it reduced
withdrawal symptoms earlier in the day. Whether this interaction
was due to diurnal variation in the intensity of withdrawal symptoms
or in the intensity of nicotine effects is unclear.
NICOTINIC VS. EXPECTANCY EFFECTS
Subjects in "double-blind" studies of psychoactive drugs can often
tell if they are receiving active drug (e.g., Brownell and Stunkard
1982, Johnson and Hughes 1976). There is anecdotal evidence that
smokers (Schneider et al. 1977) and their therapists (Fagerstrom
1982; Westling 1976) are able to discriminate nicotine from placebo
gum. Such knowledge of drug receipt may produce expectancies that
will influence tobacco withdrawal symptoms (Gritz 1980) and the
efficacy of nicotine gum (Fagerstrom and Strom 1981); thus, it is
particularly important to verify that any effects of nicotine gum
are not actually expectancy effects.
In our study we directly tested whether the reduction in withdrawal
symptoms by nicotine gum could have been due to subjects' identi-
fication of whether they received nicotine or placebo gum (Hughes
and Krahn, in press). Although many subjects in our study could
identify their drug assignment, the effect of nicotine gum on with-
drawal discomfort was present independent of identification of drug
assignment (table 3).
SIGNIFICANCE
The studies reviewed indicate that nicotine gum does relieve
withdrawal discomfort. This fact might be interpreted to support
the hypothesis that tobacco withdrawal is due to nicotine depriv-
ation (e.g.. Schachter 1978); however, the logic of this inter-
pretation can be questioned. Demonstration that a drug relieves a
syndrome is consistent with, but not equivalent to, a demonstration
that the syndrome is due to deprivation of the drug or class of
drugs. Morphine relieves congestive heart failure but congestive
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Table 3. Analysis of variance of withdrawal discomfort
score by drug group and belief of drug assignment
Placebo
Drug Group
Nicotine
Identification of Drug Assignment
Correct Incorrect Uncertain
5.34 2.14
(n=19) (n=15)
1.10 0.03
(n=34) (n=6)
3.03
(n=16)
0.74
(n=9)
F for main effect of drug group (1,90)=14.8, p<.001
F for interaction between drug group and belief (2,89)<1.0, p>.10
t for nicotine < placebo within correct identification group
(14)=14.4, p<.001
t for nicotine < placebo within incorrect identification group
(16)=1.7, p=.06
t for nicotine < placebo within uncertain (24)=2.1, pp.04
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heart failure is not due to morphine deprivation. Several alter-
native explanations are available. Perhaps nicotine relieves
irritability, etc., regardless of its source.
Another interpretation of the finding that nicotine reduces with-
drawal discomfort is that this indicates the efficacy of nicotine
gum is due to its ability to relieve withdrawal. However, none of
the previous studies have directly related reduction in withdrawal
discomfort by nicotine to improved long-term cessation success.
In summary, many of the short-term effects of nicotine gum are
consistent with theories that nicotine dependence plays a role in
maintaining smoking. However, other results directly contradict
this hypothesis and crucial tests of the hypothesis (e.g., does
nicotine gum relieve withdrawal which then improves cessation?) have
not been reported.
FUTURE RESEARCH
In the introduction we mentioned that several nonpharmacologic
factors can control nicotine's actions (e.g., instructional set).
Thus, one explanation for the many inconsistent results of studies
of nicotine gum is that nonpharmacologic factors that control nico-
tine's actions varied across the studies. If this is true, then
empirical studies are needed to determine those factors that are
necessary and sufficient for nicotine gum to have beneficial ef-
fects. For example, studies that contrast different doses (1 vs. 2
vs. 4 mg). durations of administration (1 vs. 3 vs. 6 months),
schedules (fixed time vs. ad-lib) or subjects ("dependent" vs.
"nondependent" smokers) must be more useful than simple outcome
studies pitting nicotine gum vs. a standard treatment.
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Nicotine Gum vs. Placebo Gum:
Comparisons of Withdrawal
Symptoms and Success Rates
Nina G. Schneider, Ph.D., and
Murray E. Jarvik, M.D., Ph.D.
Until recently, the importance of nicotine in smoking and the
existence of nicotine-specific withdrawal have been hard to
demonstrate empirically. Several investigators succeeded in
focusing attention on nicotine and presenting a strong case for
nicotine as the critical factor in smoking dependence (Gritz 1980b;
Jarvik 1970; Russell 1980; Russell and Feyerabend 1978). However,
smoking is a complex dependence in which pharmacological and
psychosocial reinforcement systems are confounded. What we have
needed is a direct means of testing the relative contributions of
these factors to why people smoke, to variations in individual habit
patterns, and to why cessation is difficult and relapse rates high.
The introduction of nicotine gum and its placebo counterpart (Ferno
et al. 1973) has provided a means of manipulating nicotine intake
independent of the behaviors associated with the habit. The idea of
varying nicotine levels and studying withdrawal is not new. Manip-
ulation of nicotine was reported as early as 1942 by Johnston using
repeated doses of nicotine in injections. Johnston (1942) adminis-
tered the injections to himself and several volunteers and reported
dysphoric reactions upon their abrupt cessation. In laboratory set-
tings, intravenous nicotine studies provide basic Information for
the role of nicotine in smoking (Henningfield et al. 1983; Feyer-
abend et al. 1985). For application in cessation studies, the
intravenous method is impractical.
Surprisingly, snuff has not been used to vary nicotine levels in the
study of withdrawal nor in any formal cessation procedure. Given
that there are snuff users and absorption of nicotine is rapid
(Russell et al. 1980a). nasal snuff use may approximate the nicotine
delivery in a cigarette best while eliminating the habit rein-
forcers. Gritz et al. (1981) have noted that comparable levels of
nicotine can be achieved using chewing tobacco as with cigarettes.
In our own laboratory experience, we have found smokers reluctant to
switch to snuff in attempting cessation. Similarly, another means
of separating nicotine from the other reinforcers of smoke would be
in the use of nicotine-free cigarettes. These could be used in a
long-term cessation study and would allow alteration in nicotine
intake with controls for psychological variables. Unfortunately,
nicotine-free cigarettes have also been unacceptable to smokers even
for short periods in an experimental context.
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Finally, one of the most promising tools for the study of the role
of nicotine in withdrawal and cessation may come with a transdermal
nicotine patch (Rose et al. 1984). This would allow, as does nico-
tine gum, the testing of withdrawal and cessation in a potentially
acceptable form and for prolonged periods of time.
For the present, we have access to nicotine gum in several doses.
Nicotine gum is both easily self-administered and well received by
smokers. It allows for the manipulation of nicotine intake during
smoking abstinence while holding psychosocial and sensory factors
constant. Russell et al. (1976a). Russell et al. (1977); Russell et
al. (1980b); and McNabb et al. (1982) have demonstrated that nico-
tine in gum can theoretically produce blood levels sufficient to
prevent nicotine withdrawal. In addition, the slow buccal absorp-
tion does not produce the peak nicotine "boll" delivered in smoke.
Controlling nicotine withdrawal and nicotine seeking should enhance
success rates if nicotine is important in cessation. In effect, the
active and placebo gums allow for systematic testing of the role of
nicotine in the appearance and alleviation of withdrawal and in the
cessation process.
The specific questions we addressed in testing may be summarized for
outcome as follows: 1) Will use of nicotine gum enhance success
rates over placebo? 2) Under what conditions (dispensed, clinic-
support) will this occur?
The specific questions regarding withdrawal are: 1) Is there
nicotine-specific withdrawal? 2) Can nicotine replacement with gum
be effective in alleviating or preventing withdrawal? 3) Are
certain symptoms or emotional states more responsive to nicotine
replacement than others?
While there are many questions concerning selection of smokers (see
Jarvik and Schneider 1984) and parameters for proper use, the
present article will focus on outcome and withdrawal data. Results
are summmarized for two studies (clinic and dispensary) in which
outcome and withdrawal have been tested. Both published and
previously unpublished findings are reported.
OUTCOME
In several of the initial gum studies, titration was the focus of
study (Brantmark et al. 1973; Russell et al. 1976b; Turner et al.
1977). In the first two studies, active gum reduced tobacco
consumption compared to placebo controls. However, the efficacy of
nicotine gum is best studied when total smoking abstinence is
required. Several efforts to study total cessation with nicotine
gum were marred by lack of chemical verification (e.g., Puska et al.
1979). absence of long-term followup (e.g., Malcolm et al. 1980) or
inadequate controls. Raw et al. (1980) found improved cessation
rates with nicotine gum but compared those results to a
"psychological" control tested 2 years earlier.
Prior to our study, several investigators reported the advantage of
nicotine gum over placebo, depending, in part, upon the support
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conditions. Jarvis et al. (1982) implemented a cessation study in
which clinic support was provided and cessation was verified with
carbon monoxide. Nicotine gum significantly elevated success rates
at 1 year compared to a lower dose "placebo" control. The placebo
in that study was an unbuffered 1 mg nicotine gum which could
produce an active effect if enough was chewed (20 pieces). However,
conceptualized as a dose-response study, the results suggest that
the more nicotine replacement, the greater the success. Jarvis et
al. (1982) also reported that success rates were elevated for
nicotine gum when restarts were included. For a detailed
description of this study, see Russell and Jarvis, this volume.
Fagerstrom (1982) reported striking success rates in a Swedish
clinic for both nicotine and placebo groups with a significantly
higher success rate for the active gum subjects at 6 months. This
significant effect, however, disappeared at 1 year although the
trends still favor the active gum. In this study, as in Jarvis et
al. (1982). success is attributed to the interaction between active
gum use and clinic support.
In the above studies, the subjects were studied by researchers
knowledgeable in the effects and appropriate use of gum. In a study
reported by the British Thoracic Society (1983). nicotine gum plus
advice and a smoking dangers booklet did not improve success rates
over advice alone, advice plus the booklet, or placebo gum plus
advice and the booklet. Rates were low (between 8-12%) across
groups. The authors attribute their poor findings to the population
(chest clinic patients who may have been unmotivated) and to poor
instructions but concluded that their study reflects instructed use
in the real world. In a critique of that study, Jarvis and Russell
(1983) take issue with that conclusion and point out additional
flaws in the study. To those criticisms it should be added that
nicotine gum in the British Thoracic Society study (1983) was given
with "instructions to substitute it for a cigarette when there was
an urge to smoke." From our own pilot work, we have found that
allowing any smoking with chewing undermines cessation.
The issue of what conditions of support may be necessary for success
with nicotine gum was the focus of our outcome testing (Schneider et
al. 1983). Two studies had been designed to test the efficacy of
nicotine vs. placebo gum use. In one, clinic support was provided
for both groups; in the other, gum was "dispensed" with minimal
intervention. The latter was intended to mimic administration of,
gum by physician prescription where little support and/or followup
may be provided. The most recent clinical replications (Hall et al.
1984; Hjalmarson 1984; Killen et al. 1984) and recent physician
studies (Jamrozik et al. 1984; Russell et al. 1983) are discussed
later.
Method
In both studies, subjects were heavy smokers (30-35 cigarettes a
day) in good health who had tried repeatedly to quit smoking. The
studies were double-blind, and subjects were allowed to chew the gum
ad lib both in terms of daily number of pieces and length of time on
gum. The clinic study included measures of withdrawal which are
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described in the next section. Baseline questionnaires and repeated
measures testing are listed in table 1. The tests listed under
repeated measures were all given at baseline with the exception of
the questionnaires on side effects and gum use.
TABLE 1
Materials
Baseline Materials - All Subjects
1.
2.
3.
4.
5:
8:
9.
10.
11.
12.
13.
14.
Consent Forms
Subject Bill of Rights
Health Screening
Smoking and Quitting History
(includes demographics)
Motivation Questionnaire
Expectations Questionnaire
Why I Smoke
Smoking Occasions
Why I Want to Quit
Fagerstrom Tolerance Questionnaire
Weight Questionnaire
Gum Instructions
Address Sheet
Subject Comments and Questions
Repeated Measures - Clinic Groups
1. Pulse Rate
2. Weight
3. Daily Abstinence - 2 Scales:
Schneider Smoker Complaint Scale (SCS)
Shiffman-Jarvik Scale
4. Mood Checklist
5. Carbon Monoxide
(as verification in all groups;
as feedback in clinic groups)
6. Side Effects
7. Gum Use - Satisfaction and Open-Ended Remarks
Treatment
Treatment consisted of either 2 mg nicotine gum or placebo gum. The
low dose (2 mg) was chosen to avoid side effects associated with
4 mg gum although eventually mixed use of both doses may prove ad-
vantageous (see Schneider et al. 1977). Subjects were instructed to
chew each piece slowly for 20 to 30 minutes to insure the release of
nicotine. Buccal absorption was explained. Weaning from nicotine
may be said to begin with the switch from cigarettes to gum in terms
of both the slower absorption and reduced speed of reinforcement.
With 2 mg gum the immediate blood levels are reduced compared to
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4 mg gum or a 1.2 mg cigarette as noted earlier. Three-month
prolonged use of 2 mg gum has also recently been shown to produce
significantly less nicotine than cigarettes or 4 mg gum (McNabb
1984). The oral-manipulative component of gum use was expected to
aid cessation while not disrupting extinction of smoking behaviors.
Procedure
Subjects were given the baseline questionnaires for survey purposes
and for assessment of their selective and predictive value.
Baseline scores were obtained for all repeated measures and tests
(see table 1).
Sixty subjects participated in the clinic study - 30 subjects in the
nicotine group and 30 subjects in the placebo group. Total
abstinence was required and was verified at all test intervals
(including daily the first week) with carbon monoxide expired air
analyses. Following baseline testing (always on a Friday), clinic
subjects were instructed to quit the next Monday morning and were
given pieces of gum to take home. Subjects then came to the
laboratory dally for 1 week for testing (withdrawal, CO, pulse rate,
gum use, weight) and for individual support sessions with the
experimenter. The sessions lasted between l/2 and 1 hour. Clinic
subjects were also asked to fill out withdrawal scales at home in
the morning and evening for the first week of abstinence (see
withdrawal section). Followup test intervals (including ail
measures and support) occurred weekly for 4 additional weeks and
then at 3 months, 6 months, and 1 year. Not counting baseline, this
amounted to a total of 12 visits for subjects completing the study.
The dispensary groups consisted of 13 nicotine gum subjects and 23
placebo gum subjects. Testing at baseline was identical for clinic
and dispensary groups. However, subjects in the dispensary groups
did not return to the laboratory for first-week testing and
support. One appearance was required (on Thursdays) for gum
supplies and CO verification of abstinence in the first week.
Thereafter, subjects appeared once a week for 4 more weeks and at 3
months, 6 months, and 1 year for verification and supplies. No
testing (besides CO) was allowed at any of the followup intervals.
Thus, the baseline testing and abstinence checks served as minimal
intervention compared to the clinic groups.
Results
Results of the clinic study and dispensary study appear in Schneider
et al. (1983). A survival analysis was performed on outcome curves
for both groups in the clinic study. The success rates are
presented in figure 1. The nicotine group was significantly more
successful than the placebo group in abstinence over time (p<.03).
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FIGURE 1
Clinic Group Success Rates: Nicotine vs. Placebo Gum
Adapted from Schneider et al. (1983). Copyright 1983, Pergamon
Press, Ltd.
As can be seen from figure 1, the differences between groups are
most apparent at 3-4 weeks and at 6 months. The groups are fairly
equivalent during first-week treatment and separate by the second
week with a peak difference at  6 months (28%). Between 6 months and
1 year, relapse in the nicotine group reduces the difference to 10%.
Success curves for the two dispensary groups are presented in figure
2. The data in figure 2 indicate that neither 2 mg nor placebo gum
was effective in cessation when no support or guidance was offered.
After 1 week, both groups had dropped to the same level and by 1
year, low rates of 8% for nicotine and 13% for placebo were
observed. It should be noted that subjects stopped using gum in the
dispensary groups within the first few days to 1 week of the study.
The only difference in the clinic and dispensary groups following
baseline testing and instructions was the first-week support and
testing provided for the clinic groups. It is assumed that the
clinic appearances indirectly and directly encouraged the subjects
to continue gum use.
With support, nicotine gum clearly enhanced short-term (6-month)
success rates over placebo (Schneider et al. 1983). These clinic
results are consistent with the placebo-controlled findings of
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FIGURE 2
Success Rates: Dispensary Study
Adapted from Schneider et al. (1983). Copyright 1983, Pergamon
Press, Ltd.
Fagerstrom (1982) and Jarvis et al. (1982), although in the latter
success rates between treatments were still significant at 1 year.
The differences between the groups in the Jarvis et al. (1982) study
were as high as 47% with nicotine gum vs. 21% treated with an un-
buffered 1 mg nicotine placebo. When a stricter criterion of out-
come was used in which no relapses between the initial assessment
and end assessment were allowed, these figures remained significant
at 31% in the active group vs. 14% in the placebo group.
In a study comparing nicotine gum to placebo gum (Hjalmarson 1984),
success rates w
the active gum
(1984) and Kill
combination wit
format. In Hal
nicotine gum wi
ment by itself,
treatment plus
ere also doubled at 1 year, with 29% abstaining in
group vs. 16% in the placebo group. In Hall et al.
en et al. (1984), the value of clinic support in
h active gum use was demonstrated in a different
l et al. (1984), subjects were assigned to either
th minimal intervention, intensive behavioral treat-
or to a combination of the intensive behavioral
nicotine gum. The combination of the nicotine gum
plus the intensive treatment produced better success rates than the
other two conditions. This was significant at the 3-month and
6-month intervals, but not at 1 year. This was validated with blood
cotinine levels and those with the higher levels appear to be helped
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more by nicotine gum than those with lower levels at the start of
the study. Interestingly, and in contrast to the physician studies
to be discussed below, the low contact nicotine gum group did better
than the behavioral only group; however, the low contact group did
meet four times over a 3-week period, which in itself constitutes
some intervention.
In Killen et al. (1984) the subjects were assigned to one of three
conditions: nicotine gum only, skills training only, or a combi-
nation of skills training and nicotine gum. There was some inter-
vention in the nicotine gum only group in that they attended a
clinic weekly for 7 weeks to receive gum and complete assessments.
Abstinence rates at 10-l/2 month followup were 23% for nicotine gum
only, 30% for skills training only, and 50% for a combination of the
skills training plus nicotine gum. Carbon monoxide and thiocyanate
levels verified the subjects' reports of abstinence. In this study
a combined treatment doubled the rates obtained with nicotine gum
alone.
The studies which look at some form of dispensary tactic show mixed
results. In our study, simply dispensing nicotine or placebo gum
resulted in early failure and in no differences between the groups.
Similar findings were observed in the British Thoracic Society
(1983) and Jamrozik et al. (1984) studies. The British study has
been correctly critiqued by Jarvis and Russell (1983) and, in
general, problems with dispensing may be due to inadequate
instruction and training in proper gum use.
While the clinical studies clearly show that support systems are
instrumental in producing successful cessation, we cannot conclude
that dispensing cannot be successful. It may be that variables
involving the carefully instructed use of the active gum may play a
part in its viability as a smoking cessation tool. For example,
Russell et al. (1983) reported a study in which there was a
nonintervention group; a second group receiving advice to stop
smoking, a booklet, and a warning of followup; and a third group
receiving the same as the second group but with the offer of
nicotine chewing gum. The results showed that the overall rate of
cessation is lower than anything observed in clinics. For the
no-advice group there was a 3.9% success rate, for advice only a
4.1% success rate, and for advice plus nicotine gum an 8.8% success
rate. However, when the data were analyzed by the amount of gum
used, those subjects who used more than one box of gum had a
long-term success rate of 24% after validation. This is a
surprisingly high success rate considering the very minimal
intervention in this study. It suggests that if we can identify the
use variables which enhance success, we can increase success rates
with the dispensing of gum. This is particularly important in that
physicians can prescribe this preparation and have the opportunity
to help in the treatment of cigarette smoking.
In a variation of the low contact physician studies, Fagerstrom
(1985) looked at short- vs. long-term followup with nicotine gum vs.
no gum. He found significant differences between nicotine gum and
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no gum groups at 1 year with validation. Again, the rates were
lower than in any of the clinical studies, but differences were
still observed. At 12 months the following was reported for four
groups: a group given advice, long-term followup, and nicotine gum
showed a 27% success rate. Advice, short-term followup, and
nicotine gum yielded a 22% success rate. Advice, long-term
followup, and no gum reduced success to 15%. Finally advice,
short-term followup, and no gum produced a low 3% success rate.
The clinic and physician studies taken together show that success
rates can be enhanced 1) with active gum compared to no gum or
placebo, and 2) with support vs. minimal or no behavioral
intervention. It should be noted that in the present study it is
not necessarily known which aspects of the support system
contributed to success. On the one hand, individual attention and
problem-solving were offered by the experimenters. Lowered carbon
monoxide levels served as positive feedback. Test taking, in
itself, may have helped by allowing the subject an outlet for
dysphoria and the difficulty of quitting. Thus, strong
psychological support was provided in the first week and ensuing
followup visits. On the other hand, by coming to the laboratory
daily, the subject was encouraged to continue using the gum. Side
effects and fears associated with use could be allayed and increased
use tested in a "safe" setting. It may be this initial monitoring
of use per se that accounts for success.
One final issue that also has not been systematically tested is that
of length of use. Several investigators have observed post hoc that
longer use (3 to 4 months) may be a significant factor in outcome
(Russell et al. 1980b, 1983; Wilhelmsen and Hjalmarson 1980) and
that by extending use past at least one box, success rates can be
elevated.
In summary, initial use and prolonged use of nicotine gum may both
figure prominently in outcome. We cannot conclude from the present
work that the enhancement of success with clinical support is due to
psychological factors alone. Use variables (dose, number of pieces,
length of time on gum, instructions) must be defined through
controlled evaluation. We suggest that appropriate dose and
carefully instructed use are critical and that intervention should
focus on long-term relapse prevention. Ultimately, a combination
consisting of physicians advising patients to stop, treatment of
pharmacological dependence, and long-term behavioral training and
support could provide the most valuable smoking cessation inter-
vention to date.
WITHDRAWAL
Underlying the development of nicotine gum and its use in cessation
are the assumptions that nicotine withdrawal occurs and that its
alleviation through a replacement procedure will improve success
rates. The questions are 1) Can nicotine-specific withdrawal be
demonstrated? and 2) If so. will replacement other than in bolus
smoke delivery be effective? If nicotine gum alleviates or prevents
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symptoms compared to placebo, then it is effective. By inference,
withdrawal symptoms (to the degree they are relieved) can be
attributed to the removal of nicotine per se. Ultimately, symptom
relief should correlate with short-term and/or long-term success in
cessation.
In the early studies using nicotine gum, titration effects, by
combining gum and smoking and continued partial reinforcement with
smoking, precluded the assessment of withdrawal. Brantmark et al.
(1973) acknowledged that their attempts to measure withdrawal were
rendered "meaningless" because of the simultaneous use of gum and
smoking. In Puska et al. (1979) the same problem is encountered.
In a recent and interesting study by West et al. (1984), smokers'
baseline blood levels were taken and compared in one group with a
switch to an ultra-low nicotine cigarette. It was observed that
plasma nicotine concentrations dropped 60% when they were switched
to the ultra-low cigarette. A slight drop in heart rate and an
increase in hunger were observed with the lowered levels. However,
it was not paralleled by typical withdrawal symptoms such as
irritability. Ironically, this is consistent with the concept of a
lesser replacement of nicotine with nicotine gum. That is. in both
instances the partial amount of nicotine obtained provides enough
nicotine to alleviate irritability. Although some physiological
changes were observed in this study, nicotine-specific withdrawal
will probably be best demonstrated by comparing nicotine replacement
to no replacement.
In Jarvis et al. (1982). withdrawal symptoms were measured in
nicotine and placebo groups during total abstinence from smoking.
Ratings of withdrawal were taken once a week and averaged across 6
weeks. Unfortunately, abstinence was confirmed with carbon monoxide
breath analyses only at 1 year and not at earlier intervals. It
should also be noted that not all subjects attended all sessions,
although this probably occurred for both groups. The authors used
an unbuffered 1 mg nicotine gum as their placebo which, as they
point out, can produce a pharmacological effect when enough is
chewed (20 pieces). In this sense, the study is a dose-response
comparison. Given these qualifications, this remains one of the few
early tests of withdrawal during total abstinence. Jarvis et al.
(1982) reported significantly "less irritability" and "less hunger"
for the 2 mg group compared to the 1 mg unbuffered controls.
Several other symptoms were reduced in the 2 mg group but these
differences were not significant.
In our clinic study, withdrawal measures were obtained daily for 5
days for 50 subjects remaining abstinent. Twenty-six subjects
formed the nicotine group and 24 formed the placebo group. To
insure completion of scales, the scales were given in the laboratory
(in-lab) each day. Carbon monoxide tests were also taken daily to
confirm self-reported abstinence.
Pulse rate was taken as a physiological measure of withdrawal.
Subjective responses were obtained using a Smoker Complaint Scale
(SCS), the Shiffman-Jarvik (1976) Scale, and a mood checklist.
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Ratings were obtained for four physical symptoms associated with
withdrawal from smoking (Shiffman 1979). Because of item wording
and scaling problems in the Shiffman-Jarvik Scale, the study focus
was on the SCS. This scale was derived from smokers' reports on the
nature of withdrawal symptoms experienced in previous cessation
attempts. These reports were obtained from pilot subjects and
subjects in a "cold turkey" study. Responses were scaled so that I
represented "very definitely not" and 7 represented "very defi-
nitely." The SCS consisted of the following 14 items: anxiety,
irritability, fluctuations in mood, craving for cigarettes, concern
about weight, trouble sleeping, disorientation, impaired concen-
tration, depression, feeling left out, restlessness, hostility,
annoyance, and frustration. Where items overlapped with the
Shiffman-Jarvik Scale (e.g., irritability), responses were checked
for consistency between the scales. The mood checklist is described
in the following section along with those results. The four
physical items included: nausea, constipation, diarrhea, and
headache.
Results
Pulse rate and SCS total scores appear in Schneider et al. (1984).
Pulse rates decreased significantly for placebo subjects (15 bpm
over 5 days) compared to a slight reduction in those using active
gum (4 bpm over 5 days). For SCS totals a repeated measures ANOVA
with trends was performed on the data. A significant effect of
treatment was observed (p<.03) as well as a significant quadratic
treatment x time interaction (p<.Ol). The pattern was as follows:
baselines did not differ between groups (separate ANOVA); for both
groups there was a rise from baseline to Day 1; thereafter,
withdrawal in the placebo group continued to increase in severity
while symptom reduction occurred in the nicotine group. Differences
between groups were significant for Days 2, 3, and 4, By Day 5, the
group scores tended to merge. When baselines were covaried, the
results were the same except that the quadratic component became
linear. Figures for the pulse rate and withdrawal findings by
treatment are presented in Schneider et al. (1984).
We also attempted to look at which items were more sensitive to
nicotine replacement than others (previously unreported data, table
2). As can be seen from table 2. almost every symptom on the SCS
scale except for weight concern and craving showed a significant
increase from baseline smoking levels to abstinence days. In
addition, annoyed, hostile, irritable, and fluctuations in mood
showed significant changes between groups with frustration and
depression showing borderline effects.
Craving and weight concern showed no effects on the SCS. From the
Shiffman-Jarvik Scale, craving was assessed by asking the question
differently in two ways: Do you have an urge to smoke right now?
and do you miss a cigarette? On that questionnaire those two items
showed significant quadratic treatment effects at the p<.05 level.
Given that craving is one of the most important issues, these three
items taken together suggest that semantics are going to be a key
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TABLE 2
Item Analyses for the SCS Scale*
Withdrawal Symptom Main Effect Main Effect Interaction
Time Treatment
Annoyed p<.001** p<.OO8
Hostile p<.001** p<.03 p<05**
Irritable p<.OOl p<.05 P<.03
Fluctuations in Mood p<.Ol p<.05 P<.04
Frustration p<.001** p<.O6 ns
Depression p<.002** p<.07 ns
Left Out p<.02** ns ns
Anxiety p<.OOl ns ns
Concentration p<.001 ns ns
Disorientation p<.OOl ns ns
Restlessness p<.OOl ns ns
Trouble Sleeping ns ns P<.01
Concern About Weight ns ns ns
Craving ns ns ns
*Analyses of Variances were performed on each item and included
baseline and 5 days of abstinence.
**These differences disappeared when baseline was used as a
covariate. Thus, there was an initial rise from baseline (still
smoking) to abstinence days but no additional differences in
temporal course beyond that rise.
issue in assessing "craving." These data represent a preliminary
analysis of the item-by-item data for this study. Hunger on the
Shiffman-Jarvik Scale was significantly reduced with nicotine gum
(p<.05) compared to placebo gum, whereas for the item measuring
weight concern no differences were found.
It should be kept in mind that with ad lib use we are not certain to
what degree differences in amount of chewing accounted for the
results. For example, where there are no differences between
groups, it may be that more pieces of 2 mg gum or a higher dose is
indicated, particularly in the first week. In a current
uncontrolled clinical trial it has been observed that lethargy,
spaciness, and disorientation respond to the 4 mg dose of gum where
the 2 mg dose is less effective. Also, consistent and minimal use
of 2 mg gum (10 to 15 pieces daily) helped reduce symptoms such as
anxiety, irritability, and restlessness better than low level (5 to
6 pieces daily). A dose-response study should define the extent to
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which symptoms can be alleviated with nicotine gum (Schneider,
unpublished data; manuscript in preparation).
above
SCS
into
figure
3. The number of subjects within each category were as follows:
nicotine gum female (12); nicotine gum male (14); placebo gum female
(14); placebo gum male (10).
An ANCOVA was also performed on the withdrawal data described
for treatment x sex. Thus, these results are the same as the
totals described above except that conditions are subdivided
male and female. The treatment x sex findings are graphed in
The main effect of treatment was significant (p<.O5), and there is
little overlap between treatments (both placebo groups vs. both
nicotine groups in figure 3). The pattern (with baselines covaried)
showed a significant quadratic component (p<.Ol) with all groups
reporting withdrawal at Day 1. separating during the middle 3 days,
and merging at Day 5. No main effect of sex was observed and there
were no interactions between treatment and sex over time. This may
have been a consequence of the small sample size when groups are
divided in this manner. It is tempting to explore possible gender
effects further in a larger sample. As Gritz (1980a) has noted,
male/female differences have received little attention.
The pattern of responding suggests that nicotine gum may not be
effective in first-day withdrawal. This could be a consequence of
anticipation factors, of inadequate dose (including the initial
Baseline Day 1 Day 2 Day 3 Day 4 Day 5
FIGURE 3
SCS Withdrawal Responses by Treatment and Gender
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change from inhalation bolus to gum). improper gum use (subjects may
have waited for first clinic visit). or may be attributable to
changes with cessation (e.g., loss of ritual behaviors). The
effectiveness of the gum becomes apparent as cessation progresses.
A dose-response study should clarify whether symptoms can be
alleviated entirely with replacement.
In addition to totals, specific items, and sex differences, we
looked at a time-of-day effect in compliant subjects. Subjects were
asked to fill out the withdrawal scales at home in the morning and
evening. Of the 50 abstinent subjects providing the in-lab data, 3.2
cooperated in filling out the home scales. These results have been
reported in Schneider and Jarvik (1984). The basic finding was a
treatment x time-of-day effect. For placebo subjects, the severity
of withdrawal symptoms was significantly higher than nicotine
subject responses and increased in the evenings compared to a more
stable withdrawal level in the nicotine group. The results indicate
that withdrawal varies within a given day as well as across days and
that nicotine is implicated in these fluctuations.
Mood Effects
A mood checklist (items were taken from the POMS mood scale)
included 27 items reflective of positive and negative states.
Thirteen items were positive: active, alert, carefree, cheerful,
clear-headed, considerate. efficient, friendly, full-of-pep, lively,
optimistic. proud, and relaxed. Thirteen items were negative:
angry, bad-tempered, confused, hopeless, miserable, muddled,
nervous, sad, shaky, spiteful, tense, unworthy, and worn-out. One
item was dropped (ready-to-fight) because some subjects perceived
this as positive and others as negative. In responding, the subject
checked as many of the adjectives as applied at the moment. There
was no mandatory responding on a scale as required with the SCS
items. Responses were recorded as total number checked for the 13
positive items and total checked for the 13 negative items. These
totals were obtained for baseline scores and for each of the 5 days
of abstinence. For the positive items, the results (previously
unreported) are presented in figure 4.
A repeated measures ANOVA with trends was performed on the positive
item totals for all days. The results showed a significant effect
of treatment (p<.Ol) as well as a significant quadratic treatment x
time effect (p<.02). Subjects on nicotine gum showed only a slight
decrease in positive responses checked. For placebo subjects, the
drop from baseline to Day 1 is fairly sharp and stays lowered
through the first few days. Note that for the SCS scores, the
effects are also quadratic but the separation between groups does
not occur until Day 2.
The results for negative items (also previously unreported) are
consistent with the positive affect pattern by treatment. Placebo
gum subjects showed a greater increase in negative responses than
nicotine subjects. The repeated measures ANOVA with trends showed
no significant main effects or overall interactions, so a
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FIGURE 4
Positive Items Checked During
5 Days of Abstinence From Smoking
significant quadratic treatment x time effect was ignored. The
problem with the negative item testing was that a floor effect
occurred. Out of the 13 possible responses, mean responding ranged
from 0.50 to 1.70 for the placebo group and 0.53 to 1.11 for the
nicotine group. A review of the items suggests that a social
desirability effect may have been operating. The items are very
strongly negative and tend to go against feelings of self-worth that
a smoker trying to quit may be seeking. Because the items are
checked, there is no qualifying of the response. By contrast, we
were able to assess negative changes in state with the SCS through
use of scaled responding and through use of specific complaints
associated with smoking cessation.
The withdrawal findings for 5 days of first-week abstinence provide
support for the proposed mechanism of action with gum use during
cessation. Nicotine replacement alleviated or prevented symptoms
compared to nonreplacement with placebo. These findings have been
supported by recent reports in the literature of nicotine-alleviated
withdrawal (Hughes et al. 1984; West et al. 1984).
In the Hughes et al. (1984) study, symptoms of withdrawal were
measured in 100 smokers. After baseline measurement subjects
received either nicotine or placebo gum in a double-blind study and
were tested in the first, second, and fourth evenings of abstin-
ence. Hughes et al. (1984) report reductions in irritability.
anxiety, difficulty concentrating, restlessness, and impatience
between groups, with nicotine gum alleviating the symptoms. The
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nicotine replacement did not reduce increases in craving. hunger,
eating, insomnia, tremulousness, or supine heart rate after
cessation.
In West et al. (1984) 48 smokers were either given 2 mg nicotine gum
or a .5 mg unbuffered nicotine gum "placebo" for 24 hours of
cigarette deprivation. In that study, the 2 mg gum alleviated
irritability, depression, and difficulties with social interaction,
but not hunger or ability to concentrate. As in our study, the drop
in heart rate was reduced with active gum. In West et al. (1984)
and Hughes et al. (1984) the authors conclude that nicotine
replacement reduces symptoms of withdrawal and that nicotine
deprivation plays a significant role in producing these effects.
In a recent paper, West (1984) has summarized the four studies
representing tests of withdrawal during total abstinence. In
conclusion, we suggest that with proper dosage we may reduce most,
if not all, symptoms of withdrawal. Maintenance of higher blood
levels will be important while the person is already reducing levels
of nicotine from cigarettes. As the person adjusts to changing
levels, relief should require less and less replacement with gum.
However, we cannot view nicotine dependence and withdrawal as
operating only in the short term. Urges to smoke long after
cessation may represent conditioned nicotine-seeking and coping
behavior.
SUMMARY
Our data and that of researchers in the area clearly provide
evidence for nicotine-specific withdrawal and its relief with
nicotine gum. In addition, outcome efficacy is enhanced when
nicotine gum is combined with behavioral treatment.
Nicotine gum appears to be valuable both as a systematic tool and as
a means of combatting short- and long-term nicotine seeking that
contribute to maintenance of smoking and the inability to quit.
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Nicotine Chewing Gum in Smoking
Cessation: Efficiency, Nicotine
Dependence, Therapy Duration, and
Clinical Recommendations
Karl-Olov Fagerstrom and Bo Melin
This paper will deal with four topics pertinent to nicotine gum:
(1) A review of the placebo-controlled trials of the nicotine gum;
(2) An analysis of how nicotine dependence interacts with nicotine
gum therapy; (3) An analysis of duration of nicotine gum therapy;
and (4) Experiences and recommendations derived from clinical
practice.
REVIEW OF CONTROLLED TRIALS WITH NICOTINE GUM
The review covers smoking cessation studies that satisfy the
criteria of (a) placebo control, (b) blindness, (c) randomization of
subjects, and (d) long-term followup.
Table 1 shows the studies that meet the above requirements. The
studies are characterized in terms of additional therapy format,
number of subjects, time of followup and abstinence rates.
TABLE 1 Outcome from Placebo-Controlled Cessation Studies
Trial % nonsmokers Follow- Additional
Active Placebo up at therapy
Fee, Stewart *+ 1982 13 9 1 year Lectures
Puska et al. * 1979 35 28 6 months Group
Fagerstrom 1982 49 37 1 year Individ.
Jarvis et al. 1982 47 21 1 year Group
Malcolm et al. 1980 23 5 6 months Individ.
BTS 1983 10 14 1 year None
Hjalmarson 1984 29 16 1 year Group
Schneider et al. 1983 30 20 1 year Group
Jamrozik 1984 10 8 6 months Indlvid.
N
352
160
96
116
210
802
205
60
200
* No CO-verification of claims
+ Only 18% of subjects were followed up
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Eight of the nine studies show an advantage for the nicotine gum,
although it does not, in most cases, reach statistical signifi-
cance. When the studies are analyzed in terms of setting and the
therapist's profession, it is evident that the best results are
obtained by psychologists experienced in smoking cessation therapy
and working in a cessation clinic with probably more motivated and
dependent patients (Fee and Stewart 1982; Fagerstrom 1982; Jarvis et
al. 1982; Hjalmarson 1984; and Schneider et al. 1983). That does
not mean that psychologists' interventions are inherently better.
Rather, physicians and other health care professionals would obtain
the same effects if they used it in the same ways as it is used
within a special cessation clinic.
NICOTINE DEPENDENCE
The concept behind the nicotine gum is that, while substituting
nicotine gum for cigarettes, the need for nicotine can be satisfied
while the psychosocial part of tobacco dependence may first be
addressed. In the next step the pharmacological dependence of
nicotine should gradually be dealt with. The smoker's dependence on
nicotine is, thus, a crucial factor in the therapeutic rationale of
the nicotine gum. Nicotine dependence varies considerably from
smoker to smoker, and a hypothesis would be that the more the smoker
is dependent on nicotine, the better the effect of the gum should be
relative to placebo or a non-gum condition. In Table 2 is a scale
(Fagerstrom Tolerance Questionnaire) for measuring the dependence of
nicotine among smokers (Fagerstrom 1978).
The questions are individually scored and summed to provide a
composite score in the range from 0 to 11, in which the higher
values reflect greater dependence. The results from the published
studies, where nicotine dependence has been related to nicotine or
placebo gum are presented in table 3.
The Fagerstrom (1982) study defines high dependence as 8 points and
above and low dependence as up to 6 points. In the second Fager-
strom report (1984), as in the rest of the studies, the patients
have been divided into halves, split by the median value 6 or 7
points. The followup times are for Fagerstrom (1984) and Jarvik et
al. (1984) 12 months, for Fagerstrom (1982) 6 months, and for
Christen et al. (1984) 6 weeks. As can be seen from table 3, the
increased likelihood among high nicotine dependent smokers to reach
long-term abstinence with the help of nicotine gum is greatly
enhanced.
DURATION OF NICOTINE GUM THERAPY
When smokers who are trying to quit are offered nicotine gum without
any instructions concerning how long they should use it, the
duration of use varies considerably. Some will only use a few
pieces of gum throughout the whole therapy, while 5-10% will have
difficulties in terminating nicotine gum use. How long then should
nicotine gum treatment be continued in order to secure the best
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TABLE 2 The Fagerstrom Questionnaire
Questions
1 How soon after you wake do
you smoke your first
cigarette?
2 Do you find it difficult to
refrain from smoking in
places where it is forbidden;
e.g., in church, at the
library, in cinemas, etc?
3 Which cigarette would you
hate most to give up?
4 How many cigarettes a day
do you smoke?
5 Do you smoke more frequently
during the early morning
than during the rest of the
day?
6 Do you smoke if you are
so ill that you are in bed
most of the day?
7 What is the nicotine level
of your usual brand of
cigarettes?
8 Do you inhale?
Answers Points Score
Within 30 min 1
After 30 min 0
Yes 1
NO 0
The first one in 1
the morning
Any other 0
15 or less 0
16-25 1
26 or more 2
Yes 1
No 0
Yes 1
No 0
0.9 mg or less 0
1.0 mg - 1.2 mg 1
1.3 mg or more 2
Never 0
Sometimes 1
Always 2
long-term abstinence rates? At the moment there are few scientific
data on which to draw. Russell et al. (1980) suggest that "it might
be worth encouraging smokers to persist with the gum for at least 4
months." To support their view they rely on clinical experiences
and a finding from a trial by Raw in 1980, where 67% of the patients
using the gum for 3 months or longer were abstinent at 12 months in
contrast to the overall figure of 38%. Another figure, cited by
Russell et al. (1980). is a 68% 4-year abstinence rate obtained by
Wilhelmsen and Hjalmarson (1980) for the subjects who had used
nicotine gum for at least the first 4 months. However, the
abstinence rate at 4 years was the same for those persons who were
neither smoking nor chewing gum at 4 months after stopping smoking
(Hjalmarson 1982). In a placebo-controlled trial from the Addiction
Research Unit, Maudsley Hospital, some data pertinent to the length
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TABLE 3 Abstinence Rates in Relation to Nicotine or Placebo Gum and
Nicotine Dependence
High dependent N Less dependent N
Nic. Placebo Nic. Placebo
gum gum gum gum
Fagerstrom (1982) 71% 39% 35 75% 65% 40
Fagerstrom (1984) 26
Christen et al. (1984) 46
5* 67 32 13 76
9 80 28 12 113
Jarvik et al. (1984) 41 8 17 0 30 8
* No gum
of chewing were reported by Jarvis et al. (1982). The l-year
abstinence rate for the subjects chewing for 3 months was 75% for
nicotine chewing and 62% for placebo gum. In another controlled
trial (Fagerstrom 1982), no difference in long-term abstinence rates
could be seen as a function of time on nicotine gum.
The fact that long-term chewers of nicotine gum generally have good
or excellent abstinence rates should not be surprising and may not
be caused by gum use. Both longer use and abstinence may be
modulated by a third variable such as motivation. A long-term
chewer is a former smoker who has managed to terminate, and maintain
non-smoking for a number of reasons. Nicotine chewing gum is one of
several factors in obtaining and maintaining abstinence, and it may
serve as both a dependent and an independent variable.
At the Smoking Cessation Clinic in Uppsala, Sweden, a prospective
study has been completed (Melin 1984). "Time on gum" has been
deliberately manipulated for 121 consecutive patients. They were
randomized into 1 (n=61) or 6 (n=60) months of nicotine gum use.
They were given access to the gum for their respective time without
instructions to continue chewing until the deadline. In addition to
nicotine gum, they received the standard, individual, cognitive
behavioral-oriented counseling offered at the clinic. The number of
sessions varied according to the subjects' need. Both 2 and 4 mg
doses of the gum were used, according to the need of the subject.
Figure 1 shows that the 6-month group is somewhat superior to the
one-month group at 3 and 6 months. However, the long-term
abstinence rates are equal, since many of the 6-month subjects
relapsed when gum therapy was discontinued at 6 months. Thirty-nine
percent were abstinent in the l-month group at 12 months follow-up
and 32% in the 6-months group.
Many subjects, forced to cease chewing nicotine gum at 1 month,
relapsed. Since their treatment protocol allowed for individual
variation in the number of sessions given each patient, a post hoc
analysis of number of sessions given the groups was made to deter-
mine if the nonpharmacological part of the treatment compensated for
discontinuing chewing. No significant difference was seen during
the first month. However, when the whole length of treatment was
reviewed, 5-7 months after quitting, the l-month group
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Figure 1: Abstinence Rates Over Time for 1 Months and 6 Months
Nicotine Gum Treatment
had significantly more treatment sessions than the 6-month group
(8.5 compared to 7.2, t=2.0, p<.05). It appears that time on
nicotine gum was unintentionally traded for more nonpharmacological
treatment sessions.
Optimal time on nicotine gum may therefore interact with the degree
of psychological support given. The less support, the more the
ex-smoker has to rely on nicotine gum, and vice versa. At the
moment, no hard scientific evidence exists for recommending any
specific duration of nicotine gum therapy. The best advice
available today is to keep in close contact with the ex-smoker and
let him or her determine the duration.
EXPERIENCES AND RECOMMENDATIONS FROM CLINICAL PRACTICE
Many smokers feel anxious about terminating smoking. Smokers
seeking help often expect and are afraid of physiological and
psychological reactions that they have encountered in earlier
unsuccessful attempts. Describing the nicotine gum's effect on
physiological abstinence and concurrently conveying a skilled and
experienced therapist's commitment to giving psychological support,
usually creates a therapeutic effect on patients' anxiety and
instills a sense of optimism despite several prior cessation
attempts. Naturally, a warm and accepting attitude may increase the
likelihood of a favorable outcome. The therapeutic atmosphere with
renewal of nicotine gum prescription as well as other methods of
nonpharmacological support does motivate the patients to come to
scheduled appointments.
Consumption of gum is likely to vary across patients. Most patients
chew about 8-10 pieces of gum per day, but there are considerable
individual differences. The patients usually chew the gum for 2-3
months. After 3 months most of the patients cease chewing. About
5-10% will have difficulties in stopping using the gum and need
strong psychological support to finally break their addiction to
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nicotine. One way to handle the patients who find it difficult to
give up using nicotine gum may be to have them switch to a
nicotine-free chewing gum. Sometimes patients may simply have
developed a new habit (gum chewing) and may be quite able to stop
using nicotine.
At the clinic in Uppsala. where the authors have been working, the
abstinence rate rose by about 15% when nicotine gum was introduced
in the treatment. However, it should also be kept in mind that
nicotine gum alone -is seldom sufficient. Nicotine gum is a comple-
ment to psychosocial treatment for helping people to stop smoking
(see Hall and Killen, this volume). We have not observed any severe
side effects in the 6 years during which nicotine gum has been used
in our clinic. As long as chewing instructions are appropriately
given, the adverse reactions usually involving taste and irritation
in throat and stomach can be well controlled. It is found that
nicotine gum is tolerated by approximately 90% of the smokers.
Recommendations
Nicotine gum should be used only when smoking is completely
terminated and not in conjunction with successive reduction of
smoking.
When nicotine gum is prescribed, it should be in sufficient
quantity and for a sufficiently long time period. The exact
quantity and time period are best judged by the patient. The
more nicotine-dependent smokers usually chew more pieces per
day, need nicotine gum for a longer period, and also tend to
prefer the 4 mg strength more often than the less dependent
smokers.*
Nicotine dependence should be assessed. If the smokers'
dependence score is in the upper half of the distribution
(usually about 7 points and above), it is a strong indication
for prescribing nicotine gum.
It is firmly recommended that a sample of nicotine gum should be
kept in the therapist's office. Let the patients chew a piece
of gum while instructed and supervised. This will facilitate
the acceptance of nicotine gum and the choice between 2 and 4 mg
dosage.*
Since many patients are at high risk for relapse when nicotine
gum therapy is discontinued, it is suggested that an appointment
be made with the patients after nicotine gum chewing has
terminated.
*Note: The 4 mg gum is not currently available in the U.S.
Dosage must be adjusted by number of pieces chewed.
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Theoretical Background and Clinical
Use of Nicotine Chewing Gum
M. A. H. Russell, FRCP, FRCPsych., and
M. J. Jarvis, MPhil.
If we accept the fact that the use of tobacco in its
various preparations is a form of drug addiction, even
though a pleasant one not affecting criminal statistics,
we can more readily help our patient when he finds that
his problem has gotten out of hand.
John L. Dorsey, MD, FACP, Baltimore, Maryland, 1936.
INTRODUCTION
For many years campaigns and treatments to promote smoking
cessation have had disappointing results. In our view, this is
because for most smokers cigarette smoking is a form of drug
dependence and our programmers have failed because they have not
taken this sufficiently into account. But the prospects are now
brighter for more successful intervention in the future.
Firstly, there is more widespread appreciation of the addictive
nature of smoking and, secondly, the development of nicotine
chewing gum has provided the first effective aid to overcoming the
pharmacological problem of withdrawal. But it is crucial that the
pendulum does not swing too far towards over-reliance on
pharmacological treatments and neglect of the important social and
psychological factors which are a fundamental part of all addictive
disorders. It is also important that the labelling of smoking as
an addiction does not lead to the belief that permanent cessation
is therefore impossible for smokers who are addicted. An addictive
state is in no way impossible to overcome, although it is likely to
be difficult and therefore to require commitment, planning, and
possibly support as well.
Another significant recent advance that gives grounds for expecting
more success in the future is the recognition of the value and
cost-efficacy of minimal intervention or self-help, and the
potential role of physicians in applying this approach. Most
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important of all, perhaps, is the possibility that physician
advice could be combined synergistically with the use of nicotine
gum. Besides enhancing the efficacy of brief advice to stop
smoking, it is likely that the availability of nicotine chewing gum
will in turn encourage physicians to be more active in advising and
helping their patients to give up smoking.
It is our purpose first to discuss briefly the nature of smoking as
a form of drug dependence. This provides the theoretical basis for
developing pharmacological approaches to cessation. We then focus
on nicotine chewing gum as the first pharmacological approach with
proven efficacy and discuss the theoretical rationale for its use,
its mode of action, and various practical aspects necessary for
effective use in different settings. Finally, besides its use as
an effective aid to cessation, it has provided a means for
advancing knowledge of the role of nicotine in smoking.
SMOKING AS A FORM OF DRUG DEPENDENCE
People smoke cigarettes for many reasons - social, psychological,
sensory, behavioural, and pharmacological. But of all these the
pharmacological motives are the most powerful and the most
fur&mental. If tobacco contained no nicotine, there would be no
problem. People wouldn't smoke it, nor would they snuff it or chew
it.
Although people begin to smoke for social and psychological
reasons, pharmacological motives gradually take over as the smoker
learns to inhale and a regular dependent smoking pattern becomes
established. This escalation to dependence usually takes two or
three years but sometimes occurs far more quickly. Other factors
such as taste, smell, sensory irritation, and behavioural
components such as handling also become important. This is mainly
through frequent and close association with the pharmacological
effects of nicotine. In other words, they are secondary. Without
the presence of nicotine few people would develop a strong taste
for tobacco.
Many surveys have shown that at least three out of every four
smokers want to stop smoking or have tried to stop - some of them
many times. Surveys also show that only about one in three smokers
succeeds in stopping permanently before the age of 60. Thus most
people smoke not because they really want to, but because they
cannot easily stop. In other words, they smoke because they are
hooked and dependent on nicotine. Blood nicotine levels of smokers
vary widely, from 5 ng/ml to over 70 ng/ml, with an average level
for heavy smokers of about 35 ng/ml. The distribution of peak
blood nicotine concentrations just after a cigarette is shown in
figure 1 for a sample of heavy smokers. Although the curve for
smokers in the general population would be somewhat to the left,
measurable pharmacological effects are produced with blood nicotine
levels of 10 ng/ml or less. It is thus apparent that most regular
smokers inhale and absorb sufficient nicotine to produce
pharmacological effects.
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FIGURE 1
Figure 1. Distribution of peak plasma nicotine
concentrations in a sample of 393 heavy smokers (250 women,
143 men) with a mean cigarette consumption of 30.1 per day.
Blood was taken 2 minutes after completing a cigarette during
the afternoon of a day of usual smoking. The average plasma
nicotine concentration was 35.8 ng/ml (SD 13.7) and was not
significantly different between men and women.
It is not our brief here to go into all the pharmacological effects
of nicotine or into the details of the evidence for its role in
smoking and the tobacco withdrawal syndrome. But it should be
emphasised that the modern cigarette is a highly efficient device
for getting nicotine to the brain. The smoke is mild enough to be
inhaled deeply into the alveoli of the lungs from where nicotine is
rapidly absorbed into the bloodstream to reach the brain within
about 7 seconds. This means that the inhaling cigarette smoker
receives a rapid intravenous-like "shot" or bolus of nicotine to
the brain after each inhaled puff. This contrasts with the slower
steady rate of absorption from chewing tobacco or non-inhaled cigar
smoking. Furthermore, the nicotine concentrations in the
post-inhalation boli must be many times higher than those measured
in mixed venous blood after completion of a cigarette. The pattern
of pharmacological effects is no doubt correspondingly different
following the different forms of intake.
PHARMACOLOGICAL APPROACHES
The concept of pharmacological approaches to smoking cessation is
not new. In 1936, Dorsey suggested the use of lo&line as a
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substitute for nicotine because of some putative pharmacological
similarities (Dorsey 1936). But the pharmacological effects of
lobeline are weak. It does not substitute for nicotine in animal
experiments, and clinically it has never proved superior to
placebo. The story is similar for other potential substitutes.
Amphetamine, for example, increases smoking behaviour rather than
diminishing it, and sedatives have no effect in tranquillizing
doses. The subtle dual stimulant and sedative actions of nicotine
appear to be unique. Animals discriminate these actions from those
of all other drugs that have been tested (Hendry and Rosecrans
1982), and there is evidence for its effect on specific nicotine
receptors in the brain (Abood et al. 1981) in addition to its
classical effects on aceylcholine receptors.
Receptor blockade is another potential pharmacological approach.
A drug that blocks the rewarding effects of nicotine could
theoretically be used as an agent of extinction. Beta-adrenergic
blockade by propranolol has been shown to block the peripheral
effects of smoking on heart rate and blood pressure (Carruthers
1976). However it has no effect on reducing subjective
satisfaction from smoking and has no potential, therefore, as a
means to produce extinction. Mecamylamine, on the other hand, is a
blocker of the nicotinic receptors of acetylcholine and appears to
effectively block some of the subjective effects of nicotine
(Henningfield and Jasinski 1983). Its short-term effect is to
increase smoking behaviour (Stolerman et al. 1973), possibly in an
attempt on the part of smokers to overcome the receptor blockade.
But this is not an appropriate test of its potential as an aid to
smoking cessation. More prolonged use would be necessary to test
its capacity to produce extinction. It is our view, however, that
cognitive factors and the capacity of humans to discriminate
between conditions of smoking with and without mecamylamine make it
unlikely that an extinction model based on old-fashioned learning
theory would work. For similar reasons pharmacological aversion
therapy with drugs such as emetine and apomorphine is unlikely to
be effective. There is no punishment-model drug for smoking, such
as disulfiram for alcohol abuse. There is also no prospect of one,
since none of the known metabolites of nicotine are aversive in
realistic concentrations. All this leaves nicotine substitution as
the only feasible potentially effective pharmacological approach to
smoking cessation.
NICOTINE SUBSTITUTION
There are many potential routes for administering nicotine.
Besides the rate of absorption and other issues relating to
bioavailability, the therapeutic potential of a particular route
will also depend on factors such as safety and social
acceptability. A number of routes can be excluded immediately. In
the case of ingestion, absorption is slow and most of the nicotine
is metabolised by the liver to metabolites which are
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pharmacologically inert. Nicotine suppositories or pessaries would
be inconvenient and unacceptable. Injections would need to be
repeated too frequently to be practical, and would not be feasible
for widespread use. Transdermal delivery certainly has potential
but has not yet been developed in the case of nicotine. This
leaves the three routes - lungs, buccal and nasal mucosae - which
have been used for tobacco for over 500 years.
Of these three routes, the rate of absorption through the lungs is,
as mentioned earlier, far and away the most rapid. This is simply
a matter of surface area, that of the lungs being roughly
equivalent to the size of a tennis court. Although it is
technically possible to produce aerosols with particles small
enough to reach the alveoli, to our knowledge no satisfactory
nicotine aerosol has yet been developed. We have seen and tested
four. They have been either too clumsy or have failed to produce
potentially useful blood nicotine concentrations. Irritancy to the
throat has been another major problem. A notable exception has
been the development of a vaporiser shaped like a cigarette
(Jacobson et al. 1982). Inhalation through this device enables
nicotine in vapour form to be taken into the lungs. It is not
excessively irritating and is capable of producing therapeutically
useful blood nicotine concentrations. If a problem of safety can
be overcome, such a device would be well worth further study.
The historical fact that tobacco has been chewed and taken as "wet"
snuff in the north and "dry" snuff in the nose suggests that
absorption of nicotine by either route is sufficient to produce
pharmacological effects. Blood nicotine concentrations after "wet"
and “dry” snuff have been shown to be equivalent to those produced
by cigarette smoking (Gritz et al. 1981; Russell et al. 1981).
Various nicotine-containing lozenges and tablets have been produced
from time to time for help with smoking cessation, but they have
never been systematically tested, and in most cases their nicotine
delivery has been inadequate for therapeutic value.
Nicotine-containing chewing gum, on the other hand, has been
extensively tested (see below). One possible limitation of
nicotine gum is that the rate of nicotine absorption is slow
compared with inhaled cigarette smoking. Preliminary study with a
nasal nicotine solution (NNS) used as a kind of liquid snuff shows
that nicotine is absorbed more rapidly and efficiently through the
nose than through the lining of the mouth (Russell et al. 1983a,
see figure 2). With refinements in flavour and acceptability, it
is possible that a form of NNS could be clinically useful for those
smokers who get insufficient help from nicotine gum or who have
problems with dyspeptic symptoms.
Finally, as a general principle , it is likely that more therapeutic
success might be expected from those forms of nicotine substitution
which also provide a sensory experience and a socially acceptable
behavioural component to act as substrates for conditioning as
acquired secondary reinforcers.
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FIGURE 2
Figure 2. Plasma nicotine concentrations before, during, and
after chewing a single piece of nicotine chewing gum containing
4 mg (top) and 2 mg nicotine (bottom). The plasma nicotine
concentrations produced by smoking a cigarette are also shown as
are those produced by the non-inhaled smoking of a large Havana
cigar (top) and use of a single 2 mg dose of nasal nicotine
solution (NNS) (bottom). (Top is from Russell et al. Brit Med J,
280:1599-1602, 1980, and bottom from Russell et al. Brit Med J,
286:683-684, 1983). Copyright 1980 and 1983, The British
Medical Association.
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NICOTINE CHEWING GUM
A nicotine-containing chewing gum was first developed more than 10
years ago by Ove Ferno in Sweden for use as an aid to smoking
cessation (Ferno et al. 1973). Its purpose is to ease withdrawal
symptoms by providing an alternative source of nicotine and, in
addition, a substitute oral activity. It enables the smoker to
break the habit in two stages. In the first stage, the smoker is
able to focus on overcoming the behavioural and psychological
components of dependence without at the same time having to cope
with nicotine withdrawal. The dependence on nicotine is overcome
at a later stage when there is no longer any urge to smoke.
It should be stressed, however, that the slower rate of nicotine
absorption through the buccal mucosa and the absence of
puff-by-puff high-nicotine boli (see above) make the gum an
incomplete nicotine substitute for smokers who inhale. For the
same reason cigarette smokers who inhale deeply gain little
satisfaction from cigars unless they too are inhaled. The purpose
of nicotine gum, therefore, is to relieve nicotine related
withdrawal symptoms rather than provide the same positive pleasure
as inhaled smoking.
The product
Since the early days of its development the nicotine-containing
chewing gum (Nicorette) has been considerably refined and improved.
It is available in two strengths, each piece containing either 2 mg
or 4 mg of nicotine (only the 2 mg strength is available in the
United States). The nicotine is bound to a resin and its release
depends on the rate and vigour of chewing. About 90% of the
nicotine is released after 30 minutes of normal chewing (Ferno et
al. 1973). The gum also contains a buffer to maintain the pH in
the mouth at about 8.5, at which the nicotine is well absorbed
through the buccal mucosa. Swallowed nicotine is absorbed and
rapidly metabolized in its first passage through the liver (Russell
and Feyerabend 1978).
Pharmacology
The rate of absorption of nicotine from the gum is relatively slow
(see figure 2). The peak plasma concentration is reached 15-30
minutes after starting to chew the gum, compared with 1-2 minutes
after completion of a cigarette. However, a 4 mg piece of gum
chewed every hour for 2-3 hours produces plasma nicotine
concentrations similar to those in heavy cigarette smokers (McNabb
et al. 1982; Russell et al. 1976a and 1977; see figure 3).
Cardiovascular effects, such as increase in heart rate and blood
pressure, produced by 4 mg gum match those after cigarette smoking,
but the 2 mg gum has less effect (Fredholm and Sjogren 1979; Nyberg
et al. 1982).
Effect on Ad Libitum Smoking Behaviour
In two short-term studies in subjects who were instructed to
smoke freely without making any deliberate attempt to reduce their
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FIGURE 3
Figure 3. Plasma nicotine concentrations in the same subject
when smoking one cigarette per hour ad when chewing a piece of
4 mg nicotine gum every hour. (From Russell et al. Brit Med J,
1:1043-1046, 1976). Copyright 1976, The British Medical
Association.
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smoking, nicotine chewing gum had a modest inhibitory effect on
smoking behaviour (Kozlowski et al. 1974; Russell et al. 1976b).
While chewing active gum, the subjects smoked fewer cigarettes,
smoked them less intensively, and inhaled less deeply (as measured
by COHb) than when chewing a placebo gum.
Effect on Withdrawal Symptoms
In an early short-term crossover study (Russell et al. 1976b),
nicotine chewing gum was rated as more satisfying than a placebo.
It was also rated as significantly more effective at putting the
subjects off cigarettes and as more helpful after stopping smoking.
In more recent clinical studies (see below), besides being more
effective than placebo in helping smokers to give up cigarettes,
active gum was significantly more effective than placebo at
relieving irritability, hunger, and sleepiness during the first 6
TABLE 1
Significance levels of changes in mood and other ratings
before and after 24 hours abstinence in subjects
receiving active nicotine chewing gum or placebo
Placebo
(n=21)
Active Difference
G u m between
(n=27) groups
Depressed .06 NS .025
Irritable .OOl NS .025
Less sociable .025 NS .05
Less composed in company .05 NS .Ol
At a loose end
Restless
Dizzy
.05 NS NS
.05 NS NS
.05 NS NS
Reduced concentration .025 .OOl NS
Hunger .OOl .OOl NS
Note: Ratings of all the withdrawal symptoms listed above
changed significantly in those on placebo gum. In those
on active gum, the only ratings to show significant
change were reduced concentration and increase in hunger.
Comparison of the changes in the two groups (3rd column)
shows that nicotine replacement provided by 2 mg nicotine
gum alleviated symptoms of depression, irritability,
reduced sociability and composure in company.
(See West et al., Brit J Addict, 79:215-219, 1984).
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weeks of treatment (Jarvis et al. 1982). However, the active and
placebo groups differed in abstinence rates during this period, and
this may have partially accounted for the differences in withdrawal
symptom ratings.
In a study designed specifically to test the effect of partial
nicotine replacement on withdrawal symptoms during the first 24
hours of abstinence from smoking, 48 smokers were randomly assigned
to chew either active 2 mg nicotine gum or a placebo (West et al.
1984). Subjective ratings were recorded &fore and during
abstinence. The results in table 1 show that those who received
placebo gum experienced a number of withdrawal symptoms during
abstinence, whereas those given active gum experienced very few.
In other words, the active gum was successful in alleviating some
but not all the withdrawal symptoms. Similar findings have been
reported in other studies (Hughes et al. 1984; Schneider and Jarvik
1984). It is noteworthy that these results were achieved despite
the fact that plasma nicotine concentrations on the active 2 mg gum
averaged only 8.3 ng/ml compared with base-line smoking
concentrations of 31 ng/ml and 25 ng/ml for peaks and troughs
respectively (West et al. 1984). More effective nicotine
replacement with 4 mg gum and/or more experience of chewing could
lead to greater relief of withdrawal symptoms.
In view of the capacity of nicotine chewing gum to produce blood
nicotine levels comparable to smoking, albeit more slowly, in view
of its capacity to produce some of the pharmacological effects of
smoking, to inhibit ad libitum smoking, and to relieve tobacco
withdrawal symptoms, in addition to providing an oral substitute,
it would be suprising indeed if it were not also to prove a useful
aid to cessation.
CLINIC-BASED TREATMENT
Over the past 20 years, many kinds of treatment methods have
been tried to help people to give up smoking. These include
hypnosis, group treatment, acupuncture , aversion therapy, and other
psychological methods. None of these has been shown to give better
results than an equivalent amount of simple attention and support
which produces success rates ranging from about 10% - 25% abstinent
at l-year follow up. Drugs such as lobeline and tranquillizers
are no better than placebos, probably because they are inadequate
substitutes for nicotine (see above). In our view, the main
obstacle to success is the addictive nature of smoking. This is
the root of the problem and, until recently, none of the cessation
methods have been applied directly to it. However, since the
development of nicotine chewing gum, the situation has changed.
In a comparative study at our clinic (Raw et al. 1980), those
treated with nicotine gum had a success rate of 38% at l-year
follow up, compared with only 14% for those who had intensive
psychological treatments. More recently, in a double-blind
placebo-controlled trial (Jarvis et al. 1982) we obtained a success
rate of 47% not smoking at l-year follow up, compared with 21%
for those on placebo gum (see table 2). The active gum was also
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significantly more effective than the placebo at relieving
withdrawal symptoms. In both these studies abstinence from smoking
was confirmed by carbon monoxide measures. Adverse side-effects
were limited to gastrointestinal symptoms such as nausea,
indigestion, and hiccups. These were minor and transient and in no
case warranted discontinuance of gum use. About 7% of the subjects
became dependent on active gum (none on placebo). Probably because
absorption of nicotine is less rapid than from smoking, the
dependence was also less severe and was usually overcome without
relapse to smoking. Similar results have been obtained in
placebo-controlled trials in Sweden and the U.S.A. (Fagerstrom
1982; Hjalmarson 1984; Schneider et al. 1983).
TABLE 2
Treatment with nicotine chewing gum (% abstinent)
Placebo Active Statistical
SignificanceGum Gum
(n=58) (n=58)
Abstinent at 1 month 33% 62% p<.01
Abstinent at 1 year 21% 47% P<.01
Lapse-free abstinence 14% 31% P<.025
throughout 1 year
Jarvis et al. Brit Med J, 285:537-540, 1982. Copyright 1982,
Medical Association.
LIMITATIONS OF INTENSIVE METHODS
Intensive treatment and support at specialised smoking withdrawal
clinics can achieve l-year abstinence rates of up to 40%, but
the average is nearer 20%. Even if higher success rates could be
obtained, the clinic-based approach has two major limitations.
Firstly, only a minority of smokers will ever attend a clinic and,
secondly, if they did attend, there are simply too many smokers for
clinics to cope with. Few clinics in Britain attract as many
as 200-300 clients a year, and many of these attend only once and
so do not avail themselves of the treatment offered. A relatively
busy and effective clinic is unlikely to achieve more than 100
long-term ex-smokers per year and the yield of the average clinic
is probably below 50 per year.
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THE MINIMAL INTERVENTION STRATEGY
The rationale behind this strategy is that the yield of long-term
ex-smokers will be greater if the therapist/counsellor/advisor
spends less time with more smokers rather than focusing on
intensive effort with a few. A method with a low but proven
success rate, achievable with minimal effort and readily applicable
to large numbers of smokers, could be more useful in terms of
public health than a time-consuming intensive method with a far
higher success rate. In this respect we have been impressed by the
powerful role that physicians could exercise. In the course of
their everyday work physicians have face-to-face access to the
majority of the 17 million cigarette smokers in Britain. Some 95%
of the British population attend their family physician at least
once in a 5-year period, and about 75% attend at least once in a
year. Attendance rates in other developed countries are unlikely
to be very different.
In a previous study we showed that brief advice against smoking
given by family physicians in their own style, together with a
leaflet and warning of follow-up, achieved a success rate of 5.1%
who stopped smoking within the first month and were still abstinent
at 1 year, compared with 0.3% in non-intervention controls
(Russell et al. 1979). It is emphasised that these results were
based on all cigarette smokers who attended the physicians'
offices, irrespective of whether they wanted to stop at the time or
whether they had or had not already got a smoking-related disease.
Although small, this effect was highly significant statistically,
and for the reasons stated above has the potential for creating
more ex-smokers than is ever likely to occur via intensive methods.
PHYSICIAN INTERVENTION WITH NICOTINE CHEWING GUM
We have recently completed a further study designed to see whether
the offer and prescription of nicotine chewing gum (2 mg Nicorette)
would enhance the efficacy of brief routine advice by physicians
(Russell et al. 1983b).
The target sample comprised all cigarette smokers, aged 16 or more,
who attended the offices of 34 family physicians in six group
practices during a 3 1/2-week period. They were assigned by week
of attendance (in a balanced design) to one of three groups.
Group 1 were non-intervention controls. Group 2 received advice
to stop smoking plus a booklet and a warning of follow up.
Group 3 received the same as Group 2 but, in addition, were
offered nicotine chewing gum. If the offer was accepted, a
prescription and instruction booklet were also given, A postal
follow-up was done after 4 months and again after 1 year.
Expired-air carton monoxide was checked in two-thirds of those
claiming abstinence at 1 year. The results are based on the 1,938
(89%) who had not moved to an unknown address or died during the
year. Among these 1,938 there were 327 who did not provide
adequate data. They were counted as continuing smokers. The main
results are shown in table 3.
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485-874 0 - 85 - 5
TABLE 3
Minimal intervention by family physicians
No Advice Advice and
Advice Only Nicotine Gum
(N=584) (n=675) (n=679)
Tried to stop 36.6 46.1 61.1
Abstinent at 4 months 10.3 14.1 20.2
Still abstinent at 1 year
Self-report 6.0 6.4 11.9
Adjusted for 3.9 4.1 8.8
non-validation
Note: The results are showrr as percentages based on all
subjects in each group. All comparisons between the
nicotine gum and the other groups were significant at the
p<.OO5 level. (Russell et al. Brit Med J, 287:1782-1785,
1983). Copyright 1983, The British Medical Association.
As with the clinic based studies, use of the gum in a family
physician setting doubled the success rate achieved by advice
alone. Further analyses, which can be found in the full report
(Russell et al. 1983b), showed that the offer and availability of
the gum achieved its overall effect in three ways. It motivated
more smokers to try to give up smoking (p<.OOl), it increased the
success rate among those who tried (p<.05), and reduced the relapse
rate among those who had stopped at 4 months (p<.05) .
The greater efficacy of Group 3 intervention was achieved despite
the fact that the results are based on all subjects and that only
53% actually tried the gum. There was a complex relation between
initial cigarette consumption, gum use, and success rate. Heavier
smokers tended to use more gum, and heavy gum use was associated
with a higher success rate. In particular, the self-selected
subgroup (8% of Group 3) who used more than a box of gum (105
pieces) had a long-term success rate of 34.6% (24% after adjustment
for failed validation). These successes had had an initial
cigarette consumption prior to intervention averaging 23 cigarettes
per day compared with 13 and 12 per day for the successes in Groups
1 and 2 respectively and 12 per day for the remaining successes in
Group 3.
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An 8.8% success rate may at first seem unimpressive compared with
rates of 40% obtained with intensive methods at specialised
clinics. It may help to get it in perspective. We calculated that
if the 34 physicians in this study were to continue the Group 3
procedure routinely, the net yield of long-term ex-smokers (over
and above the spontaneous cessation rate in the non-intervention
controls) mold average about 38 per physician in the first year.
Extrapolated to all 28,000 family physicians in Britain, and
assuming they could achieve similar results, the initial yield
would be around 1 million w-smokers a year, and possibly similar
results could be obtained for several ensuing years.
Finally, although higher success rates could undoubtedly be
achieved if physicians had the time for more intensive support and
follow up, we suggest that the overall yield of ex-smokers would be
greater if physicians allocated their time by spending a little of
it with many smokers rather than a longer time with a few.
Ideally, physicians should know, by enquiring if necessary, the
current smoking status of every patient they see, advise all
cigarette smokers to stop, and offer nicotine gum and an
instruction booklet to all those who want to stop but have little
confidence in being able to succeed without help. Such activity by
physicians could achieve more than most other approaches to smoking
cessation.
PRACTICAL ASPECTS OF GUM USE
Success rates achieved with the use of nicotine chewing gum depend
on many factors, including the degree of motivation and dependence
of clients, the intensity of psychological support in the short
term, and in the longer term the degree of care given to follow-up.
However, one factor is essential if the gum is to be used
successfully in any setting. This is adequate information on what
the gum will and will not do, and careful instruction on its use.
As mentioned previously, the gum is at best a partial substitute
for cigarettes and does not provide as much positive satisfaction.
It follows that it is a treatment aid rather than a complete
treatment. Smokers who approach it naively, hoping, as many do,
that it will somehow magically stop their smoking without the need
for any effort on their own part, are inevitably disappointed and
may wrongly conclude that the gum has nothing at all to offer. It
is therefore vital that clients be made aware of the positive and
negative aspects of the gum in order to gain maximum benefit from
its use. The failure of a recent multicentre trial of nicotine
chewing gum to achieve even a placebo effect may reflect among
other things inadequate attention to the crucial aspects of subject
instructions (British Thoracic Society 1983; Jarvis and Russell
1983). We summarise in appendix 1 the main points that we have
found helpful to communicate to clients.
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Management of treatment with nicotine gum is relatively
straightforward. The main issues are firstly whether all patients
need the gum, and secondly whether long-term dependence on it is a
matter for serious concern. Motivation to give up cigarettes is a
prerequisite for success, and it is sensible to seek evidence of
this in serious unaided attempts to quit before considering the
offer of nicotine chewing gum. Light smokers are more likely than
heavy to stop without any formal help, but present evidence
suggests that their success rates, like those of heavy smokers, are
enhanced by use of the gum. The main point to resolve therefore
should be whether the client's history suggests that dependence as
opposed to lack of motivation has been the main block to achieving
smoking cessation.
Most people do not find it difficult to stop using the gum, but a
small minority do become dependent on it and may continue to use it
for a year or longer. While long-term use of the gum should be
discouraged, both because continuing dependence on nicotine
increases the risk of relapse to smoking and because of possible
health risks of gum use per se, in our view it is not advisable to
refuse to continue to prescribe to a client who is not smoking.
This is almost guaranteed to produce relapse to smoking, which is
far more harmful to health. We summarize in appendix 2 the main
issues of treatment management.
THEORETICAL IMPLICATIONS
Like most new treatments, nicotine chewing gum given with
enthusiasm no doubt has a strong placebo effect. Some people
dismiss this quality with scorn. In our view, this is mistaken.
As a principle, a safe placebo may be turned to better use than an
active treatment that carries a risk. Placebo response is a valid
and potentially useful psychological effect. It would seem
preferable in treatment situations to view it as an asset to be
used positively to enhance results rather than negatively as a
reason for undermining the value of treatment.
There is no doubt, however, that nicotine chewing gum has an effect
over and above that of the attention-placebo response. Besides
achieving higher success rates than placebo, it significantly
alleviates withdrawal symptoms, as has been discussed already.
There is one further point. In our placebo-controlled trial
(Jarvis et al. 1982) we found that among those who were abstinent
at 1 month, gum consumption (number of pieces per day) correlated
with pretreatment blood nicotine concentration in the active group
(r= .48) but not in the placebo group (r= .17). Pretreatment
cigarette consumption, on the other hand, correlated with gum use
in the placebo group (r= .47) but not in the active gum group
(r= .ll). These findings were statistically significant and point
to different processes underlying the use of nicotine gum and
placebo gum. The evidence for the specific efficacy of nicotine
chewing gum over and above that of attention-placebo factors is
summarized in table 4.
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TABLE 4
SUMMARY OF EVIDENCE FOR SPECIFIC
EFFICACY OF NICOTINE CHEWING GUM
1. Can produce blood nicotine levels
similar to cigarette smoking.
2. Produces some pharmacological
effects equivalent to smoking.
3. Inhibits ad libitum smoking.
4. Clinical efficacy: doubles
long-term abstinence rates.
5. Subjectively helpful to smokers.
6. Reduces withdrawal symptoms.
7. Gum use correlates with
pretreatment blood nicotine;
placebo does not.
8. About 7% become dependent on
nicotine gum, none on placebo.
Besides its use as an effective aid to smoking cessation, nicotine
chewing gum has already proved a useful tool for research.
Firstly, it has stimulated a new wave of clinical trials in which
far more rigour has been applied than previously to important
methodological issues such as biochemical validation and success
criteria. Only recently, for example, has a clear distinction been
made between abstinence at 1 year follow-up and lapse-free
abstinence throughout the year.
Secondly, and more importantly, its effect compared with placebo in
enhancing smoking cessation success rates, in alleviating
withdrawal symptoms, and in inhibiting ad libitm smoking has
provided new evidence for the role of nicotine in smoking.
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SUMMARY AND CONCLUSIONS
In our view, nicotine chewing gum is the most significant single
advance achieved so far in the whole field of smoking cessation.
It is the only treatment that has yet been shown to have a specific
effect over and above that of attention-placebo factors, and this
has been demonstrated repeatedly by several research groups in
different countries. It is suitable for use as an adjunct both to
intensive psychological methods of treatment and to minimal and
largely self-help types of intervention. In either case, it
approximately doubles the success rates achieved by intervention
without the use of gum. It can be administered effectively by
psychologists and family physicians and no doubt by other
adequately trained health professionals too.
The efficacy of nicotine chewing gum is not limited to the smokers
who use it. Its incorporation into a treatment or intervention
programme revitalises and maintains the morale of therapists.
Until the advent of nicotine gum it has required either a research
interest, financial reward, or a degree of masochism to remain for
long at the sharp end of the business of helping people to give up
smoking. Without a treatment capable of reducing withdrawal
symptoms, therapists became drained by having constantly to give
out encouragement and support to help their clients to tolerate
withdrawal long enough for the difficulties gradually to wane. The
rapid and tangible effect of the gum in relieving withdrawal
symptoms is a boost to the morale and confidence of client and
therapist alike. It is perceived as helpful even by those who
fail. This encourages people who relapse to return for further
therapy. A discouraging feature with other treatments has been the
tendency for those who relapse to avoid contact with their
therapists even to the extent of not responding to data collection
at long-term follow up.
In view of its efficacy, its potential for use in many settings,
its minimal demands on therapists' time, and its synergistic effect
in encouraging and boosting the confidence of clients and
therapists alike, it is possible that over a period of years
nicotine chewing gum could have a significant impact on national
smoking prevalence. But to achieve this, it is essential that it
be used correctly.
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APPENDIX 1
INFORMATION FOR CLIENTS ABOUT NICOTINE CHEWING GUM
AND INSTRUCTI0NS ON ITS USE
The gum is not a magic cure. Personal commitment and effort are
still necessary for success.
The gum contains nicotine which is released as it is chewed and
absorbed through the lining of the mouth.
Absorption of nicotine is slower than from cigarettes; therefore
the gum does not give the same positive pleasure as smoking.
The gum does not stop the smoker from smoking, but it does make
it easier to cope without cigarettes after stopping.
The gum reduces craving for cigarettes and makes withdrawal
symptoms less severe.
Its use should be started after quitting cigarettes.
Each piece should be chewed for 20-30 minutes to allow all the
nicotine to be released.
The gum should be chewed gently, with frequent pauses. Too
vigorous chewing causes excessive salivation. Nicotine which
is swallowed is destroyed and wasted. It may also cause
indigestion.
A piece of gum should be chewed whenever the urge to smoke is
very strong. On average pack-a-day smokers use about 7 gums per
day.
The gum may taste unpleasant at first and irritate the throat.
Most people adapt to it after persisting for a day or two, but it
may take up to a week to get used to it.
The gum should be used for up to 3 months before attempting to
discontinue its use. Even then it is a good idea to carry a few
pieces in case of emergencies.
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APPENDIX 2
MANAGEMENT OF TREATMENT WITH NICOTINE CHEWING GUM
Offer only to smokers who seriously want to quit, and have tried
previously without success or have little confidence in succeeding
without help, including light smokers who meet these criteria.
Give usual guidelines on quitting - e.g., setting a target day for
stopping, avoiding difficult situations, etc. The gum is probably
less suitable for gradual cessation, but can be readily
incorporated into most other programs.
Give verbal and written instructions to all clients, along the
lines suggested in appendix 1. In most countries a manufacturer's
booklet is available.
Discontinue the gum if the client continues to smoke. We usually
warn clients who have not quit by 2 weeks that they will get no
more if they have not quit by their next visit.
Consider 4 mg gum if the client uses more than 15 per day of the
2 mg strength. (4 mg gum is not yet available in the U.S.A.)
Encourage gradual withdrawal from gum after 3 months abstinence
from smoking. Most will not find this difficult. Longer term
dependence develops in a few, but may be preferable to relapse to
smoking, which is the probable alternative if the gum is withheld
from clients who feel they cannot do without it.
Unwanted effects such as sore mouth, hiccups, and gastric symptoms
are relatively common initially but are rarely a cause for
discontinuance. They are often a sign of excessively vigorous
chewing.
In our view the following conditions are cause for caution but do
not exclude use of the gum: pregnancy, peptic ulcer, coronary
heart disease, hypertension, peripheral vascular disease. In all
these conditions continued smoking is probably more harmful than
moderate gum use.
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Psychological and Pharmacological
Approaches to Smoking Relapse
Prevention
Sharon M. Hall, Ph.D., and Joel D. Killen, Ph.D.
This paper reports data from two studies which examined the effects
of smoking treatments combining psychological and pharmacologic
treatment methods. Nicotine chewing gum (Nicorette) was used as a
pharmacologic aid to help achieve nonsmoking and maintain absti-
nence. Aversive smoking procedures were used to produce rapid
cessation. Cognitive behavioral skills training was included to
help subjects develop strategies for identifying and coping with
high risk episodes.
NICOTINE CHEWING GUM: A PHARMACOLOGIC THERAPY
The use of nicotine gum as a therapeutic agent is based on the
assumption that smokers smoke for nicotine. The evidence supporting
nicotine as the dependency-producing agent is suggestive but incon-
clusive. The dependency premise has led to proposals of nicotine
regulation or "titration." That is. it has been assumed that
smokers. once dependent, regulate nicotine through relatively stable
patterns of self-administration. Data supporting the nicotine
regulation model come mostly from experiments showing variation in
smoking rates accompanying experimental manipulation of nicotine
levels (for example, e.g., Mangan and Golding, 1978; Herning et al.
1981). However, the regulation in most studies is imprecise. Some
investigations. especially those correlating nicotine yield and
nicotine blood levels, have failed to demonstrate a regulation
effect (Kumar et al. 1977).
Initial trials with nicotine gum conducted in Great Britain and
other European countries produced mixed results. Russell et al.
(1976) compared 2 mg nicotine chewing gum with placebo in a
double-blind cross-over trial during which 43 smokers were either
smoking "as inclined" or were attempting cessation. Use of the gum
signficantly reduced smoking during the ad lib period, but differ-
ences between the two conditions disappeared when subjects attempted
to quit smoking. At 6-month followup, Puska et al. (1979) found 35%
abstinence for nicotine gum treatment subjects and 25% for placebo.
Malcolm et al. (1980) found 23% abstinence for gum treated subjects,
5% for placebo, and 14% for a no-drug control. Recent studies re-
ported by Russell have produced higher abstinence rates, probably
due to improvements in the formulation of the gum and to better
instructions in its use. One year COHb validated abstinence rates
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of 38% have been reported (Russell et al. 1980). These may be
increased to 67-68% for subsample which continue to use the gum for
at least four months (Russell et al. 1980; Wilhelmson and
Hjalmarsson 1980).
However, at least one recent placebo-controlled trial has failed to
demonstrate an effect for the active gum (British Thoracic Society
1983). and two others reported failures to maintain initial signif-
icant differences at 1-year assessments (Fagerstrom 1982; Fee and
Stewart 1982). a negative result replicated in a sample from the
United States (Schneider et al. 1983).
ADVANCED PSYCHOLOGICAL TREATMENTS
Multicomponent psychological interventions represent "state-of-the-
art" efforts in psychosocial approaches to smoking cessation the
relapse prevention (e.g.. Hall 1984). Treatments typically combine
aversive smoking strategies to produce quitting with behavioral
skill training. The skill training gives clients skills to suc-
cessfully overcome high risk situations.
Results from controlled investigations of multicomponent programs
have been mixed. Although some have reported 12-month abstinence
rates above 50% (Delahunt and Curran 1976; Lando 1977), the data
from most of these studies are less than persuasive. Rates are
either lower (e.g., Danaher 1977). or they are based on self-
reported abstinence without biochemical verification.
COMBINING PSYCHOLOGICAL AND PHARMACOLOGICAL APPROACHES
Most investigators agree that both psychological and pharmacologic
factors maintain smoking (Jaffe and Kanzler 1979). Therefore,
procedures enabling quitters to cope with the psychological factors
precipitating relapse combined with pharmacological management of
withdrawal symptoms may enhance long-term treatment outcomes. In
one such trial. Fagerstrom (1982) reported a 12-month abstinence
rate of 49%.
The two trials reported in this paper combined nicotine gum with
similar multicomponent psychological interventions. The studies
were designed and executed independently. One was Implemented at
Stanford University (Killen), the other at the University of
California, San Francisco (Hall).
THE STANFORD TRIAL
Sixty-four subjects were assigned to one of three maintenance
treatment conditions: (1) nicotine gum (n=22); (2) skills training
(n=20); (3) combined. The latter included gum plus skills training
(n=22). Abstinence was assessed at 6 and 15 weeks and 10.5 months
following cessation. Expired air carbon monoxide levels were
measured at all three points. Serum thiocyanate levels were
collected at 6 weeks.
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Subjects
Subjects met the following criteria: (1) did not present cardio-
vascular cr pulmonary disease symptoms; (2) were not pregnant; (3)
paid a 50 dollar deposit; and (4) obtained physician's consent to
participate. Subject characteristics are presented in table 1.
TABLE 1
The Stanford Trial - Demographics
Mean number of cigarettes per day 31.7
Mean age 44.1
Mean number of years smoked 23.8
Mean (SD) expired air CO (PPM) 28.2 (12.5)
Mean (SD) blood cotinine (NG/ML) 192.9 (100.0)
Mean (SD) serum thiocyanate (UMOL/L) 165.9 (53.1)
Cessation Phase
A 7-week treatment program consisting of cessation and maintenance
phases was developed. The cessation phase occurred during week 1.
Maintenance training was conducted during weeks 2-7.
All subjects participated in the cessation phase, designed to
produce rapid quitting. Therapists met with participants in groups
of 10-12 in four consecutive 1.5-hour sessions. All smoking was
expected to cease after the third session so that subjects would
have achieved abstinence for 24 hours at session four.
During the first hour of each session, a four-step skills training
procedure was used to help participants develop strategies for
coping with the multiple determinants of smoking. In Step 1.
self-efficacy scales developed by Condiotte and Lichtenstein (1981)
were used to target high-risk situations. In Step 2, therapists led
group members in a discussion of potentially effective coping
strategies. In Step 3, therapists demonstrated how strategies for
selected target situations might be implemented. In Step 4.
participants rehearsed responses specific to personal high-risk
situations in front of the group. Therapists and group members
provided feedback following each rehearsal.
During the final 30 minutes of each session participants engaged in
an aversive smoke holding procedure. Imagery training with home
practice was used with smoke holding to promote more potent,
self-regulated use of aversion effects.
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Maintenance Phase
Condition 1: nicotine gum. Subjects in this condition used
nicotine gum (2 mg) for 7 weeks. Nicotine gum was begun on day 1 of
the cessation phase. Participants were informed that-a variety of
psychophysiological withdrawal symptoms accompany cessation and may
increase the chance of relapse. They were instructed to chew nico-
tine gum at each occurrence of an urge, craving, or other symptom;
they were told that symptoms would diminish within 10 to 15 minutes
of onset. Participants were also told that the gum was only viewed
as an adjunct to cessation, and that skill development and practice
were essential to continued abstinence. They were instructed to
reduce gum usage beginning in week 3 in order to terminate gum use
completely at the end of treatment. Gum was not available beyond
week 7.
During the maintenance phase, participants in Condition 1 attended a
drop-in clinic for 20 minutes once a week beginning in week 2. At
each session participants received new gum supplies if desired and
returned unused portions of gum allotments distributed at the pre-
vious session. Carbon monoxide levels were measured and self-
regulatory efficacy scales were completed.
Portions of the $50 deposit were returned for attending weekly
sessions.
Condition 2: skills training. Participants in Condition 2 met in
small, therapist-led groups during weeks 2 and 3 for additional
skills training designed to strengthen nonsmoking skills. Nicotine
gum was not administered.
In weeks 4-7 they directed their own maintenance program and
received performance feedback during weekly drop-in clinic
sessions. Participants used efficacy scales to target high-risk
situations and wrote treatment plans detailing the (a) problem
situation; (b) appropriate coping strategies; (c) change plan
implementation procedures; and (d) outcomes. Portions of the de-
posit were returned for completion of weekly homework assignments.
Condition 3: combined. During the maintenance phase, participants
in Condition 3 received the skills training program developed for
those in Condition 2 (ST). They also began; nicotine gum on day 1
and discontinued use at the end of treatment (week 7).
RESULTS
Abstinence rates are presented in table 2.
At 6 weeks, the rate for the combined group was significantly higher
than the rate achieved by the skills training condition only format
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TABLE 2
Stanford Trial - Abstinence Rates
NG ST NG+ST
(n=22) (n=20) (n=22)
6-week followup
N 14 11 19
% Quit 64 55 86
15 week followup
N Quit 11 9 16
% Quit 50 45 73
10.5 month followup
N Quit 5 6 11
% Quit 23 30 50
(ST) (X2=3.63, p<.05, one-tailed), but not different from the gum
only format (NG). At 10.5 months, differences between the gum
formats were not significant at (p<.O5) but were in the predicted
direction (X2=2.46, p<.10, one-tailed). Carbon monoxide values
were used to verify self-report: at each assessment. Thiocyanate
was used to verify reports at 6 weeks. Ninety percent agreement was
obtained between biochemical measures.
Withdrawal Symptoms
A Tobacco Withdrawal Scale, developed by Bachman (unpublished) was
used to assess the frequency and severity of withdrawal symptoms
associated with cessation. Subjects rated the severity of each of
24 symptoms on a scale ranging from 0 (no symptom) to 4 (extremely
severe). Withdrawal symptoms were collected daily during weeks
2-4. At week 3. gum users reported significantly less severe
symptoms t(48)=2.39, (p<.O5). Differences at weeks 2 and 4 were not
significant but in the predicted direction.
Physical Dependence Predictors
A stepwise logistic regression analysis was conducted to examine the
utility of seven factors (Fagerstrom Tolerance Questionnaire,
reported cigarette consumption, withdrawal symptom severity, urge
severity, cotinine, expired-air carbon monoxide and serum
thiocyanate) in predicting resumption of smoking. Urge severity
accounted for about 14% of the relapse variance (X2=10.93,p<.009)
at the 15-week followup. Symptom severity accounted for about 3% of
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the variance (X2=3.95,p<.05). Suprisingly. cotinine failed to
predict relapse at any assessment.
Side Effects of Gum Use
Most users reported some side effects, but only three discontinued
use due to personal discomfort. Table 3 presents the most fre-
quently reported side effects.
TABLE 3
The Stanford Trial - Reported Side Effects
Side Effect
oral soreness
hiccups
nausea
lightheadedness
mouth sores
jaw muscle ache
appetite loss
headache
heartburn
Percent Reporting
32
11
20
14
36
9
23
5
THE UNIVERSITY OF CALIFORNIA - SAN FRANCISCO TRIAL
Subjects
Subjects were 120 smokers who attended an orientation meeting and
(1) did not have cardiovascular or pulmonary disease; (2) were not
pregnant; (3) were between the ages of 21 and 55; (4) paid a $75
deposit; and (5) obtained physicians' concurrence about their health
status. Demographic and smoking characteristics of these subjects
at pretreatment are in table 4.
Subjects were assigned by order of entrance into treatment to one of
three treatment conditions. These were nicotine gum in a low con-
tact group, entensive behavioral, or combined.
All subjects were told to stop smoking on the first day of treatment
and were precautioned against smoking outside the sessions there-
after. All meetings lasted 75 minutes.
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TABLE 4
UCSF Trial - Sample Description (N=l20)
N %
SEX: Male 64 53
Female 56 47
Treatment Completion:
Treatment Completers 114 95
Dropouts 6 3
Years Smoked: l-5 Years 5 4
6-10 Years 15 13
11-20 Years 52 46
>20 Years 42 37
Pretreatment Blood X = 186.55
Cotinine Level SD = 92.94
(NG/ML) Range = 15-469
AGE X = 38
SD = 7.6
RANGE = 24-56
Intensive Behavioral Treatment
This treatment was modeled on that studied earlier in the senior
author's laboratory. In that trial, it produced 50% abstinence rate
at 6 months. and 39% at 1 year (Hall et al. 1982). The treatment
had two phases, a quitting phase and a relapse prevention phase.
The quitting phase consists of eight aversive smoking sessions held
during the first 3 weeks. Subjects puffed and inhaled every 30
seconds. Videotape feedback of the smoking sessions was used to
provide negative images for the smoker to use when tempted to smoke
outside the session. Carbon monoxide feedback was given before and
after each treatment session, to emphasize the physical effects of
smoking.
The relapse prevention phase had three components. These were
relaxation training, smoking situation training, and structured
feedback. Subjects were taught a modification of Benson's (1974)
relaxation method. They made a commitment to use this technique or
another of their choosing to combat feelings of tension and irri-
tability. Subjects role-played typical relapse situations and
learned ways of rethinking responses to urges. Structured feedback
consisted of paper and pencil exercises with group discussion on the
costs of smoking and the benefits of quitting. CO levels were also
used as feedback during this phase of treatment.
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Nicotine Gum plus Low Contact Group
Four treatment sessions were held over a 3-week period. Subjects
were given detailed instructions in use of nicotine gum, including
when and how to taper off the gum. During treatment sessions, use
of the gum was monitored, reading materials were discussed, and
individual plans to quit smoking were formulated. As part of that
plan, subjects made a commitment to the group to use specific
strategies. Materials presented included three booklets: a tip
sheet taken from the American Cancer Society, information on the
American Lung Association Tel-Med Phone line, and a magazine article
on nicotine gum. Gum was available for 6 months from study start.
Combined Treatment
The combined treatment was identical to the behavioral treatment
except that nicotine gum and instructions in its use were provided
and gum was available for 6 months from study start.
Assessments were held at weeks 0 (pretreatment), 3 (posttreatment).
12, 26. and 52. Abstinence was verified by CO. Plasma thiocyanate
analyses were used to verify abstinence at 26 and 52 weeks. Blood
cotinine and Tolerance Scores were collected at pretreatment.
RESULTS
Abstinence rates are shown In table 5.
TABLE 5
UCSF Trial - Abstinence Rates
Treatment Group
Low Contact Combined Behavioral
(N=43) (N=41) (N=36)
3-Week Assessment
N Abstinent
% Abstinent
12-Week Assessment
N Abstinent
% Abstinent
26-Week Assessment
N Abstinent
% Abstinent
52-Week Assessment
N Abstinent
% Abstinent
35
81
39 28
95 78
25 30 17
58 73 47
20 24 11
47 59 31
16 18 10
37 44 28
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Differences between the Combined condition and the two single
modality treatment conditions considered together were significant
at weeks 3 (X2(1)=5.00, p<.O2), 12 (X2(1)=4.50, p<.O3), and 26
(X2(1)=4.05, p<.04), but not at week 52 (X2(1)=1.40, p<0.24).
Hierarchial logistic regression indicated significant treatment
condition by cotinine level interventions. For subjects above the
median, differences in abstinence rates between gum and no gum
conditions were significant at all assessments at week 3 (X2(1)=
3.89, p<.05, 26 (X2(1)-4.71, p<.O3), and 52 (X2(l)= 5.31,
p<.05). A nonsignificant trend in the same direction was noted at
week 12 (X2=2.97, p<.08).
There were no significant differences between gum and no gum
conditions for subjects below the cotinine median. Results for the
Tolerance Scale followed a similar pattern, but differences between
gum and no gum for subjects above the median were significant only
at weeks 12 (p<.026) and 26 (p<.O27). Cigarettes per day showed a
similar pattern, but differences were significant only at week 26
(p<.O34).
Abstinence rates at each assessment for both gum and no gum
conditions for subjects above and below the median on cotinine are
shown in table 6.
TABLE 6
Number (and Percent) Abstinent at each Assessment
for Subjects High and Low
on Blood Cotinine in Gum and No Gum Treatment
Gum
(n=37)
Week 3 37 (93)
Week 12 27 (67)
Week 26 21 (53)
Week 52 16 (40)
DISCUSSION
Above
Cotinine
Median
No Gum
(n=17)
13 (68)
7 (37)
3 (16)
2 (11)
Below
Cotinine
Median
Gum No Gum
(n=40) (n=l9)
30 (al) 15 (88)
23 (62) 10 (58)
18 (49) 8 (47)
15 (41) 8 (47)
The two studies produced similar outcomes. In both, the intensive
behavioral treatment combined with nicotine chewing gum produced
some of the highest longer term abstinence rates ever reported,
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especially in relatively early assessments. Biochemical
verification of self-reported abstinence strengthens the
persuasiveness of the findings.
The results suggest that nicotine gum should be combined with
considerable psychological support. While the short-term per-
formance of subjects in Killen's gum-only format was encouraging,
only 23% remained abstinent at 45 weeks. Relapse rates for the
other conditions were not nearly so marked. Subjects in the
gum-only format may have been less prepared to cope with psycho-
logical factors, since their exposure to the behavioral intervention
was brief. Hall's low contact condition did not produce nearly so
sharp a relapse rate. Of these subjects, 37% were abstinent at 1
year. Several factors may have contributed to differences between
the two studies, including the long period of gum availability for
Hall's subjects, or the emphasis on self-reliance in the low contact
groups, or the formulation of a plan and commitment to use it. It
should be noted, however, that in both studies even the low contact
conditions provided more support than patients will probably receive
when the gum is administered as a prescription drug.
Physicians should be cautioned that mere prescription of the gum
cannot be expected to produce optimal performance. Psychological
and behavioral factors clearly influence outcomes and must be
addressed if treatments are to produce durable results. How the gum
will be combined with behavioral treatments in clinical practice is
unclear, and is likely to be neglected unless considerable effort is
directed to physician education. Research designed to develop and
evaluate physician-administered treatments combining both nicotine
and psychological interventions is clearly needed.
Controlled placebo comparison trials testing the effects of the gum
and standardized psychological treatments are essential to clarify
the importance of different mechanisms in the change process.
Fagerstrom (1982) has reported 6-month abstinence rates of 63% and
45% for active and placebo gum combined with psychological therapy.
Fee and Stewart (1982) reported posttreatment rates of 46% and 33%
for active and placebo gum respectively. Given their sample sizes,
the 18% difference reported by Fagerstrom and the 13% difference
reported by Fee and Stewart were statistically significant.
However, the so-called placebo effect of the gum would appear to be
important, since abstinence rates in both placebo conditions were
respectable. Thus, as Russell notes (this volume), the placebo
effect can be used to advantage. It should also be noted that
significant differences between the active and placebo gums vanished
at 12-month followups in both reports.
Periods of gum availability have ranged from 5 weeks (Fee and
Stewart, 1982) to 1 year (Schneider et al. 1984). Research on
different gum administration schedules is also needed. Russell
(1980) suggested that nicotine gum be available for at least 4
months. The data are mixed, but relapse may be, in part, a function
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of the effects of tobacco dependence. However, we know very little
of the process by which presumed psychological and pharmacological
manifestations of dependence promoted relapse (Jarvik 1979).
The Stanford and UCSF trials examined several biochemical and
self-report measures of physical dependence. Previous work suggests
that cotinine may be a useful measure of chronic tobacco dependence
and might serve to identify those smokers most likely to relapse
following smoking cessation (Hall et al. 1984b; Zeidenberg et al.
1977). Findings from Hall's study support the earlier work. Sub-
jects above the median cotinine level did poorly without nicotine
gum. Availability of the gum had little effect for subjects below
the median. Killen's data showed no correlation between cotinine
levels and abstinence. Reasons for differences in outcome are
unclear. Blood samples were drawn in Hall's study after an 8- to
12-hour cigarette fast. Thus, the levels reported represent con-
stant levels, unconfounded by length of time since last cigarette.
This was not the case in Killen's sample, where time since last
cigarette was not controlled. However, this procedural difference
cannot entirely account for the differences between the two studies,
since Hall et al. (1984b) used procedures similar to those of Killen
in earlier work, and were able to predict outcome. In Hall's sam-
ple, cotinine was an especially good predictor when a median split
was used, suggesting measurement at some points of the distribution
may be more reliable than at others.
The Fagerstrom Tolerance Questionnaire was also examined in both
trials. Prediction of relapse was reasonably good only in the UCSF
study.
Killen also examined measures of withdrawal symptoms severity and
urge severity. Reported urge severity accounted for about 14% of
the relapse variance at the 15-week followup. This is one of the
first studies to demonstrate a relationship between urge, strength
and relapse. Although modest, the level of prediction achieved with
this measure compares well with the predictive power of measures
such as self-efficacy or cotinine which typically account for be-
tween 10% and 15% of the variance in treatment outcome. The results
suggest that further efforts to develop measures of smoking urge may
be warranted.
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